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Mucins are high molecular weight glycoproteins and have critical functions in
protecting epithelial cells from a myriad of cellular stress. However, mucins are
expressed aberrantly under cancer conditions that allow tumors to progress and
metastasize. Among many mucins, Mucin 4 (MUC4) serves as one of the topdifferentially expressed proteins in pancreatic cancer (PC), however, the precise
mechanism responsible for its aberrant expression is still not clear. The evolving view of
cancer as an energetic and growing ecosystem underlines an intricate interplay between
cancer and its microenvironment. In spite of being recognized as one of the most critical
oncogenic proteins in PC, MUC4 regulation in terms of micro-environmental stress has
not been determined. In my dissertation research, I have investigated the role of PC
microenvironment in the regulation of MUC4. From my studies, I have demonstrated that
MUC4 stability is significantly reduced due to hypoxia-mediated induction of reactive
oxygen species (ROS), which promotes autophagy by inhibiting pAkt/mTORC1 pathway.
Hypoxia-mediated degradation of MUC4 provides necessary metabolites to ensure the
survival of highly stressed PC cells.
The longstanding model of cancer development involves that presence of
cytokines can trigger chronic inflammation and impact tumor development, including PC.
In addition to cytokines, bile acids (BA) facilitated chronic inflammation has shown to
induce intestinal metaplasia, but their role in PC is still elusive. Elevated levels of BA
(p<0.05) and its receptor were observed in pre-clinical and clinical serum samples from
human and mouse models. Further, their significantly higher levels were also observed

in pancreatic juice obtained from PC patients in comparison to controls, establishing the
direct involvement of BA in PC pathobiology. It prompted us to hypothesize that BA have
tumor promoting functions in PC. Mechanistically, the tumorigenic functions of BA were
explained by BA-mediated upregulation of mRNA expression of MUC4, which, in turn, is
primarily dependent on FXR-mediated activation of FAK. Activation of FXR further leads
to an increase in the expression of c-Jun that binds to AP-1 motifs present on MUC4
distal promoter region resulting in transcriptional upregulation of MUC4.
In addition to the regulation, I have pinpointed the novel functional roles of MUC4
in determining the fate of receptor tyrosine kinases (RTKs) in PC. Multiple studies have
associated MUC4 overexpression with increased stability of RTKs for sustained
proliferation; however, no studies have so far highlighted the implicated mechanism. I
have demonstrated that the presence of MUC4 leads to increased internalization and
recycling of EGFR and HER2 to the plasma membrane compared to MUC4 silenced PC
cells. Mechanistically, the impact of MUC4 on RTKs trafficking is associated with its
ability to regulate the activity of RAB5A, which is known to catalyze the rate-limiting step
in receptor internalization. Lastly, I have detected the presence of MUC4 in pancreatic
cancer associated stellate cells (PaSC). This was an unexpected finding given that
MUC4 is normally expressed in the epithelial cells. These results indicate towards the
involvement of MUC4 expression in determining the activation status of PaSC and
provide us an additional strong rationale to therapeutically target MUC4.
Altogether, in my dissertation research, I have elucidated the novel regulatory
mechanisms and functions of MUC4 in PC condition.
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CHAPTER I
INTRODUCTION
CHAPTER IA: Regulation of Mucins by the microenvironmental stress of
pancreatic cancer microenvironment
CHAPTER IB: Regulation of MUC4 by the Bile acids (BA) in PC condition
CHAPTER IC: Novel mechanism implicated in MUC4-mediated increase in the
stability of EGFR-family members in PC
Parts of this chapter are driven from:
1. Joshi S, Kumar S, Bafna S, Rachagani S, Jain M, Wagner KU et al. GeneticallyEngineered Mucins Mouse Models for Inflammation and Cancer. Cancer Metastasis
Rev. 2015; 34(4): 593-609.

2. Joshi S, Kumar S, Choudhary A, Ponnusamy MP, Batra SK. Altered Mucins (MUC)
Trafficking in Benign and Malignant Conditions. Oncotarget. 2014; 5(17): 7272-84.
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CHAPTER IA: Regulation of Mucins by the microenvironmental stress of
pancreatic cancer microenvironment
1A.1 An outline of mucins

Mucins comprise a complex family of high molecular weight, membrane-bound or
secreted O-glycoproteins which are produced by glandular and ductal epithelial cells.
Mucins play critical roles in lubrication and protection of mucosa, renewal and
differentiation of the epithelia, cell adhesion, and cellular signaling (Figure 1.A.1) (3-5).
So far twenty one mucins have been recognized in human; out of them twelve are
attached to the cell membrane, whereas the others are secreted by the cells [1].
Multiple studies have shown the diverse and tissue-specific expression profile of
mucins. Nonetheless, a single tissue can express number of different mucins (Table
1A.1). Qualitative and quantitative alterations in mucins have been correlated with the
inflammatory, pre-neoplastic and neoplastic conditions (6-12). Studies have shown that
some of the membrane-spanning mucins could serve as cell-surface receptors and
facilitate signal transduction in response to external stimuli that lead to cell proliferation,
differentiation, apoptosis, migration, and invasion of cancer cells (Figure 1A.1) (3, 1318). Despite ongoing research efforts, the structure and function of various mucins and
mucin-mediated molecular mechanisms under normal and pathological conditions
remain poorly understood. Moreover, the awry molecular and cellular mechanisms
which lead to the aberrant expression and upregulation of various mucins under
different disease conditions have not been completely comprehended (19).
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Figures and Figure Legends

Figure 1A.1. Illustration of the various physiological outcomes of aberrant mucin
expression under

normal and pathological

conditions:

A)

Under

normal

physiological condition, mucins provide lubrication and protection to the epithelial
surface by providing a physical barrier from a hostile environment. Mucins shield the
epithelium against the action of various pathogens (

), enzymes, gastric and bile

acids.(20). Mucins are involved in the cellular differentiation of epithelial and immune
cells. The expression of mucins in BM progenitors and mature immune cells are involved
in hematopoiesis. B) Under pathological conditions, mucins are aberrantly expressed
and undergo differential post-translational modifications. The mucous layer sequesters
many molecules involved in inflammation, cellular migration and healing processes [1].
Mucins help transformed cells to avoid immune surveillance by masking epitopes of
tumor antigens on the cell surface. Loss of apical-basolateral polarity allows interaction
between membrane bound mucins (MBMs) and growth factor receptors such as receptor
tyrosine kinases ( ), leading to sustained proliferative signaling cascades. Furthermore,
the overexpression of mucins promotes cells motility, invasiveness and induces
resistance to chemotherapeutic agents. Interestingly, the aberrant expression of
secretory mucins (SMs) occasionally facilitates pathogenic infection, though the exact
mechanism is still not understood.
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Figure 1A.1
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Drug resistance
MAPK
Activation

Table 1A.1 Specific expression patterns of different mucins in the human body

Mucin
MUC1
MUC2
MUC3

MUC4

MUC5

MUC6
MUC7
MUC8
MUC10

MUC11
MUC12
MUC13
MUC15
MUC16
MUC17
MUC19
MUC20
MUC21

Normal Expression Pattern (3, 5, 12, 21)
Expressed in the epithelial surfaces of the respiratory, female
reproductive and gastrointestinal tracts as well as in the middle
ear, salivary and mammary glands.
Expressed in the intestinal and colonic goblet cells.
MUC3 is the product of two genes, MUC3A and MUC3B that are
both present in the gastrointestinal epithelium.
Mainly expressed by the epithelial surfaces of the eye, oral cavity,
middle ear, lachrymal glands, salivary glands, mammary gland,
prostate gland, stomach, colon, lung, trachea, and female
reproductive tract.
MUC5 is the product of two genes, MUC5AC and MUC5B.
MUC5AC is primarily expressed in the tracheobronchial goblet
cells and in the gastric epithelial cells, whereas MUC5B is present
in the salivary, tracheobronchial and esophageal mucous glands
as well as in the pancreatobiliary and endocervical epithelial cells.
Detected in the gastric and duodenal mucous glands,
pancreatobiliary and endocervical epithelial cells.
Expressed in the oral cavity epithelial cells, minor salivary gland,
and possibly in the respiratory tract. Its expression is also
detected in the pancreas and bladder.
Expressed in the airway and middle ear epithelial cells and male
and female reproductive tracts.
The expression pattern of MUC10 has not been determined to
date.
The MUC11 sequence is part of the very large VNTR domain of
MUC12 and may represent a differential splice variant, which is
normally expressed in the colon and stomach. Its expression has
also been shown in the middle ear and lung epithelium.
Normally expressed by the stomach and colon.
Highly expressed in the epithelium of the gastrointestinal and
respiratory tracts.
Expressed in the lung, mammary gland, hematopoietic tissues,
gonads, and gastrointestinal tract.
Expressed in the ocular surface, respiratory tract, and female
reproductive tract epithelia.
Expressed in the gastrointestinal tract with the highest expression
in the duodenum and conjunctival epithelium.
Mainly expressed in the mucosal cells of major salivary glands
and the epithelial cells from corneal, conjunctival, lacrimal gland,
middle ear and trachea.
Highly expressed in the kidneys and moderately in the placenta,
colon, lung, prostate, and liver.
It is a novel transmembrane mucin and normally expressed in the
lung, large intestine, thymus, and testis.
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1A.2 Types of mucins

Mucins consist of multiple domains (Figure 1A.2): Sperm protein enterokinase, and the
agrin (SEA) domain involved in protein interactions; epidermal growth factor (EGF)-like
domain that can act as a ligand; cysteine-rich dimerization or D domain (including D1,
D2, D', D3 similar to vWD domains) for oligomerization; variable number of tandem
repeats (VNTR or TRs) rich in serine (Ser), threonine (Thr), proline (Pro) (collectively
known as S/T/P) for O-linked glycosylation; the hydrophobic transmembrane (TM)
domain for cell surface localization and cytoplasmic tail (CT) to facilitate signal
transduction (22, 23).
1A.2.1 Membrane-bound mucins
Muc1 was the first murine mucin gene identified and characterized (24). The human
MUC1 gene and its murine ortholog is 87% identical in the non-TR domains and 74% in
the promoter regions. The VNTR region of human MUC1 consists of 20 amino acid
repeats, while that of mouse Muc1 has 20 to 21 amino acids each (25). The maximum
similarity between Muc1 and MUC1 exist in their TM and cytoplasmic domains. The
tissue-specific expression pattern of the mouse Muc1 is also very similar to that of its
human counterpart (Table 1A.2). Similarities in the sequence and expression pattern of
human MUC1 and murine Muc1 are indicative of their similarities in function(s),
interacting partners, mode of internalization, sub-cellular localization and routing to the
plasma membrane during their recycling or after their synthesis.

Muc4, like its human ortholog, is encoded by 25 exons (26). It consists of at least
20 TRs of 124-126 amino acids each, whereas human MUC4 has 146-500 repeats of 16
amino acid residues. The Ser/Thr region located upstream of TRs in murine Muc4 is
significantly different and much smaller in size (63 amino acids) as compared to human
sequence (951 amino acids) (26). Interestingly, 12 potential N-glycosylation sites, which
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are downstream of TR region, are perfectly conserved in Muc4 and MUC4 and both
orthologs exhibit similar expression patterns (26).

Two large exons of mouse Muc16 at the N terminal region have sequence
homology to exons 1 and 3 of human MUC16. Murine Muc16 possesses only one SEA
domain in its extracellular (EC) region, whereas the number of SEA domains in the EC
region of human MUC16 goes upto 60. Muc16 also shares the similar characteristic
repeat structure of human MUC16 along with 66% homology in their C-terminus (27).
The overall expression pattern of Muc16 and MUC16 is similar (Table 1A.2). Both of
them are expressed by the ovarian surface epithelial cells, though their cellular
localization is different. Human MUC16 is present on the cell surface and soluble fraction
due to its shedding from the cell membrane, whereas murine Muc16 has shown to be
secreted by MOVCAR ovarian cells (28).

Other membrane-bound murine mucins including Muc13, Muc15, Muc3, Muc20,
and Muc21 are either partially characterized or have not been characterized yet. The Cterminus of Muc13 shows 52% identity to the human MUC13 ortholog. However, the Nterminus of the Muc13 mucins domain shows a significant divergence from the human
MUC13, as the murine form has a nearly perfect repeat structure in contrast to the
human form which retains many degenerate repeats (29, 30). The carboxyl terminal of
MUC17 was found to be 59.6% similar to murine Muc3, while there is only 46.4% amino
acid sequence similarity between murine and human MUC3. MUC17 has 52% similarity
with the first EGF domain and 63.5% similarity with the second EGF domain of Muc3.
Altogether, there is greater similarity between Muc3 and MUC17 compared to Muc3 and
MUC3, suggesting that MUC17 is the ortholog of Muc3 (31). Comparison of the amino
acid sequences of human and mouse Muc20 showed 48% overall similarity (32). Both
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mucins comprise several hydrophobic domains and three mucin-like repeats of 18 amino
acid residues in their N-terminal regions, and are expressed predominantly in kidney.

1A.2.2 Gel-forming mucins

Gel-forming mucins are the main components of mucus and consist of multiple
“cysteine-rich” vWF C and vWF D domains in the flanking region of the mucin-like
Thr/Ser-rich repeats and C-terminal cystine knot-like domain (CTCK) (33), which allow
them to oligomerize by forming intermolecular disulfide bonds. Currently, five gel-forming
murine mucins have been recognized; Muc2, Muc5ac, Muc5b, Muc6 and Muc19.
Interestingly, four of these genes (Muc2, Muc5ac, Muc5b and Muc6) are clustered on
chromosome 7F5 (34), a region that exhibits synteny with the human chromosome
11p15 (35). The order of clustering of secretory mucin genes is Muc6–Muc2–Muc5ac–
Muc5b, which is conserved in both human and mouse (35).

Muc2 forms the basic framework for the formation of an intra-luminal mucus gel
of various gastrointestinal (GI) organs (36). Apart from their 75% homology at the Nterminus, mouse and human MUC2 promoter regions also exhibit a strong sequence
similarity which might subject them to similar transcriptional regulation (37). Muc2, like its
human counterpart, is predominantly expressed in the colon, to a lesser extent in the
small intestine and undetectable in the stomach (38).

The TR of Muc5ac contains a 16 amino acid sequence, whereas the human
MUC5AC has only 8 amino acid residues per repeat (25, 39). The TR domain of Muc5ac
is followed by a 133 amino acid cysteine-rich non-repetitive region (CRRI), a 63-residue
non-repetitive Ser/Thr-rich domain and a second cysteine rich region (CRRII) which
share around 81% and 76% similarity, respectively (40). Despite the lack of sequence
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similarity between the TR units of the murine and human MUC5AC, their non-repetitive
regions are nearly identical.

Alignment of the Muc5b gene with its human orthologue indicated few common
features. Overall, there is 43% identity between the murine Muc5b and human MUC5B
which is predominantly contributed by N- and C-terminal regions which are 64% and
62% similar, respectively (41). However, the expression pattern of Muc5b does not
match the human MUC5B as the murine form is principally expressed in the laryngeal
mucous glands and at a low level in the stomach and duodenum, whereas the MUC5B
gene is expressed in many tissues including the airway, gall bladder, and tongue (41).

The mouse Muc19 gene is located on chromosome 15, which is homologous to
human MUC19 on chromosome 12 (33). Like other gel-forming mucins, Muc19 also has
vWD, vWC and CTCK domains (33). Paired analysis of mouse Muc19 and human
MUC19 has shown 27% homology (42), mainly at the C-terminus and the putative Nterminus of the peptide sequences, whereas the central repetitive regions did not show
any homology (33). Similar to the human MUC19, Muc19 is predominantly expressed in
the salivary glands.

The murine Muc6 is composed of 33 exons and comparative analysis suggested
that the human and mouse Muc6 lack both the cysteine-rich domains and the cysteinerich subdomains which are frequently found in the S/T/P-rich regions of other human and
mouse secretory mucins (MUC2, 5AC, and 5B). The absence of these cysteine-rich
domains and sub-domains possibly make them resistant to proteolytic degradation (43)
and could be the reason for their high expression in the stomach in both humans and
mice. In addition to the stomach, murine Muc6 also exhibits high expression in the
duodenum, whereas it is expressed at low levels in the salivary glands (34).
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Figure 1A.2. Representation of the prototype structure of mucins along with the
characterized and putative roles of their functional domains: MBMs and SMs have
a TR domain with variable numbers and lengths of the repeats. They are predominantly
get O-glycosylated and separated by unique sequences. They also have few Nglycosylation sites with varying localization with different mucins. Most of the MBMs
possess SEA domains with a potential cleavage site (G/SVVV), except MUC4 where
GDPH (also present in MUC2 and MUC5ac secretory mucins) is considered to be a
putative site for cleavage. Mucins have varying lengths of cytoplasmic tails, (MUC4 CT is
shortest with 22 amino acids) which are believed to facilitate signal transduction due to
the presence of potential phosphorylation sites such as Ser, Thr and Tyr residues. Other
domains present in mucins include EGF-like motifs, nidogen and adhesion-associated
NIDO and AMOP, and vWD domains. SMs are rich in cys-rich domains (D1, D2, D3 and
D4), which are similar to the D domains of the vWD factor and flank the TR region.
These domains are important for disulfide cross-linking to allow oligomerization between
the mucin molecules required for gel-forming network.
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Figure 1A.2
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Table 1A.2. Different human mucin homologues of mice and their genomic
localization

Type

Chromosomal
Location in Human

Mouse
Homologue
of Human

Chromosomal
Location in
Mice

MUC1

TM

1q21

Muc1

3F1

MUC2

Gel

11p15

Muc2

7F5

MUC3A

TM

7q22

MUC3B

TM

7q22

Muc3*

5G2

MUC4

TM

3q29

Muc4

16B3

MUC5AC

Gel

11p15

Muc5ac

7F5

MUC5B

Gel

11p15

Muc5b

7F5

MUC6

Gel

11p15.5 - p15.4

Muc6

7F5

MUC7

Soluble

4q13–q21

Muc7

NP

MUC8

Gel

12q24.3

Muc8

NP

MUC10

NP

NP

Muc10

5qE1+

MUC11

TM

7q22

Muc11

NP

MUC12

TM

7q22

Muc12

NP

MUC13

TM

3q13.3

Muc13

16B3

MUC15

TM

11p14.3

Muc15

2E3

MUC16

TM

19p13.2

Muc16

9A3

MUC17

TM

7q22

Muc3*

5G2

MUC19

Gel

12q12

Muc19

15E3

MUC20

TM

3q29

Muc20

16B3

MUC21

TM

6p21

Muc21

17B1

Human
Mucins

Abbreviations: TM, transmembrane; NP, Not present

(* Muc3 is 46.4% and 59.6% similar to human MUC3 and MUC17, respectively [36,
37]. Therefore, murine Muc3 is considered as true ortholog of human MUC17)
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1A.3 MUC4 and its genomic structure
In our laboratory, we have extensively studied human MUC4. The first partial cDNA of
MUC4 was obtained from a human tracheobronchial library (44), where it was found to
be localized on chromosome 3q29 (45). The 5′-region of the MUC4 gene is
characterized by an extremely lengthy exon-2 which is mainly comprised of 48bp minimal unit repeated in tandem and encodes for a large Ser/Thr-rich domain (46).
The tandem repeat could vary from 7 to 19 kb and gives rise to variable number of
tandem repeat polymorphism (46). On the other hand, the 3′-end region of MUC4 is
primarily made up of two EGF-like domains, a transmembrane domain, and a short
cytoplasmic tail (47). Due to the presence of 26 exons having number of repetitive
sequences, MUC4 extensively generates many splice variants which give rise to a family
of putative secreted and membrane-associated MUC4 isoforms.
In situ hybridization studies have detected MUC4 expression on various normal
tissues such as trachea, lung, stomach, colon, uterus, and prostate, whereas normal
pancreas, gall bladder, biliary epithelial cells, liver, or intrahepatic bile ducts were
negative for MUC4 expression (48-50). MUC4 expression appears very early during the
development of the primitive gut (6.5 weeks of gestation) (51). Expression of MUC4 has
shown to be developmentally regulated in the pulmonary and GI segments, and was
associated with cell and tissue differentiation. Remarkably, aberrant expression of MUC4
has been noticed in multiple human epithelial cancers such as lung and pancreatic
carcinomas (5, 52). Silencing of MUC4 expression led to noticeable decrease in the
proliferation, migration and chemo-resistance of PC cells, points out an important role for
MUC4 in human tumor biology (18). Therefore, understanding of the underlying
molecular mechanisms responsible for the dysregulation of MUC4 is necessary to
understand its precise role and contribution during carcinogenesis. Studies have
highlighted the importance of soluble and insoluble factors in the regulation of MUC4
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expression. For instance, Gollub et al. have shown that MUC4 expression is induced at
the transcriptional level upon estrogen and dexamethasone treatment in the endometrial
Ishikawa epithelial cell line. RA and all-trans-RA have also showed to induce MUC4 at
the transcriptional level in PC cell lines (53). However, the exact reason that leads to an
aberrant expression of MUC4 in pancreatic ductal adenocarcinoma (PDAC) is still
unknown.
Earlier studies have revealed that rat Muc4 has a TATA less promoter with 2.4 kb
of size (54, 55). On the other hand, functional studies of the 5′-flanking region of MUC4
in human PC cells have demonstrated that MUC4 transcription is regulated by two
regulatory regions (−219/−145 and −2781/−2572) (55). This led to the characterization of
a classical TATA box flanked by an extremely long 5′-UTR which is generally referred as
a distal promoter, and the 3′-end of the 5′-UTR is characterized by a GC-rich region that
serves as a second transcription unit and generally called as proximal promoter (56).
Due to the presence of two promoters with numerous binding sites for transcription
factors which gets activated in response to growth factor stimulation, MUC4 regulation is
somewhat complicated.
1A.4 PC microenvironment
The tumor microenvironment is the environment at the cellular and acellular level in
which cancer cells either interact with each other (homotypic interactions), different cell
types (heterotypic interactions) and with the extracellular matrix (ECM) (57). This
interaction is highly critical for the sustained tumor development and growth. Under
normal and healthy conditions, extracellular signals play a critical role by tightly
regulating the growth and differentiation programs of epithelial cells. However, defects in
such signaling pathways may circumvent the normal pathway of epithelial differentiation
and drives the cells towards malignant transformation (57, 58). As repeatedly mentioned
in multiple scientific reports, the PC microenvironment is extremely complex and
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consists of components of the ECM, connective tissues, stromal cells, and polypeptide
growth factors. The ECM itself is composed of complex components of fibronectins,
laminins,

collagens,

glycoaminoglycans

and

proteoglycans

(59).

In

this

microenvironment, epithelial cancer cells do not only interact with each other, but also
interact with mesenchymal cells (which includes, cancer associated fibroblasts and
stellate cells) and the ECM. These interactions are quite specific. Cell-cell interactions
are mediated by specific cell-cell adhesion molecules, while cell-matrix interactions are
mediated by specific integrin receptors for each of the major components of the ECM. It
has long been recognized that changes in the microenvironment accompany the
transformation process. This is often indicated by increased activation of cancer
associated fibroblasts (CAFs) and pancreatic stellate cells (PaSCs), which in turn is
accompanied by increased proliferation, aberrant expression or overexpression of
proteins, increased migration and extensive ECM remodeling, particularly in areas where
cancer cells are found. The tumor stroma, in many aspects, resembles the processes of
wound healing and inflammatory response.
Despite of the presence of tremendous amount of literature regarding cellular
and acellular component of PC tumor microenvironment, there are limited studies which
has extensively concentrated to link microenviromental stress, such as hypoxia, serum
starvation and oxidative stress, with PC aggressiveness. Increasing evidence strongly
emphasizes that hypoxia exerts profound impact on the development and advancement
of the tumor microenvironment which in turn controls the differentiation of tumor and
stromal cells (60). In detail, tumor cells and their microenvironment reciprocally regulate
each other. In the following chapters and section, I am going to present the background
information in pertinent to the following chapters where I have elucidated the novel
regulatory mechanisms which are involved in the aberrant overexpression of MUC4
mucin.
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1A.5 Hypoxia in PC
Under cancerous condition, imbalance between cellular supply and consumption of
oxygen leads to depletion of oxygen (O2), a condition known as hypoxia (61). Ambient
air is approximately 21% O2 (or 150 mmHg), however, most human organs are exposed
to 2% to 9% of O2 (average, 40 mmHg) (62) . The levels of oxygen varies among
organs, however, most experimental studies consider ≤ 2% O2 as hypoxia (62). Hypoxia
has been acknowledged as one of the distinctive and common feature observed for
locally advanced solid cancers (63). In multiple cancer models, hypoxia has been
associated with poor clinical outcomes; including, cancer cell invasion and metastasis. In
order to adjust with the hypoxic microenvironment, tumor cells have to alter the
expression of multiple genes, which encodes for metabolic enzymes, vasoactive, and
proangiogenic molecules and so on. Tumor hypoxia activates multiple signal
transduction pathways, which produce significant impact on the tumor biology by
promoting metastasis, angiogenesis and tumor progression (64, 65).
Koong and colleagues were the first one who demonstrated that PC are
notoriously hypoxic in nature, where they directly measured intratumoral O2 levels in
patients undergoing a Whipple procedure (n=7) (66). It was revealed that areas of
pancreatic carcinoma had a median pO2 level of 0–5.3 mmHg. Contrarily, tumor adjacent
areas consisting normal pancreatic tissue had median tissue pO2 levels of 24–92.7
mmHg (66). Such momentous reduced tissue oxygenation has also been noticed in
chronic pancreatitis, a condition that usually co-exists in PC patients (67). This is already
known that pancreatic tumors are highly resistant to common therapies (68, 69). It could
be attributed to the presence of low oxygenation and the extraordinary ability of PC cells
to withstand and grow aggressively in highly stressed microenvironment (5, 70). These
reasons are further supported by the studies which have directly associated hypoxic
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tumor regions with the resistance against chemo- and radiation therapy, both of which
are clinical hallmarks of human PC (71, 72). Besides therapy resistance, recent studies
have implicated tumor hypoxia with a variety of growth-modulating effects including
tumor metastasis. Altogether, hypoxia, a condition when cancer cells are deprived of
oxygen, has profound effect on its overall growth, development and therapy resistance.
1A.6 Hypoxia inducible factors (HIFs) in PC
A crucial component required for the induction of hypoxia-regulated genes is the hypoxia
inducible factor-1 (HIF-1) complex, which is composed of HIF-1α and HIF-1β subunits
(73, 74). The HIF-1β subunit (also known as aryl hydrocarbon nuclear translocator,
ARNT) is constitutively expressed, whereas the HIF-1α subunit is accumulated only
under hypoxic exposure by evading proteasome-mediated degradation (74). Under
hypoxic conditions, the active HIF-1α/β heterodimer is translocated to the nucleus and
binds to a specific cis-acting regulatory sequence referred to as the hypoxia response
element (HRE) in target genes, which leads to transcriptional activation of their target
genes. HIF-1α serves as a master regulator of several hypoxia-inducible genes,
including vascular endothelial growth factor (VEGF), glucose transporter-1 (Glut-1) and
survivin (75). VEGF plays a central role in the tumor neo-angiogenesis which is a crucial
step in tumor growth and progression. Glut-1 mediates cellular glucose uptake, and thus
facilitates anaerobic glycolysis, a prerequisite for cancer cell proliferation under hypoxic
microenvironment. Survivin, a member of the apoptosis inhibitor protein family, is
uniquely expressed in various kinds of human malignances but not in normal adult cells
and its over-expression in cancerous condition has been associated with reduced cell
death (75). In PDAC condition, immunohistochemistry performed in 58 PDACs and 20
normal pancreatic tissue samples by Sun HC et al, have clearly demonstrated
expression of HIF-1α, VEGF, Glut-1 and survivin in 70.7%, 77.6%, 67.2% and 84.5% of
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the patients with PDACs, respectively, which is substantially higher than in the normal
controls (75).
Under chronic hypoxia, stabilized HIF-1 complex binds to HRE2 in 5'flanking
region of miR-191 in PC cells, which is followed by increased transcription of miR-191
(76). Expression of miR-191 was significantly higher in pancreatic tumor tissues,
compared to normal pancreas (76). The overexpression of miR-191 was associated with
increased tumor size, pTNM stage, lymph node metastasis, perineural invasion and poor
prognosis of the disease (76). Similar to miR-191, increased HIF-1α expression also
indicates increased lymph node metastasis and a tendency of larger tumor size as well
as advanced TNM stage, irrespective of its expression pattern (75). Multiple studies
have shown that 50-70% of the investigated PDA samples have positive staining for HIF1α molecule. HIF-1α expression has shown primarily two patterns depending upon the
underlying source. For example, lack of oxygen leads to necrosis where HIF-1α exhibits
prominent focal positive staining, whereas in an oxygen-independent pathway, HIF-1α
has strong diffused nuclear and/or cytoplasm staining in the tumor cells (75).
Due to the implicated role of HIF-1 in increasing the expression of genes required
for increased tumor growth and metastasis, disruption of the HIF-1 pathway could be an
effective strategy to treat PC. In a study by Chen et al, it has been demonstrated that
expression of dominant-negative HIF-1α in PC cells leads to reduction in tumorigenicity
due to interruption of glucose metabolism, which made cancer cells sensitive to
apoptosis and growth inhibition upon hypoxic condition (77). Taken together, it can be
concluded that PC patients may noticeably receive clinical advantage from treatments
targeting HIF-1α, and a routine assessment of these proteins by IHC may expand our
understanding into improved treatment after surgery.
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1A.7 Oxidative stress association with PC progression
Around 90% of PC patients have K-ras mutations, implying their critical role in
the molecular pathogenesis (78), which has been associated with ROS homeostasis
under cancer condition. Vaquero et al. have recently shown that ROS have pro-survival
and anti-apoptotic functions in PC (79). They showed that ROS generation by the
activation of nonmitochondrial NAD(P)H oxidase due to the stimulation of growth factors
facilitates survival of PC cells, whereas suppression of ROS production leads to PC cell
death. Therefore, the pro-survival effect of ROS may be an important mechanism which
is utilized by PC cells to evade therapy response. Further, Santillo et al. have shown that
in K-ras–transformed mouse fibroblasts, there is elevated ROS levels which leads to the
activation of signal transduction pathways (80). Not only k-ras, transfection of viral H-ras
oncogene in mouse fibroblasts also led to increased synthesis of superoxide (O2−),
where they execute their cell proliferating functions by plausibly acting as a second
messenger molecule. In addition to fibroblasts, ras-transformed keratinocytes also
demonstrated increased generation of O2-, and this augmented production was
effectively paused when an adenovirus construct containing the cDNA of the antioxidant
protein superoxide dismutase was expressed (81). Contrarily, most of the studies have
encouraged the usage and clinical testing of ROS-inducing small molecules for the
treatment of PC. For instance, in NAD(P)H:quinone oxidoreductase (NQO1)overexpressing pancreatic tumors, administration of ROS inducer β-lapachone leads to
significant cytotoxicity by tempering PARP, NAD+/ATP levels. It is subsequently followed
by increased single-stranded DNA breaks, and results in necrosis (82, 83). Another
small molecule pro-oxidant, imexon, which is an aziridine-derived iminopyrrolidone, has
shown to induce apoptosis in multiple PC cell lines by increasing ROS levels and
facilitating cell cycle arrest at G2 phase (84). Considering its effective anti-cancer
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properties, this drug has been used for phase I and II clinical studies for PC patients
(85).
In a recent study, Dhillon and colleagues have investigated the in vitro and in
vivo effects of the ROS-inducer piperlongumine (PPLGM) on PC cell death (86). PPLGM
is an bioactive alkaloid found in the fruits of long pepper plants and have potent growthinhibitory properties in a variety of cancer cell lines and animal models (86). Though it
exhibits cytotoxic effects on tumor cells, PPLGM is not at all toxic to its normal
counterparts. In this study, authors have evaluated the therapeutic potential of PPLGM
for PC treatment. Similar to other cancer types, PPLGM exhibited growth inhibitory
effects on PC cells by inducing ROS levels and generating DNA damage (86). The effect
of PPLGM was found to be ROS-dependent because its effect on cytotoxicity and DNA
damage was reversed, when PC cells were concomitantly treated with antioxidant.
These anticancer effects of PPLGM were confirmed in a xenograft mouse model of
human PC, where they observed significant reduction in tumor size. IHC analysis further
revealed that PPLGM-treated animals had reduced Ki-67 and increased 8-OHdG
expression. Taken together, it can be proposed that further studies evaluating the antitumor effects of ROS-inducer on normal and K-ras mutant pancreatic tumors in
combination with chemotherapy should be encouraged and executed.
1A.8 Autophagy status in PC condition
Autophagy

is

a

highly

regulated

destructive

cellular

mechanism

in

which

autophagosomes are fused with lysosomes that lyse or recycle the contents (87).
Therefore, this catabolic process provides building blocks for use within the cell and
dynamically control and maintain cell function. Particularly, stress conditions, such as
starvation, are known to induce autophagy which leads to energy redistribution to
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sustain cell survival; however, if the attempts to sustain viability are failed, autophagy
facilitates cell death. The dual role of autophagy is also applied to tumorigenesis
because it can serves both as a guardian for cancer initiation and as a stimulator for
cancer growth, by providing energy for advanced malignancies (88). For instance, loss
of Atg5 predisposes mice to develop benign liver adenomas; however, these lesions do
not headway to form malignant tumors (89). Supportively, upon lung specific
concomitant loss of Atg5 or Atg7 in conjunction with oncogenic Kras, mice developed
increased benign lesions (adenomas) which were again failed to progress to malignancy
(90, 91).
In PC, the role of autophagy has been examined by different research groups
and the results are quite interesting. Mukubou and colleagues have investigated the in
vivo and in vitro effects of gemcitabine and ionizing radiation (IR) upon modulation of
autophagy (92). Treatment with gemcitabine and/or IR had significant inhibitory effects
on cellular viability and tumor growth, but addition of autophagy inhibitors ostensibly
increased the dose requirement of gemcitabine in order to suppress cell viability,
suggesting that autophagy sensitize PC cells for gemcitabine-mediated cell death (92).
However, most of the available literature has associated autophagy with increased
survival, tumorigenicity and aggressiveness of PDAC. Yang and colleagues, for
instance, have suggested presence of constitutively instigated autophagic pathway in
PC neoplasm (93). They assessed the autophagic status using both static and flux
measurements in different cells. Upon comparison, it was revealed that all PDAC cell
lines showed a significant increase in autophagic activity as well as flux compared to
non-transformed pancreatic cells, breast and lung cancer cell lines (93). To directly
relate the induction of autophagy with the survival of PC cells, ATG5 was silenced using
targeted small interfering RNA (siRNA), which led to 50% reduction in the growth of
PDAC cell lines compared to the other cancer cell lines. Altogether, their results
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provided evidence that activation of autophagy is required for the maintenance of PDAC
(93). Further, clinicopathological study in a cohort of 71 resected PDAC patients
revealed an association between activated autophagy (high LC3 protein expression) and
poor outcome of PDAC patients (94).
Increased basal levels of autophagy has been observed in human cancer cell
lines bearing activating mutations in H-ras or K-ras, even in a nutrient abundant
microenvironment, suggesting that autophagy maintains tumor cell survival. Therefore,
by subduing the expression of proteins required for autophagy, the growth of cancer
cells was significantly suppressed, indicating that Ras-driven cancers are addicted to
autophagy, and blocking autophagy in such tumors could be an effective treatment
approach (95). Interestingly, xenografts obtained from PC patients who contain Kras
mutation were extraordinarily susceptible for the treatment of anti-autophagy based
therapies including, chloroquinone derivatives (96). In a recent report, Perera et al. have
gauged both autophagosomes and lysosomes using IHC and found them significantly
larger in PDAC cell lines than in controls (97, 98). Additionally, high resolution
transmission electron microscopy showed that not only the size, numbers of lysosomes
are also higher in PDAC samples than in normal pancreatic tissues. Mechanistically, the
authors have associated this increase with an elevated expression of genes involved in
lysosomal biogenesis (98). It is already known in the literature that MiT/TFE family of
transcription factors play important role in increased lysosome and autophagosome (99).
After melanoma and kidney cancer, PDAC had the third highest expression levels for
MiT/TFE factors; particularly TFE3, TFEB and MITF. Suppression of these MiT/TFE
factors in PDAC cells led to significant change in lysosomal morphology and
functionality. Particularly, metabolite profiling in TFE3 kd PC cells revealed a substantial
reduction in the cellular levels of amino acids and their breakdown products due to
impaired uptake of extracellular factors through macro-pinocytosis (98). In a parallel
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experiment, PDAC cells overexpressing TFE3 or MITF exhibited increased clonogenic
growth compared with controls when cultured in low amino acid, indicating that induction
of autophagy make PC cells to survive better under nutrient deprived conditions.
Moreover, MITF overexpression considerably increased the tumorigenicity of mouse
pancreatic epithelial cells expressing KRAS-G12D when orthotopically injected into
recipient mice.
The pro-survival role of autophagy in PDAC progression has been further
substantiated by using highly defined genetically engineered mouse models (GEMMs)
(100). For example, pancreas-specific depletion of Atg5 or Atg7 in the presence of
constitutively active Kras, significantly abrogated the progression of pre-malignant
lesions to invasive cancer; however, due to the embryonic homozygous p53 deletion in
the pancreas, these observation might not be physiologically relevant (100). Because
p53 alterations are mainly loss of heterozygous (LOH) in human PC condition, these
conclusions derived from p53 homozygous model might not be representative of human
tumors. Interestingly, Atg5 deletion impairs the progression of pre-malignant PanIN to
invasive PDAC in the setting of heterozygous deletion of p53 (101). Altogether, it led us
to conclude that in the physiological setting of p53 loss during tumor progression,
autophagy seems to be required for optimal development of PC. The intricate and highly
complexed relationship between autophagy and p53 is of great importance and required
further studies. To increase the clinical relevance of the study, authors did acute
inhibition of autophagy by chloroquinone (CQ)-treatment or RNAi approaches, and
observed significant growth inhibition of murine PDAC cell lines with various p53
alterations, which is quite consistent with the prior data using p53 harboring human
PDAC cell lines. Upon treating of patient derived PDAC xenografts that harbor p53
mutations with hydrochloroquinone (HCQ), significant attenuation in the growth was
observed (101). Taken together, majority of the evidence indicates that autophagy has
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oncopromoting functions in PDAC, which makes this process to look appealing as a
potential target in PC therapy and has prompted multiple anti-autophagy based ongoing
preclinical and clinical trials.
1A.9 Role of hypoxia in the regulation of autophagy
Previous reports have confirmed that hypoxia induces autophagy in a HIF-1α dependent
manner in both normal and cancer cell lines to promote cell survival, implying that HIF1α plays an important role in maintaining and regulating cell autophagy. However, the
underlying mechanism of hypoxia-induced autophagy has started to get unearthed by
recent studies. The activation of HIF-1α-dependent autophagy occurs via the induction
of Bcl-2 (B-cell lymphoma 2)/adenovirus E1B 19 kDa protein-interacting protein 3
(BNIP3), which has two HRE (HRE-1 and 2) sites on its promoter region. HIF-1 directly
binds to HRE2 site on BNIP3 promoter and leads to the transcriptional upregulation of
BNIP3 (102). Due to established role of BNIP3 in disrupting the autophagy inhibitory Bcl2: Beclin 1 complex, BNIP3 overexpression under hypoxia led to the release of BECN1,
which is now free to initiate autophagy by assembling a pre-autophagosomal structure
(103).
In addition to HIF-1 dependent pathways, there are HIF-1 independent pathways
as well, known to regulate autophagy under hypoxic condition. One of such pathway is
the regulation of the mammalian target of rapamycin (mTOR), which consists of two
specific mTOR complexes; mTORC1 and mTORC2. Their downstream effectors
orchestrate several biological processes, including autophagy. mTORC1 has been
associated with autophagy suppression by inhibiting ATG1 ser/thr protein kinase, which
is involved in the formation of autophagosomes (104). Under hypoxia, mTORC1
pathway is suppressed by cancer cells by utilizing multiple pathways; one of them is
mediated through hypoxic activation of the tuberous sclerosis protein (TSC) complex

24

(104). It is a heterodimeric complex formed by TSC1 and TSC2. Under nutrient deprived
conditions, there is an increase in AMP/ATP ratio, which is sensed by the heterodimeric
5′ AMP-activated protein kinase (AMPK) complex, which phosphorylates many
downstream targets, including TSC2 on serine residues positioned at 1270 and 1388
(104). Phosphorylation of these sites has inhibitory effect on the activity of the
TSC1/TSC2 complex. Due to the inactivation of the TSC1/TSC2 complex, Ras homolog
enriched in brain (RHEB)-dependent activation of mTOR is prevented. Activation of the
unfolded protein response (UPR), a program which leads to major transcriptional and
translational alteration due to endoplasmic reticulum (ER) stress with a goal to clear
misfolded proteins, is an additional HIF-1-independent pathway that activates autophagy
(105). There are mainly three ER stress sensors which facilitate UPR program: PKR-like
ER kinase (PERK), ER to nucleus signaling 1 (ERN1), and activating transcription factor
(ATF). Under hypoxic conditions, autophagy seems to be facilitated by PERK.
Phosphorylation of the eukaryotic translation initiation factor 2 alpha (elF2α) in a PERKdependent manner leads to the activation of ATF4 transcription factor which
subsequently induce the expression of MAP1LC3B and ATG5 at mRNA level (105).
1A.10 Role of oxidative stress in autophagy regulation in PC
Different stress signals or genetic alterations prompt ROS production leading to the
stimulation of autophagy, which regulates cell death or cell survival pathways. In a
classical paper by Scherz‐Shouval and colleagues, it has been clearly demonstrated that
during amino acid starvation, PtdIns3K class III-dependent generation of H2O2 by the
mitochondria, serves as a local signaling molecule to modulate the activity of the
cysteine protease Atg4 (106). In their in vitro studies, they have demonstrated that a
critical cysteine residue near the catalytic site of Atg4 undergo oxidative alteration, which
inhibits the activity of Atg4, and thus ensures the conjugation of Atg8 to the
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autophagosomal membrane (106). This could lead to a ROS-dependent accumulation of
LC3-PE on the autophagosomal membranes in close vicinity, thereby facilitating the first
steps in autophagosome formation.
Furthermore, autophagy regulation by intracellular ROS levels during starvation
has shown to involve p53-inducible protein TP53-induced glycolysis and apoptosis
regulator (TIGAR). TIGAR functions as a fructose- 2,6-bisphosphatase, and diverts
glycolytic metabolic intermediates to the oxidative branch of the hexose monophosphate
pathway, which led to increased cellular production of NADPH, and thereby, lowers
intracellular ROS levels and the sensitivity of cells to oxidative stress associated
apoptosis (107). Therefore, suppression of TIGAR expression increases the production
of ROS and autophagy in hepatocellular cancer cells, independent of mTOR- and p53,
However, induction of autophagy due to loss of TIGAR is considered to be cytoprotective
and reduces the apoptotic response by limiting oxidative stress (plausibly by the
degradation of ROS producing mitochondria) (108).
The redox-regulation by Akt-mTOR and AMPK signaling systems are other
critical mechanisms responsible for ROS-mediated induction of autophagy. ROS
production following growth factor-stimulation results in the inactivation of phosphatase
and tensin homologue (PTEN) through the formation of a disulfide bridge between a
cysteine in the catalytic site with a proximal cysteine residue. This PTEN inactivating
process leads to an increment in the levels of PtdIns(3,4,5)P3, which promotes the
activation of Akt, a well-known proto-oncogene (109). Furthermore, the selective
degradation of the H2O2 converting enzyme, catalase, by autophagy can provide an
auto-stimulatory feedback loop, while the autophagic degradation of mitochondria or
other ROS-producing organelles alleviates oxidative stress progression and acts as a
negative feedback loop (110). These results are also consistent with a model in which
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ROS act as signaling molecules upstream of autophagy, whereas the stimulation of
autophagy further limits ROS levels by removing ROS-generating mitochondrial
therapies.
1A.11 Regulation of mucins by hypoxia in cancer condition
Accumulating evidence suggests a number of physiological roles and regulatory
mechanisms for mucins; however, there are limited studies which have demonstrated
the effects of local microenvironment on mucins regulation. Studies have identified and
appreciated the involvement of HIF-1α regulated pathway in mucins regulation. The first
study came back in 1990s, where a molecular link between hypoxia and mucins
regulation was observed in intestinal epithelial cells. The hypoxia-dependent induction of
MUC3 signified a novel innate mechanism that may protect the immunologic
components of the lamina propria from exposure to various insults including, pathogenic
luminal bacteria, antigens, and toxins under oxygen deficient conditions (111). Of note,
HRE was not precisely mapped on MUC3 promoter, which could be due to the
complexity of the flanking region around the HIF-1 consensus sequence (111). Following
HIF-1 consensus site, the immediate region contains potential binding sites for the
transcription factors such as, c-rel, NFκB, glucocorticoid receptor, the estrogen receptor,
and CREB, where some of these transcription factors have been implicated in either
gene induction or repression under hypoxia. Therefore, MUC3 gene at this site is quite
complicated and might involve interplay between positive and negative regulatory
signals. Efforts to better understand MUC3 signaling pathways and to identify other
hypoxia-elicited protective elements could provide future focus for development of novel
treatments.
Polosukhin et al. demonstrated that hypoxia induces metaplasia in goblet cells
which is followed by increased gel-forming MUC5AC mucin expression in primary
human bronchial epithelial cell lines (112). Zhou et al validated the presence of HIF-1α
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transcription factor–binding sites (HREs) on the MUC5AC promoter region (113). The
expression and secretion of MUC5AC in human bronchial epithelial cells was found to
be significantly reduced when HIF-1α expression was inhibited using HIF-1α inhibitor
(YC-1) and HIF-1α small interfering RNA (siRNA).
Another transmembrane mucin, MUC17, has been reported to be overexpressed
in pancreatic ductal adenocarcinomas (PDAC) compared with its lack of expression in
normal pancreas or pancreatitis. Additionally, Hirono et al. also reported that MUC17 is
an independent prognostic factor associated with lymph node metastasis in PDAC (114).
MUC17 expression has also been found to be enhanced under hypoxic condition in a
HIF-1α dependent manner (115). Further investigations revealed that DNA methylation
of HRE is a key determinant of the hypoxic inducibility of MUC17 in PC (115). Clinically,
hypomethylation of HRE within the MUC17 promoter is a frequently occurring event in
the pancreatic tissues of patients with PDAC. In the future, the significance of these
findings in PC pathogenesis needs to be reconnoitered.
MUC1 is the most studied mucin in terms of hypoxia under cancerous condition.
The first study which showed the connection between MUC1 and hypoxia came in 2007,
where Yin et al. first related MUC1 expression with reduced ROS production which had
inhibitory effects on the activity of HIF-1α expression (116). According to the report,
MUC1 overexpression blocks hypoxia-induced apoptosis and necrosis by suppressing
accumulation of ROS, and therefore, MUC1 expression leads to better survival response
in response to hypoxic stress (116). The subsequent studies have related HIF-1
signaling mechanism in MUC1 upregulation, which is the main pathway involved in renal
carcinogenesis. Hypoxia-derived conditioned media (HCM) from MUC1 kd AsPC1 cells
demonstrated profound inhibitory effect on the migration and proliferation ability of
endothelial cells compared to hypoxia-treated control cells, suggesting the potential
involvement of MUC1 in the process of hypoxia-driven angiogenesis (117). Not only wt-
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MUC1, this study has also shown that hypoxia strongly induced the translocation of
MUC1-CT to the nucleus as well as HIF1α in AsPC1 cells, but not under normoxic
culture conditions. In another study, hypoxia-mediated induction of MUC1 has been
linked with increased glucose uptake and glycolysis by nutrient-deficient PC cells (118).
The physical interaction of MUC1 with HIF-1α and p300 in a hypoxia-dependent manner
is ensued by enhanced promoter occupancy of the HIF- 1α and p300 on glycolytic gene
promoters, which regulates the expression of multiple metabolic genes. This is further
supported by the observed positive correlation of MUC1 expression with the expression
of glucose metabolic enzymes such as GLUT1 and LDHA (118). Presence of MUC1 has
also been associated with enhanced stability by diminishing the levels of 2-oxoglutarate
in PC cells. Altogether, the interrelationship between MUC1–HIF-1α oncogenic signaling
networks serves to facilitate tumor growth and metastasis and could present a potential
therapeutic target for the treatment of malignant diseases that rely upon MUC1 and HIF1α.
In addition to PC and CRC, the association between HIF-1α and MUC1 is also
established in invasive ductal breast carcinoma (n=243). MUC1 overexpression was
observed in 37.0% of patients and it correlated positively with estrogen receptor
(p = 0.0001), progesterone receptor (p = 0.0001), HIF-1α (p = 0.006), VEGF (p = 0.024),
and p53 (p = 0.025) (119). Here, authors have also demonstrated that MUC1
overexpression leads to the increased degradation of inhibitor of NF-κB (IκBα). It
subsequently promotes the nuclear translocation of NF-κB which blocks apoptosis and
promotes cell survival (119). Moreover, it has been reported that MUC1 has the ability to
promote autophagy which provides a survival advantage in a low glucose-stressed
microenvironment by suppressing excessively generated ROS levels in colon cancer
condition.
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CHAPTER IB

Mucins Regulation by Bile acids (BA) in PC condition
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1B.1 An outline of Bile acids
Bile acids (BA) are amphiphilic molecules and are the main component of bile along with
cholesterol, phospholipids, and bilirubin (1). BA are derived from cholesterol and
synthesized primarily in the liver. They are initially synthesized as primary bile acids,
namely cholic acid (CA) and chenodeoxycholic acid (CDCA), but get conjugated with
glycine and taurine (2). Subsequently, these conjugated BA are excreted from the liver
into the gall bladder, at a concentration of approximately 100 mM, and remains stored,
until gall bladder receives stimulus (2). Dietary fat is a stimulus for BA secretion into the
intestine, and the primary function of BA is to facilitate digestion absorption of fats and
liposoluble vitamins in the intestine throughout the enterocyte barrier (1). It is the same
region, where approximately 95% of the BA are re-absorbed into ileal columnar
epithelium cells, by an active apical sodium-dependent BAs transporter ASBT (Apical
Sodium-Dependent Bile Acid transporter) (3). After uptake into enterocytes of the ileum,
bile salts are transported to the basolateral domains of the cells for efflux into the portal
circulation, and mined from portal blood plasma by liver cells. Liver does it job efficiently
and eliminate BA from the circulation; therefore, the circulatory BA levels in healthy
individuals are generally maintained at around 0.003 mM. The remaining unabsorbed
5% of BA pool enters to the colon, where it gets further metabolized by the anaerobic
bacterial species using two major and a number of minor reactions (4). The first major
reaction is the process of deconjugation which is followed by the release of free BA,
whereas the second major reaction is 7-α dihydroxylation, which converts CA and
CDCA to DCA and lithocholic acid (LCA), respectively (4). Although partially, DCA gets
reabsorbed in the colon and enters into enterohepatic circulation, where it undergoes
conjugation in the liver and secreted in the bile. On the other hand, very little amount of
LCA is reabsorbed in the colon which can be attributed to its fairly insoluble nature. As a
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result, the circulating BA pool (after undergoing both conjugation and deconjugation
process) contains about 30–40% each of CA and CDCA, and about 20–30% of DCA,
with less than 5% of LCA (5). Besides primary and secondary BA, bacterial degradation
in the colon and alterations in the liver produce tertiary BA, such as ursodeoxycholic
acid, which is also present in the circulating BA pool (6). It has been noticed that people
on a high fat diet have substantially elevated levels of both DCA and LCA, in the fecal
water. Before delivery, BA levels are maximally present in the gallbladder, but after their
delivery towards small intestine, their maximum levels are present near the Ampulla of
Vater than any other region of the body.
1B.2 BA under cancer condition
The first evidence demonstrating the involvement of BA in cancer development
came from Cook et al. in 1940, where authors have clearly shown the induction of
malignant tumors when DCA was injected into the right flank of mice. In another model,
administration of CDCA to APC (Min/+) mice model has shown to increase number of
duodenal tumors (7). Administration of BA alone did not lead to the formation of cancer
in both mice and rat, but their treatment along with carcinogens has shown to
significantly promote colon carcinogenesis (8).
Using multiple experimental models of rodents, particularly between 1974 and
1993, different types of BA have shown to exert their tumor-promoting functions.
Administration of BA alone was failed to induce colon tumors. However, administration of
LCA, taurine conjugated and unconjugated DCA had a significant promoting impact on
colon carcinogenesis in rat after intrarectal instillation of N-methyl-N′-nitro-Nnitrosoguanidine (MNNG), which is a well-known mutagen (8). Similarly, CA also had a
promoting effect on colon tumor formation in rats after intrarectal instillation of N-methyl44

N-nitrosourea (MNU) or sub-cutaneous injection of azoxymethane (9). In addition to
colon, BA shown enhanced hyperplastic and neoplastic lesions in stomach mucosa,
when administered in the presence of MNNG (10). Therefore, BA is considered as
tumor-promoters. However, in spite of all these experimental models and related
literature, considerable indirect evidence and logical argument supports the view that BA
are carcinogens in humans. The GI tract of rodents and humans are exposed to BA for
different duration of time. Most of the discussed experiments establishing the tumor
promoting roles of BA were conducted for one year or less. However, most of the GI
cancers in humans are primarily developed at around 60 years of age. Additionally,
colonic epithelium renews themselves around 365 times during the lifespan of mice and
rats and 5110 times in human. Due to DNA damaging or mutation inducing ability of BA,
sustained exposure of BA to human colonic epithelium could have tumor initiating
actions.
In addition to colon cancer, significant amount of literature has made it apparent
that BA is also important in other gastrointestinal (GI) cancers (11). High or abnormal BA
exposure is associated with increased incidence of cancer in the laryngopharyngeal
tract, esophagus, stomach, pancreas, the small intestine (near the Ampulla of Vater) and
the colon. As the local microenvironment (both cellular and acellular) varies from one GI
organ to another, it can be speculated that both the extent of effect and the underlying
mechanism involved upon BA exposure, could be different at different organs.
The involvement of BA in the progression from Barrett's esophagus (BE) to
esophageal cancers, which is the seventh leading cause of cancer-related death
worldwide, is well established. Patients with BE disease have an estimated 30–125 fold
increased risk of developing esophageal cancers (12). BE disease occurs during healing
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of esophageal mucosal injury typically triggered by gastro-esophageal reflux diseases
(GERD), in which the exposure of esophagus is significantly increased to acidity from
stomach and to BA from duodenum. Using surgical models, several studies have shown
that GERD development is indeed result in esophageal adenocarcinoma (EA)
development without exogenous carcinogen. Furthermore, feeding mice with zinc
deficient diet containing DCA led to increased production of ROS with the visible
appearance of BE-like lesions (13). Moreover, BA induces expression of inflammatory
mediators (e.g. Interleukin-8 (IL-8), cyclo-oxygenase (COX-2), oxidative stress and DNA
damage that could be linked to mutational events over a longer period (14), to
development of resistant apoptotic cells, and ultimately cancer. However, the exact
molecular pathways involved remain unclear. Few studies have investigated the
implication of BA receptors in the development of BE disease and adenocarcinoma.
Several lines of evidence have implicated BA in liver tumorigenesis. Rodent
models showed prominent appearance of preneoplastic lesions of hepatocellular
carcinoma upon exogenous administration of DCA. Diet enriched with 0.2% CA has
shown to intensely enhance N-nitrosodiethylamine-initiated liver carcinogenesis in WTmice (15). In addition, children with progressive familial intrahepatic cholestasis type 2
(PFIC type 2), which is genetic deficiency of the canalicular bile salt export pump BSEP
or ABCB11, are known to be predisposed to hepatocellular carcinoma (HCC). Similar to
colon cancer, in vitro studies have indicated that BAs may directly affect hepatocytes by
inducing ROS production which is followed by DNA damage and apoptosis. For
example, hydrophobic BAs like DCA, glucuro-CDCA or tauro-CDCA have been reported
to produce ROS in rat hepatocytes, human hepatoma cell line or primary human
hepatocytes. Treatment of human hepatocarcinoma cells with DCA leads to the
transcription of genes that participates in oxidative stress (NF-κB, c-fos) or DNA damage
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(gadd153, c-fos). Moreover, several studies have also shown that BA induce apoptosis
in liver cells, which can be reduced by an anti-oxidant treatment like α-tocopherol or βcarotene, suggesting that increased ROS production due to BA exposure is responsible
for this cell death event. Even though we know that BA has carcinogenic potential in the
pathogenesis of liver cancer, the defined mechanisms by which they act is not known
and involvement of their receptors FXRα and TGR5 are poorly understood.
1B.3 BA receptors and their role in cancer
In addition to their mechanical role, BAs have been described as signaling molecules
binding receptors. So far, four receptors, namely nuclear receptor farnesyl-X-receptor
(FXRα, NR1H4), vitamin D receptor (VDR), G-protein-coupled receptor TGR5 (GPBAR1,
G-protein-coupled bile acid receptor) and pregnane X receptor (PXR)/steroid xenobiotic
receptor (SXR), have been recognized to bind to BA and perform tumorigenic functions.
FXR is present in high levels in liver, intestine, or kidney and it belongs to nuclear
receptor superfamily. It acts as a mandatory heterodimer with retinoid X receptor (RXR)
and binds to specific IR1 (inverted repeat-1) sequences on target gene promoters to
regulate gene transcription. Using Fxrα gene (Fxrα−/−) mouse model, its involvement in
regulating BAs biosynthesis and entero-hepatic cycle was highlighted. Fxrα−/− mice
revealed high BA plasma levels due to abnormal hepatic biosynthesis, as FXRα
represses the gene expression of cholesterol 7α-hydroxylase (CYP7A1) and sterol 12αhydroxylase (CYP8B1), key enzymes involved in BA biosynthesis (16). This is how
FXRα limits the deleterious effects of accumulated BA. In hepatocytes, FXRα decreases
BA uptake via repression of Na+-taurocholate co-transporting polypeptide (NTCP),
organic anion-transporting polypeptide (OATP)-1 and OATP-4 expressions. It also
promotes BA excretion in bile ducts through transcriptional induction of the specific BA
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transporter BSEP (Bile salt export pump) in hepatocytes. Due to the involvement of FXR
on BA homeostasis, significant upregulation was observed for the genes implicated in
inflammation and cell cycle in aging FXR−/− mice, whereas WT control mice did not
exhibit such effects. FXR-/- mice showed liver tumor formation between 13 and 15
months of age, whereas WT mice did not have any tumor formation (15). Interestingly,
feeding mice with 2% cholestyramine, a bile acid–sequestering resin, to lower BA pool in
FXR−/− mice had significant negative impact on the formation of malignant lesions,
establishing the causal relationship between BA and liver tumors (15).
The involvement of FXRα in BE disease and adenocarcinoma development has
been elucidated by several studies. In patients with BE disease, FXRα overexpressed in
both esophageal squamous epithelium and specialized intestinal BE cells, while almost
no FXRα was found in healthy squamous epithelium, whereas advanced EA patients
exhibited loss of FXRα expression (17, 18). FXR expression has shown to be reduced
remarkably in intestinal tumors developed both in human and mice models. Using two
mouse models of intestinal tumorigenesis results, it has been demonstrated that loss of
FXR is related with early death and increased size of small intestine adenocarcinomas,
indicating that loss of FXR and not merely elevated BA concentrations increases
susceptibility to tumorigenesis (19). In the absence of FXR, enhanced Wnt signaling is
observed which is attributed to increased infiltrating immune cells (neutrophils) and
cytokines (TNFα) production. It is also accompanied with an increased basal proliferative
compartment both in the ileal portion of small intestine and colon along with
simultaneous decrease in the apically localized differentiated compartment. This
scenario leads to increased progression of colon tumors along with early mortality in
utilized mice model (20). On the other hand, when FXR is activated in the differentiated
normal enterocytes and in colon cancer cells, there is an induction of apoptosis and
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removal of genetically altered cells, which may otherwise progress to complete
transformation (20). Thus, from a therapeutic standpoint, strategies aimed at reactivating
FXR expression in colon tumors might be useful in the treatment of colon cancer.
The first established G-protein coupled receptor specific for BA binding is TGR5
(21). TGR5 expresses ubiquitously both in humans and animals, and it is known to
activate multiple intracellular signaling cascades upon binding to BA (22). TRG5
activation has well established functions in the maintenance of metabolic homeostasis
and energy expenditure. IHC study has shown that TGR5 protein expression is present
throughout the GI tract (22). Unlike FXRα, significantly high levels of TGR5 was
observed both at mRNA and protein levels in human EA compared to normal
esophageal mucosa or Barrett's mucosa (23), suggesting that it might play a central role
in adenocarcinoma development. Additionally, TGR5 was established as a mediator of
ROS generation, which leads to increased proliferation of esophageal cancer cells upon
exposure to BA. Thus, TGR5 activity could be involved in the evolution of Barrett's
syndrome to adenocarcinoma (23). Additionally, prominent staining for TGR5 has been
observed in 12% of human intestinal metaplasia, without any detectable expression in
normal gastric epithelium controls (24). In a recent study, TGR5 overexpression in
gastric adenocarcinoma has been associated with poor survival (25).
Vitamin D deficiency has been considered as one of the major risk factors for the
development of GI malignancies, such as pancreatic and colon cancers (26). Vitamin D
binding to VDR, activates the receptor which makes it an active nuclear transcription
factor and leads to the transcriptional induction of the expression of various genes (27).
This is how vitamin D execute its profound antimitogenic and prodifferentiating effects on
normal and malignant cells (28). Therefore, inadequacy in the levels of Vitamin D is
plausibly causing abrupt regulation of cellular functions and growth. Besides these
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functions, VDR has also been established as a receptor for secondary BAs such as
LCA, and has a key role in the initiation of pathways which leads to the detoxification of
LCA (29). Similar to VDR, activated human xenobiotic receptor (SXR) and its mouse
homolog (PXR) have been associated with the detoxification of BA by activating
enzymes, involved in BA metabolism (30, 31). Under cancer condition, PXR/SXR
receptor is considered to be protective against oxidant induced apoptosis. Upon
progression from normal epithelia to dysplastic lesions, the enteric NR transcriptome has
been found to be reduced in both mouse and human models of colorectal cancer (20),
suggesting that these transcription factors could have therapeutic and/or diagnostic
potential that could be exploited to treat colorectal cancer.
1B.4 Association between BA and mucins expression
The first evidence that BA is important in the regulation in mucins secretion was
provided by Klinkspoor JH et al. in 1995 (32). Hypersecretion of gallbladder mucin has
been proposed as a pathogenic factor in gallstone formation. Therefore, the primary
objective of the study was to understand the effect of biliary constituents on mucin
secretion using normal, well-differentiated dog gallbladder epithelial cells. Interestingly, it
was observed that alteration in the concentration of cholesterol or phospholipid had no
effect on the extent of mucin secretion (32). However, TCA showed a dose-dependent
increase in mucin secretion, signifying that bile salts, one of the major functional
components of bile, are responsible for these stimulatory effects. Compared to
hydrophilic BA, hydrophobic bile salts; TCDCA and TCA, showed more increased mucin
secretion at 0.5 mmol/L (p< 0.01). A shift in the bile salt composition of bile towards
more hydrophobic bile salts may cause mucin hypersecretion, and thereby participate in
the initiation of cholesterol gallstone formation (32). Following, another study by DrayCharier N and colleagues have implicated the predominant involvement of calcium50

dependent signaling pathways, particularly Ca2+/CaM-kinase II and protein kinase C
(PKC) in BA-mediated hypersecretion by human gallbladder epithelial cells (33).
Similarly, human colonic epithelial cells demonstrated increased mucin secretion upon
BA stimulation. Taken together, these reports suggest that bile salts-mediated regulation
of mucins secretion might be a common mechanism and one of the plausible reasons of
increased secretion is to protect epithelia against the deleterious detergent action
of bile salts as an adaptive response throughout the gastrointestinal tract. Later studies
have apparently shown that BA play crucial role in the increased synthesis of both
transmembrane and secretory mucins (34, 35).
Clinically, atypical gastro-oesophageal reflux and BA have been associated with
the occurrence of BE premalignant lesions, which are linked with an increase in mucinproducing goblet cells and overexpression of mucins (36, 37). Multiple studies have
postulated that a pattern of mucin staining in BE patients might be indicative of their
increased tendency to progress from BE to adenocarcinoma (38). In normal esophagus,
which has stratified squamous epithelium, there is positive expression for membrane
bound MUC1 and MUC4 mucins. In the preneoplastic stage or BE, secretory mucins,
such as MUC2, MUC5AC, MUC5B, MUC6, are expressed with MUC1 and MUC4. In
high-grade dysplasia and adenocarcinoma of BE, downregulation in secreted mucins
have been observed, whereas MUC1 and MUC4 mucin expression remain persistently
high. It is therefore evident that there is a definite order in the appearance and
subsequent decrease of various mucins in the Barrett's-adenocarcinoma sequence.
MUC5AC mucin is strongly expressed in almost 100% of BE and in 61.5% of
tissues obtained from EA (39). MUC5AC mucin has been found to express at high levels
in BE tissues stimulated by duodenoesophageal in rat reflux model (39). Conjugated BA
had more impact in the induction of MUC5AC gene expression at the transcriptional
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level compared to unconjugated BA, by utilizing PI3K/AKT/AP-1 signaling pathway (39).
Similar to MUC5AC, another secretory mucin, MUC2 also showed transcriptional
induction in esophageal carcinoma cell lines (40). PKC-dependent activation of nuclear
factor-κB (NF-κB) was implicated in BA-mediated transcriptional upregulation of MUC2
in esophageal cancer (40). In addition to esophageal cancer, induction of MUC2 mRNA
has also been noticed in DCA treated gastric cancer cell lines (41). DCA showed
inhibitory effects on the invasion and migration of SNU-216 and MKN45 cell lines (41).
Supportively, increased expression in E-cadherin along with reduced expression of snail
and MMP-9 was observed upon DCA treatment. Multiple forms of BA have been
previously identified as potent inducers of MUC4 expression in esophageal
carcinogenesis associated with bile reflux (34, 42). Mechanistically, PI3K signaling, PKC
and hepatocyte nuclear factor-1α were attributed to BA-facilitated increase in MUC4
expression (34, 35). BA also leads to MUC1 upregulation via a PI3K–mediated
molecular transcriptional mechanism in human esophageal adenocarcinomatous cell
lines. The biologic consequences of the induction of mucins expression by BA in cancer
cells are still unknown, but considering the association of both BA and mucins
overexpression in cancer condition, all this data favors a role of this mode of mucins
regulation by tumor cells for their progression and metastasis. The development of a
mouse or rat model of carcinogenesis in which epithelial mucosa is exposed to bile or
acid reflux or both will be very informative regarding the following: (1) deciphering the
precise molecular mechanisms activated by BA to induce mucins expression, (2)
evaluating the consequences of mucins overexpression during the carcinogenetic
sequence on tumor cell behavior and biologic properties, and (3) demonstrating the
pivotal role of BA as the main inducer of the expression of both membrane and secreted
mucins.
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However, it is still unclear whether this is the primary cause for the persistence of
the BE in-spite of successful anti-reflux surgery, or if it reflects the genetic instability
associated with this preneoplastic condition. Further studies in patients undergoing
surveillance for Barrett's and dysplasia will help answer whether mucin gene expression
has a diagnostic role in predicting those at risk and does not merely represent an artifact
of progression. An open question is whether therapeutic manipulation of MUC gene
expression will decrease the risk of malignancy for patients with BE and dysplasia.
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CHAPTER IC
Novel mechanisms implicated in MUC4-mediated increase in the
stability of EGFR-family members in PC
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1C.1 General introduction of altered mucins expression and localization under
disease condition
Mucins (MUC) are high molecular weight O-glycoproteins, predominantly expressed at
the apical surface of the epithelial cells, and are classified into membrane bound MUC
and secreted MUC (1-4). Tissue specific expressions of MUC have essential functions to
provide protection, lubrication to epithelial cells, maintenance of epithelial characteristics,
cellular adhesion, differentiation, and immunity (1-5). The expression of MUC is
significantly altered during tumorigenesis and other pathological conditions. For
example, MUC4 is not expressed in the normal pancreas, but the early pancreatic
intraepithelial neoplasia (PanINs) precursor lesions have been shown to express MUC4,
which further increases as the disease progresses (4-6). In addition, MUC4 is also
overexpressed in breast cancer, gastric cancer and ovarian cancer (7-9), and its
overexpression has also been associated with the poor prognosis of pancreatic cancer
and cholangiocarcinoma (10, 11). However, MUC4 expression is down-regulated during
prostate carcinomas (12) and urothelial cancer (13), suggesting the complicated contextdependent role of mucins. Another example, MUC1 is overexpressed in various
malignancies and inflammatory conditions (1, 14-16). Besides the aberrant expression of
mucins, emerging evidence suggests that anomalies in their subcellular localization and
resultant changes in their endocytic trafficking play critical roles under pathological
conditions (17).
In a cell, the majority of proteins are not pre-set to any single location and are in
a steady-state distribution due to opposing egress (exocytosis) and entrance
(endocytosis) pathways (18). These two pathways are extremely dynamic and are
regulated by highly sensitive cross talks between different subcellular compartments.
Endocytic pathways have always been considered as enduring mechanisms for
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recycling molecules from the plasma membrane to different intracellular compartments,
and reduce receptor density at the cell surface resulting in signal attenuation. Proteins
could be endocytosed by utilizing; clathrin-mediated pathway, caveolae-mediated
pathway, macropinocytosis, and phagocytosis (19). The MUC1 utilizes these pathways
for endocytosis and cell surface localization (20-22) (Fig. 1C.1). Like other glycoproteins,
MUC are also sorted after their internalization in the early or sorting endosome, where
their fates are decided including, their recycling, transportation to the Golgi (retrograde),
and proteosomal or lysosomal degradation. This is not only responsible for efficient and
regulated cellular metabolism and signal transduction, but is also required for
coordinating the functions of each intracellular compartment by maintaining their specific
compositions. Intriguingly, the trafficking of MUC and other glycoproteins is mainly
regulated by post-translational modifications, including phosphorylation, glycosylation,
palmitoylation and ubiquitylation. In this chapter, we provide a perspective on MUC
trafficking and its pertinence to pathological conditions.
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Figure 1C.1 Diagrammatical representation of the intracellular transport of
glycoproteins along endocytic and exocytic pathways. Internalization of cell surface
glycoproteins occurs by clathrin-mediated, caveolin-mediated, or clathrin- & caveolinindependent pathways, followed by the fusion of internalized vesicles with early
endosomes (EE) where the cargo is sorted and targeted for either recycling (from transGolgi, late endosome and recycling endosome) or for degradation (in lysosomes). The
other exocytic route are representative of the secretory pathways, where glycoproteins
are first synthesized and processed in the rough ER followed by their entry into the Golgi,
where they are further modified, packaged and either targeted to the plasma membrane
or secreted by the exocytic machinery.
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Figure 1C.1
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1C.2 Altered localization of MUC and its association with cancer condition

In 1992, Ceriani and colleagues conducted immunohistochemistry (IHC) analysis of
MUC1 cytoplasmic and membranous expression/localization on 227 breast cancer
patients. They found that low cytoplasmic intensity and high cell surface localization of
MUC1 correlated with better prognosis of breast cancer patients and survival (23). This
observation was further validated by Rahn et al., who found that increased cell surface
MUC1 expression in lower grade and estrogen receptor (ER)-positive tumors have better
prognosis, whereas aberrant MUC1 cytoplasmic localization in tumors correlated with
worse prognosis (24). Aberrant cytoplasmic MUC1 localization has also been correlated
with high-risk papillary thyroid carcinoma (25). In breast ductal adenocarcinomas, MUC2
and MUC5AC are localized in cytoplasm with granular staining pattern (14, 26, 27),
whereas distribution of MUC5B expression changes from apical localization in nonmalignant breast cells to cytoplasmic and non-apical localization in malignant ductal
breast carcinoma (28). Similarly, MUC3 cell surface expression has been correlated with
poor prognosis, higher grade and negative ER expression in breast carcinoma (29).
These studies clearly demonstrate that, aberrant localization of MUC is associated with
cancer pathology (14, 23, 25, 26), and therefore, it is essential to investigate the
mechanisms that alter trafficking of MUC among different subcellular compartments. So
far, no definite mechanism has been established to understand the elevated intracellular
presence of MUC in cancer, but different postulations, specifically for MUC1, have been
put forth including; its impaired recycling, altered glycosylation, altered endocytosis and
other presumed changes in MUC dynamics (Fig. 1C.2), which will be discussed in detail
in the next sections.
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Figure 1C.2: Mechanisms of intracellular transport and sorting of MUC1. MUC1 has
demonstrated to be internalization by using clathrin and caveolin-mediated pathway,
which is dependent on Rab5a, an early endosome marker. MUC1 has many interacting
partners including EGFR family proteins, AP-2, Grb2 and β-catenin. MUC1 possess a γsecretase cleavage site and cleaved by the same enzyme in early endosome. Cleaved
MUC1-C, which is still in contact with β-catenin travels to nucleus to increase the
transcription of various genes that are regulated by the TCF promoter. MUC1, like other
glycoproteins, undergoes multiple rounds of sialylation and glycosylation while continuing
on the itinerary to the Golgi. MUC1 also has a CQCRRK sequence motif, which
undergoes palmitoylation. These post-translational modifications and interacting protein
partners play important roles in deciding the fate of MUC1.
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Figure 1C.2
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1C.3 EGFR family receptors
Sustained proliferative signaling is the fundamental trait of cancer hallmarks (30)
Normal cells regulate their growth by modulating the expression of growth factors and
their receptors at an optimal time and concentration. On the other hand, cancer cells
abrupt this crucial regulation in order to grow unrestrictedly (30). Role of aberrant
glycoprotein trafficking in this sustained proliferative signaling can be exemplified by the
understanding of Epidermal growth factor receptor (EGFR) family of receptor tyrosine
kinases (RTKs) which constitute four receptors; epidermal growth factor receptor
(EGFR), erbB2/HER2, erbB3/HER3 and erbB4/HER4 (31). Structurally, these receptors
have a glycosylated extracellular N-terminal ligand-binding domain, a transmembrane
region, and a C-terminal intracellular domain, which includes the kinase domain and
multiple phosphorylation sites. EGFR and erbB4 are considered to be fully functional
receptors due to their ability to bind ligands and autophosphorylate C-terminal tails
through functional intracellular tyrosine kinase domains (32, 33). On the other hand,
erbB2 is unique in that it does not have ligand binding domain, therefore, it has to
heterodimerize with other EGFR family members in order to execute active signal
transductions. Similar to erbB2, erbB3 needs to heterodimerize, but due to different
reason, which is the lack of intrinsic tyrosine kinase activity (32). Interestingly, erbB4 is
known for its established ability to transduce direct nuclear signaling by releasing its
intracellular fragment that is cleaved by ligand-dependent dual protease (34).
Upon ligand binding (EGF, transforming growth factor-alpha (TGF-α) or
amphiregulin), receptors undergo homo- or hetero-dimerization, which is subsequently
followed by the autophosphorylation of the receptor in specific tyrosine kinase residues
within the cytoplasmic tail (35). The activated receptor recruits signaling complexes and
activates the Ras/mitogen-activated protein kinase (MAPK), extracellular signal66

regulated kinase, phosphatidylinositol 3-kinase (PI3K)/Akt, signal transducers and
activators of transcription, and phospholipase C gamma pathways (31, 36). These
pathways are potent oncogenic regulators of tumor cell growth, invasion, transformation,
and survival. Moreover, EGFR-mediated signaling has also been implicated in
angiogenesis, promotes invasiveness through matrix metalloproteinases, and stimulates
tumor-cell motility that furthers metastasis (37, 38).
1C.4 General mechanism involved in the regulation of EGFR trafficking and
signaling
Multiple studies have led us to know that fate of EGFR is dependent on
various parameters comprising; the phosphorylation and ubiquitination status of the
receptor and pH sensitivity of the ligand bound receptor (39). All these regulatory
mechanisms are crucial for EGFR signaling. It is well established that binding of EGF to
EGFR is followed by receptor internalization and multi-ubiquitylation by Cbl E3 ligase
inside the endosomes while it is concomitantly participating in active cellular signal
transductions (40). This multi-ubiquitination facilitates the sorting of EGFR towards the
degradative route to lysosomes. Unlike EGF ligand, binding of EGFR to transforming
growth factor-alpha (TGF-α) ligand leads to different outcome by avoiding prolonged
ubiquitination, and thus hypo-ubiquitylated form would be prevented to take entry into
the degradative lysosomal pathway, and prefer its routing directly to the recycling route
back to the cell surface which helps cancer cells to accomplish sustain growth and
proliferation (41). Interestingly, ubiquitination of the receptor is reliant on pH tolerance of
ligand bound receptor. For example; EGF-EGFR binary complex is comparatively stable
at low pH of endosomes, and can undergo polyubiquitination by Cbl ubiquitin ligases,
followed by their targeting to the lysosomes for degradation (41). On the contrary,
increased pH sensitivity of TGF-α, makes it to disassociate rapidly from the receptor and
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prevents its polyubiquitination, and finally, facilitates its recycling back to the plasma
membrane (41).
Besides ligands, Cbl ubiquitin ligases are also among the primary
regulators of RTKs (42). As they act as a negative regulator of RTKs, cancer cells have
to come up with different strategies to inhibit their function. For instance, by facilitating its
degradation or by the presence of inactivating mutations in the RING domain of Cbl.
Approximately, 5% of human myeloid neoplasms have missense mutations, frameshift
mutations or deletion in the E3 activity in the RING domain of Cbl resulting in the loss of
its activity (43). Overexpression and mutational activation of Src along with
overexpressed EGFR, found very frequently in cancers, which constitute one of the
mechanisms that lead to Cbl degradation. Src is a non-receptor tyrosine kinase which is
known to be activated by various stimuli including, EGFR. Bao and colleagues have
reported the involvement of active Src in the obliteration of Cbl functions by inducing its
tyrosine

phosphorylation

and

polyubiquitination,

with

subsequent

proteasomal

degradation of Cbl (44). This decrease in Cbl protein expression leads to increased
EGFR localization on the cell surface, which further facilitates Src activation, and
therefore, promotes sustained cell proliferation. Receptor recycling and disintegration of
the degradative mechanisms make cells to undergo repeated rounds of EGFR
activation. Similar mechanisms have further been explored in other RTKs as well under
tumorigenic condition.

1C.5 Role of EGFR family members in PC development and progression
The phosphorylation of protein kinases leads to the activation of multiple signaltransduction pathways, which have a critical role in a many cellular processes, including
cell growth, differentiation, and death. In PC, many tyrosine kinases were found to be
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degregulated and overexpressed, such as EGFR (ErbB1), HER2/neu (ErbB2), VEGFR2,
platelet-derived growth factor-α, FGF-1, CSF- 1 receptor, steroid receptor co-activator,
and others. Interestingly, studies have shown that >70% of the known oncogenes and
proto-oncogenes in cancer are tyrosine kinases (45). Therefore, blocking tyrosine kinase
activity signifies a highly rationale and potential approach to treat cancer.
Among multiple tyrosine kinases which are overexpressed in PC, EGFR axis is
known to play the most important role in PC development and progression. EGFR
overexpression has been observed in human PDAC and PDAC spontaneous mouse
models (46). Primarily, its functions have been associated with increased proliferation
and invasiveness of PC. The expression of activated EGFR was undetectable in WTmice, however, in the KrasLSL-G12D/+; Ptf1aCre/+ mouse model, at ∼8 weeks of age,
when these mice exhibit metaplasia and mPanIN formation, had detectable expression
of activated EGFR (46). In addition to EGFR, levels of transcripts for both EGFR and
TGF-α, an EGFR ligand, were significantly upregulated by ∼2-fold. Amphiregulin
(AREG), another EGFR ligand, was also upregulated relative to WT controls (46). Due to
the observed highly prominent immunofluorescence staining of EGFR in larger acinar
clusters of KrasG12D pancreata, especially near areas of metaplasia and mPanIN, it
seems that activation of EGFR pathway is plausibly an early event in pancreatic
tumorigenesis. Additionally, EGFR is found to be critical for acinar cell proliferation and
its stimulation of MEK is necessary for trans-differentiation and transformation of acinar
cells to a progenitor cell-like, metaplastic ductal epithelial cells. Thereby, EGFR controls
the differentiation of neoplastic precursors and participates in pancreatic tumorigenesis
(46).
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Chronic activation of EGFR alone is sufficient to cause acinar to ducal
metaplasia (ADM) both in vitro and in vivo. Importantly, blocking EGFR activity
effectively eradicates KRAS-initiated pancreatic tumorigenesis, with or without
pancreatitis induction, due to its critical role in amplifying ERK activation within the
pancreas. Although subgroups of patients with defined molecular subtypes did respond
to EGFR targeting, overall, the effect of anti-EGFR therapy on the survival of metastatic
PDA patients was quite modest (47). Interestingly, KrasG12D; p53KO mice exhibited no
added survival benefit in response to erlotinib treatment, suggesting towards the
involvement of EGFR-independent mechanisms on the development and progression to
fully developed PDAC in this spontaneous mouse model. Interestingly, increased MET
activity has been observed in minority of EGFR negative tumors, suggesting that MET
activation is plausibly required to circumvent EGFR deficiency. Altogether, these studies
encourage us to define the essential molecular signals and the exact role of p53
inactivation in order to improve the efficiency and efficacy of EGFR-targeted therapies
for the better clinical outcome of PC patients.
1C.6 Modulation of sub-cellular protein trafficking of EGFR family members by
mucins
Due to the loss of polarity in cancer, MUC1 and MUC4 localize all over the cell surface,
instead of restricted confinement at the apical surface. This allows them to interact with
cell surface proteins such as the EGFR family members, which normally exist at the
basolateral sides of polarized cells (48, 49). MUC4 has shown to interact with
HER2/ErbB2 in ovarian and pancreatic cancers (48, 50). MUC4-ErbB2 complex lead to
the activation of various signaling pathways leading to cell proliferation and survival
through stimulation of p38 MAPK phosphorylation (51). In the absence of the soluble
ligand, the MUC4-ErbB2 complex leads to ErbB2 phosphorylation, which in turn, leads to
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the phosphorylation of the ErbB2-ErbB3 heterodimer in the presence of neuregulin (52).
MUC4 did not demonstrate interaction with ErbB3 in polarized cells, but loss of polarity
also leads to MUC4-ErbB3 interaction.
The tradeoff between phosphorylation and glycosylation (O-GlcNAc) is known to
regulate intracellular trafficking of EGFR (53). MUC1 is known to interact with EGFR at
plasma membranes of non-polarized breast epithelia which resulted in increased EGFR
internalization, reduced lysosomal degradation and increased EGFR recycling back to
the plasma membrane (49). Likewise, MUC4 has also shown to interact with the other
EGFR family member, HER2, via its EGF-like motifs located at the juxtamembrane
domains (54). The EGF-like motif is also present in other MUC like MUC17, and has
been implicated in the pathogenesis of colonic inflammation and cancer, can presumably
initiates

EGFR

mediated

oncogenic

signaling.

Interestingly,

activated

EGFR

phosphorylates YEKV motif in MUC1-CT to induce MUC1 interaction with c-Src and βcatenin. MUC1-CT also has a γ-secretase cleavage motif and the cleavage by γsecretase results in the release of intracellular MUC1-CT to regulate MUC1 mediated
cellular proliferation (55). The MUC1-CT and E-cadherin both compete for β-catenin
binding due to the loss of the cellular polarity (56, 57). In breast cancer, silencing of
galectin-3 strongly enhanced the interaction between MUC1 and EGFR in response to
EGF stimulation and the reduced rate of their endocytosis, which leads to the noticeable
cell surface localization of MUC1 and EGFR (58). Therefore, possibly galectin-3
overexpression in cancer may be related to the frequently observed intracellular
retention of MUC1.
Despite of the absence of a classical mitochondrial localization signal,
MUC1-C gets localized to the outer membrane of mitochondria by its interaction with
cytosolic chaperones such as HSP70 and HSP90 (59). MUC1-C mitochondrial
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localization has been correlated with the diminished cell death response to the DNA
damage and other cellular stress by inhibiting the release of cell-death causing factors.
Cytosolic sequestration of MUC1 exposes its hydrophobic TM domains that facilitate
their binding with chaperones, and thus targeting to the mitochondria. Interestingly,
Heregulin (HRG), a ligand of EGFR family receptor family, enhances the association
between MUC1-C and HSP90 due to autophosphorylation and activation of c-Src in
HCT116/MUC1 cells (60) and facilitates the translocation of MUC1-C to the
mitochondria. In breast cancer cells, FGF1 plays similar role in the mitochondrial
localization of MUC1 using similar molecular mechanism (56).
Like EGFR family members, β-catenin also resides at the lateral side of the cell.
The loss of polarity allows β-catenin to interact with the SAGNGGSSL motif present in
MUC1-C and the loss of E-cadherin-mediated cell-to-cell interaction at MUC1 positive
sites. Under normal conditions, β-catenin interacts with the similar SXXXXXSSL motif of
E-cadherin, which is required for the maintenance of the adherent junction. This
interaction

between

β-catenin

and

MUC1

is

regulated

by

EGFR

mediated

phosphorylation of the crucial tyrosine residues present on MUC1-CT (61). Additionally,
phosphorylation of the serine residue in SPYEKV sequence by glycogen synthase
kinase 3β (GSK3β), a site adjacent to the β-catenin binding motif inhibits the interaction
between MUC1 and β-catenin (62); whereas c-Src mediated phosphorylation of the
tyrosine residue in that same SPYEKV site enhances this interaction (63). MUC1 shows
binding affinity to the Armadillo repeats and the non-repetitive COOH-terminal region of
β-catenin

(64).

MUC1

and

β-catenin,

once

in

complex,

mitigates

GSK-3β

phosphorylation of β-catenin and translocate to the nucleus to transcriptional activation
of various genes implicated in increased carcinogenic potential and metastasis (65). In
breast and colon cancers, HRG stimulation facilitates the binding between MUC1-CT
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and γ-catenin, allowing MUC1 to function as a vehicle for γ-catenin nuclear translocation
(66). These findings indicate that MUC1-CD has crucial functions in integrating signals
from the EGFR and Wnt signaling pathways. Unlike in MUC1 and MUC4, the RTK
binding motif is not present in MUC16-CT (67). MUC16 secretion is influenced by EGF
stimulation through phosphorylation of MUC16-CT (68). MUC16 knockdown in ovarian
cancer cell lines caused increased cytoplasmic localization of β-catenin and E-cadherin,
and was linked with greater cellular motility and invasiveness (67). In agreement,
reduction of MUC16 expression has been related with advanced ovarian cancer (69).
Taken together, these studies pointed towards the possibility that the interactions
between MUC16, E-cadherin and/or β-catenin permit MUC16 to modulate various
signaling pathways.
Bitler et al. found evidence that MUC1 has regulatory functions in the trafficking
and nuclear activity of EGFR (61). Presence of MUC1 showed enhance interaction
between EGFR and phosphorylated RNA polymerase II, which implies that MUC1 can
impact the association of EGFR with transcriptional machinery at the promoter region as
the loss of MUC1 reduces the occupancy of EGFR at the cyclin D promoter region (61).
Besides controlling such inter-molecular interactions, MUC1-C also regulates Rab31
expression, which is an early endosome protein belonging to the subfamily of small
GTPase Rab5 (70). MUC1-C and estrogen receptor form a complex at the Rab31
promoter and are responsible for the transcriptional activation of Rab31. According to
this study, patients who express MUC1-C and Rab31 are resistant to tamoxifen
treatment indicating the possible involvement of these two molecules in determining the
efficacy of tamoxifen therapy (70).
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1C.7 Summary and Conclusions
MUC are the chief macromolecular components of epithelial mucus and have been
incriminated in the pathogenesis of various diseases. Their mislocalization has been well
associated with the pathobiology of several cancers such as, breast and colorectal
cancer. Under normal condition, MUC are localized predominantly on the apical surface,
but loss of polarity allows them to extend all over the cell. It favors multiple MUC-protein
interactions that suppose not to occur in a polarized cell. Several unique domains
present in MUC play crucial important role in determining these interactions.
Mislocalization of MUC also facilitates MUC interactions with other novel proteins, which
further help MUC as well as other proteins (Y-catenin) to translocate to the different
subcellular compartments. Though many postulations have been kept forth to attribute
the altered localization of MUC including altered glycosylation, sialylation, and differential
protein-protein interactions, still the exact mechanism behind it has not been explored
and need immediate attention to make better therapeutic interventions.
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General Hypothesis and Objectives
Over the past few decades, multiple studies have established key roles of mucins in
malignant diseases. The expression of mucins is significantly altered during
tumorigenesis and other pathological conditions. In this dissertation, I have primarily
focused on MUC4, which is one of the most differentially expressed proteins in PC and
has strongly been implicated in the progression, metastasis and chemoresistance of PC.
MUC4 is not expressed in the normal pancreas, but the early pancreatic intraepithelial
neoplasia (PanINs) precursor lesions have been shown to express MUC4, which further
increases as the disease progresses. The ability of NIH3T3 fibroblasts cells to form
tumors in nude mice upon ectopic expression of MUC4 was the first evidence which has
experimentally proved its oncogenic function. Considering the significant role of MUC4 in
tumor biology, additional studies are required to highlight its novel functions and
regulatory mechanisms. Although studies have associated extrinsic (cytokines) and
intrinsic factors (NCOA3) with the regulation of MUC4, there is no study which has
addressed the role of PC microenvironmental stress (hypoxia and oxidative stress) on
MUC4 expression. Both Hypoxia and MUC4 has been associated with PC
aggressiveness and chemoresistance. Moreover, hypoxia has been shown to regulate
mucins expression in solid tumors. All these studied led me to hypothesize that hypoxia
has a significant impact on MUC4 expression in PC, which aggravate the PC conditions.
Besides PC microenvironment, the critical anatomical position of pancreas can influence
the growth of pancreatic tumors. However, these mechanisms are unexplored. The
majority of tumors (about 75%) arise at the head of the pancreas. Most of the PC
patients develop extrahepatic cholestasis due to common bile duct obstruction by
increasing tumor size which results in hyperbilirubinemia and elevated circulatory levels
of bile acids (BA). Multiple studies have implicated BA as tumor promoter for various
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cancers. A recently performed meta-analysis has shown that patients with the history of
cholecystectomy have significantly higher risk to develop PDAC. These studies incited
me to hypothesize that BA play important role in PC tumorigenesis by regulating the
expression MUC4 oncogene.
In addition to regulation, I have also focused to elucidate the novel functional
properties of MUC4 in PC. MUC4 is known to regulate the fate of EGFR family proteins
in several cancers including PC. However the precise mechanism involved is still
ascertain. Emerging reports have shown altered expression of RAB proteins in various
cancers. Additionally, a recent study has shown that mucins can also regulate the
expression of RABs to influence the trafficking of oncogenic proteins in cancer. It
brought me to my next hypothesis that MUC4 determines the fate of EGFR family
members by modulating the expression and activity of RAB GTPases in PC. In addition
to PC cells, MUC4 expression has recently been detected in activated PaSC.
Interestingly, our preliminary studies have shown reduction of MUC4 expression upon
treatment with RA, which is known to change the status of activated PaSC to quiescent,
suggesting a plausible link between MUC4 expression and activation status of PaSC. It
led me to hypothesize that MUC4 regulates the activation status of PaSC and thereby,
promotes desmoplastic reactions in PC microenvironment, which is known to exacerbate
PC condition.
Broadly, the aims for my dissertation research were as follows:
1. To elucidate the role of microenvironment stress (hypoxia and oxidative stress) on
MUC4 regulation in PC.
2. To investigate the impact of bile acids (BA) on MUC4 expression in PC.
3. To identify the novel functions of MUC4 in epithelial (ductal tumor) and nonepithelial
(PaSC) cells under PC condition.
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CHAPTER II
Materials and methods
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II.1 Cell culture: All PC (CAPAN1, Colo357, HPAC, AsPC1, MIA PaCa-2, and Panc1)
and LS180 colon cancer cell lines were obtained from American Type Culture Collection
[ATCC] (Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), penicillin,
and streptomycin (100 µg/ml)) at 37°C with 5% CO2 and were tested mycoplasma-free
before conducting the experiments. CD18/HPAF is a metastatic clone derived from the
HPAF cell line (1), whereas T3M4 cell line is derived from lymph node metastasis of
pancreatic exocrine adenocarcinoma (2). T3M4 PC cell line was a gift from Dr. RS
Metzgar (Duke University, Durham, NC) and cultured in 10% DMEM media. UMSCC1
and UMSCC10B (head & neck cancer) cell lines were a kind gift from Dr. Thomas Carey
(University of Michigan, Ann Arbor, MI, USA) and cultured in 10% minimal essential
medium (Invitrogen, Carlsbad, CA). Human ductal pancreatic epithelial (HDPE) cells
were a kind gift of Dr. Thiru Arumugam (MD Anderson, Houston, Texas) and cultured in
keratinocyte serum-free (KSF) medium supplemented with epidermal growth factor and
bovine pituitary extract. The method of generation and maintenance of stable clones of
MiniMUC4 expressing MIA PaCa-2 and MUC4 kd CAPAN1 cells have been described
previously (3, 4). Pancreatic stellate cells (PaSC) derived from PC patient and
immortalized with E6/E7 were obtained from Dr. Pankaj K. Singh (UNMC) and were
cultured in 10% DMEM.
II.2 Procurement of human and murine PDAC samples: Formalin-fixed and paraffinembedded PC Whipple tissue specimen and Rapid Autopsy (IRB-091-01) tissue array
(consisting of 3 normal pancreas, 25 primary PC with 1 colon and 1 kidney as controls)
were

obtained

from

University

of

Nebraska

Medical

Center

and

used

for

immunohistoflorescence analysis. For mRNA expression profiling, frozen PC tissues
were obtained from cooperative human tumor network (CHTN) and UNMC.
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The detailed information for pancreatic juice collection from PC patients has been
provided in our previous publication (5). Plasma samples were collected using an
Institutional Review Board (IRB number PRO07030072) approved protocol at University
of Pittsburgh (Pittsburgh, PA) from PC patients. Further details of the study design
(including exclusion and inclusion criteria) have been mentioned earlier (6). A written
informed consent was obtained from all patients and controls prior to entrance into the
study. From triple-transgenic animals, KrasG12D/+; p53R172H/+; Pdx1-Cre (KPC), and their
contemporary littermates, mice were sacrificed and blood collection was done at 5, 7,
10, 15, 20 and 25 weeks (wk) of age. The mouse model was maintained at UNMC by
crossing LSL-KrasG12D with LSL-Trp53R172H/+ transgenic mice as described
previously (7, 8). Whipple tissue specimens were obtained from UNMC and used for
immunohistoflorescence analysis. For mRNA expression profiling, frozen PC tissues
were obtained from cooperative human tumor network (CHTN) and UNMC (IRB- 49197). For tissues obtained through UNMC, a written informed consent was obtained for all
non-archival tissue before their collection.
II.3 Treatment of cells with hypoxia and pharmacological reagents
Chapter 3
Hypoxic exposure was carried out at 37°C in a humidified incubator (CoyLab, MI, USA)
with 94% N2, 5% CO2, and 1% O2. For inhibition studies, before hypoxia or H2O2
exposure, cells were treated with pharmacologic inhibitors: MG132 (Sigma Aldrich, St.
Louis, MO), CHX (Sigma), YC-1 (Sigma), NAC (Sigma), α-TS (Sigma), VB (Sigma) and
RAP (Sigma).
Chapter 4
Deoxycholic (DCA) and chenodeoxycholic acid (CDCA) were dissolved in sterile ethanol.
For inhibition studies, wortamannin (phosphoinositide 3-kinase (PI3K) inhibitor, 1 μM,
Cell Signaling Technology), SP100625 (JNK inhibitor; 35 μM, Merck Millipore), FAK
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inhibitor 14 (FAK inhibitor, 15 μM, Cayman’s chemical), U1026 (MAPK inhibitor, 10 μM,
Promega) and actinomycin-D (2 μg/ml, Sigma) were given 1h prior to BA treatment.
Chapter 5
CBP: CREB interaction was prevented by using 20 µM of selective pharmacological
inhibitor (CAS 92-78-4-Calbiochem) to block CREB-mediated upregulation of Rab5A
gene. CAPAN1 and CD18/HPAF cells were cultured in serum free media 12h prior to
treatment. Following, cells were treated with 200 nM of insulin (CAS Number 11061-680, Sigma) for 4h and RNA isolation was performed.
Chapter 6
PaSC cells were serum starved for 8h and then overnight RA (Sigma) treatment was
given at indicated concentrations.
II.4 Knocked down and overexpression experiments: Transient knocked down of
HIF-1α and ATG7 in PC cell lines was done by established targeted ShRNA sequence
and commercially available siRNA oligonucleotides (Cell Signaling Technology,
Catalogue no. 6604 S), respectively, by using Lipofectamine 2000 (Invitrogen) according
to the manufacturer's instructions. To transiently knockdown FXR, commercially
available FXR siRNA (Santa Cruz biotechnologies (SCB), Dallas, TX, USA) were used.
For transient overexpression of RAB5A in PC cells, we used commercially available
mRFP-Rab5A construct (addgene). For transfection purposes, lipofectamine 2000 (Life
Technologies; Carlsbad, CA, USA) was used, according to the manufacturer’s protocol.
MUC4 was stably knockdown in PaSC using targeted sh-RNA constructs:
Shmuc4-1(referred as Sh-1 MUC4):5’AGCTTAAAAAGGAGATGGCTATTTCGAAATCTC
TTGAATTTCGAAATAGCCATCTCCGGG-3’and shmuc4-31 (referred as Sh-3 MUC4 on
chapter 6) 5’AGCTTAAAAAGCATGAAACTCGACGCGTTTCTCTTGAAAACGCGTCGA
GTTTCATGCGGG-3’ construct (pSUPER-Retro-sh-MUC4) in PaSC. Scramble control
(sh-control) and pSUPER-Retro-sh-MUC4 has been transfected into packaging cell
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Phoenix using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 48h post
transfection, viral particles were collected and used to infect PaSC cells. Pooled
population of MUC4 kd cells were obtained using antibiotic selection (Puromycin 4
μg/ml), and were further expanded to confluent levels to obtain stably transfected cells.
II.5 Immunoblotting: Immunoblot analysis was performed as described previously (9).
Briefly, cells were lysed with radioimmunoprecipitation buffer (50 mM Tris-HCl pH-7.5,
150 mM NaCl, 1% Nonidet P- 40, 0.5% sodium deoxycholate, and 0.1% SDS)
supplemented with complete protease inhibitor mixture (Roche), 2mM Na3VO4, 10mM
NaF and 1mM PMSF on ice. Cell lysates were cleared by centrifugation and quantified
using the bicinchoninic acid method. Due to high-molecular weights of MUC4 (~ 950
kDa) and MUC1 (~ 250 kDa), electrophoresis was performed on 2% SDS-agarose gel,
whereas molecules less than 250 kDa were resolved by SDS–PAGE under reducing
conditions and blotted onto a polyvinylidene difluoride membrane membrane (Millipore).
Membranes were incubated overnight at 40C with primary antibodies (Table 2A). Blots
were washed and probed with peroxidase-conjugated secondary antibodies, and the
bands

were

visualized

using

enhanced

chemiluminescence

(ECL)

method

(Thermoscientific).
II.6 Isolation of cytoplasmic and nuclear fractions: Briefly, after 4h of 50 µM of DCA
or CDCA treatment, CD18/HPAF cells were washed with ice-cold PBS and incubated
with a cytoplasmic extraction buffer (10 mM HEPES, pH 7.4, 10 mM KCl, 0.2% NP-40,
0.1 mM EDTA, 10% glycerol, 1.5 mM MgCl2, supplemented with protease inhibitor, 1
mM DTT, 1 mM PMSF, 5 mM Na3VO4, 5 mM NaF) for 1h at 40C. Cells were centrifuged
at 800 × g and the supernatant was labeled as cytoplasmic extract, and the remaining
pellet was washed with PBS and then incubated for 1h with the nuclear extraction buffer
(20 mM HEPES (pH 7.6), 420 mM NaCl, 1 mM EDTA, 20% glycerol, 1.5 mM MgCl2, 1
mM DTT, 1 mM PMSF, 5 mM Na3VO4, 5 mM NaF). Following incubation, the pellet was
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sonicated for 10 s at 60% amplitude, and then subjected to centrifugation at 13,000 xg
for 10 min. The obtained supernatant was collected as a nuclear extract. The purity of
the fractions were checked by analyzing the expression of SP1 (nuclear protein) and
GAPDH (cytoplasmic protein) in collected lysates (Table 2.A).
II.7 Confocal Immunofluorescence microscopy: PC cells (1X105) were grown on
sterilized cover slips for 24h and treated with appropriate vehicle control (media or
DMSO), CoCl2 (150 μM), H2O2, hypoxia and VB, and further incubated for 24h. Following
treatment, cells were fixed with 4% formaldehyde, permeabilized (0.2% saponin),
blocked (with normal goat serum) and incubated with the primary antibodies. For
immunohistofluorescence, we deparaffinized tissue sections with xylene, rehydrated with
decreasing concentrations of ethanol and incubated tissues for 30 min. with 3% H2O2:
methanol solution. Tissues sections were blocked in 2.5% horse serum for 2h and
incubated with primary antibodies (Table 2A). Following primary antibody incubation,
cells were washed and incubated with FITC and Texas red conjugated secondary
antibodies.
To label autophagic vacuoles, hypoxia and H2O2-treated PC cells were incubated
with 50 μM of MDC (Sigma) at 37°C for 10 minutes (10). After incubation, cells are
washed four times with PBS; coverslips were mounted and immediately analyzed. All the
images were taken by using LSM 510 microscope, a laser scanning confocal
microscope (Carl Zeiss GmbH, Thornwood, NY) in the respective channels. The
intensity colocalization plot was made by using the Zen lite 2012 software. Image J
software was used to determine the Pearson correlation coefficient and MFI values for
both 8-OHG and MUC4. For box plot, the fluorescence intensities (FI) of 8-OHG were
sorted, according to the median FI of MUC4. Values more than median FI of MUC4 is
considered as MUC4 high or MUC4H and values lower than median FI was taken as
MUC4 low or MUC4L.
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II.8 Immunohistochemical staining: Paraffin embedded mouse and human tissues
were deparaffinised in xylene for 4 X 10 min washes, followed by rehydration through
graded ethanol. To block endogenous peroxidase, tissue slides were kept in 3%
hydrogen peroxide/methanol for 30 min. 0.01 M preheated citrate buffer (pH −6.0, 90°C)
was used for antigen retrieval for 15 min, and the slides were cooled and then washed
with PBS. Following, slides were blocked using horse serum (ImmPRESS kit; Vector
Labs) for 2 h and sections were incubated overnight at 4°C with primary antibodies
(Table 2A) diluted in PBS. Slides were washed with PBS, incubated with the secondary
antibody (peroxidase-labeled universal anti-mouse/anti-rabbit IgG, ImmPRESS kit;
Vector Labs) for 1h at RT and then washed four times in PBS and were developed using
DAB as substrate (DAB substrate kit; Vector Labs). The sections were counterstained
with haematoxylin (Vectors Lab) and washed in tap water, dehydrated in increasing
grades of alcohol (20–100%), washed with xylene for 5 min and dried overnight at RT.
Lastly, slides were mounted using paramount mounting medium (Fisher Scientific) and
images were obtained by using Nikon Eclipse E400 light microscope (Kawasaki, Japan).
II.9 Measurement of florescence to analyze ROS levels and autophagic vacuoles:
To analyze ROS production, PC cells were incubated with 1μM 2′-7′-Dichlorofluorescein
diacetate (DCFDA) (Sigma) for 15 min (11). After three washes with PBS, cells were
collected in 500 μl of PBS and analyzed (at 488 nm) using flow cytometry.
For the detection of autophagic vacuoles (positive for MDC) (Suppl. Fig 4A), cell
lines were incubated with 50 μM of MDC at 37°C for 10 minutes. Following, cells were
washed thrice with PBS and florescence was measured immediately at 300 nm using
florescence reader (Biotek, SMATBLD). To quantify number of apoptotic and necrotic
cells, PC cells were serum starved for 12h, followed by 48h treatment of CD18/HPAF
cells with 1% hypoxia, either alone or in the presence of NAC (2.5 mM) or CQ (50 uM).
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After the completion of treatment, Annexin-V-cy5 and propidium iodide (PI) (BD
biosciences) staining were performed and analyzed by flow cytometry.
II.10. RT- PCR: RNA was isolated using QIAGEN RNeasy mini kit (Qiagen, Valenica,
CA, U.S.A.) and cDNA was synthesized using 2 μg RNA, random hexamer primers, and
Super Script II RNase reverse transcriptase (Invitrogen) and quantitative real-time PCR
(qRT-PCR) was performed using gene specific primers (Table 2B) using the
standardized protocol established in our lab, using SYBR Green chemistry. β-actin was
used as an internal control. The relative fold differences in gene expression were
calculated using the ΔΔCt method with β-actin as a normalization control (12). For
reverse transcriptase-PCR (RT-PCR), RNA was isolated and cDNA was prepared as
mentioned earlier for qRT-PCR, using the following steps: initial denaturation at 95°C for
5 min., followed by 35 programmed cycles at 95°C for 1 min., 58°C for 1.5 min. and
72°C for 1 min., with a final incubation at 72°C for 10 min. The amplified product was
detected by electrophoresis on 2% agarose gels.
II.11 Quantitative chromatin immunoprecipitation (ChIP): PC cells (CD18/HPAF)
were starved of serum for 8h and treated with DCA or CDCA for 4h. Afterward, the ChIP
experiment was performed as described previously (13) and has been repeated more
than three times. In detail, 1% formaldehyde was used to cross-linked chromatin, which
was isolated and sheared into 500–1000 bp fragments by sonication (Bioruptor UCD200, Diagenode; New York, NY, USA). As an input, 1% of the sonicated DNA was used.
The remaining sonicated DNA fraction was used for the pull down experiment. The
concentrations of antibodies used for overnight incubation at 4°C were as follows: 5 μg
of anti-c-Jun (SCB#1694X) and IgG (negative control). MUC4 promoter targeted primers
were used to amplify and study the enrichment of the fragmented DNA using real-time
qPCR. The details of the primers are given in Table 2C. Immunoprecipitated qPCR Ct
(cycle threshold) values were normalized to input Ct values.
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II.12 Total BA estimation method: To analyze total BA concentration in pancreatic
juice and plasma samples, we used a highly sensitive bile acid estimation assay kit
(Diazyme, NBT, DZO92A-k). To increase the precision of the test, each sample was
analyzed in triplicates. We used deoxycholic acid for making the reference plot and were
serially diluted from 1.25 µ mol/L to 150 µ mol/L. After completing the BA estimation
assay according to the manufacturer’s protocol, ELISA plates were read at 405 nm and
the collected data was analyzed using SOFTMAX PRO software (Molecular Devices
Corp., Sunnyvale, CA).
II.13 Growth inhibition and growth kinetics assay
Chapter 3
For the growth inhibition assay, 5 X 103 PC cells were plated onto flat-bottomed 96-well
plates (Costar, Corning, NY). After 24h, cells were treated with 1% hypoxia and
indicated concentrations of H2O2, NAC and VB for an additional 24h. Subsequently, MTT
assay was performed as per the standard procedure.
For growth kinetics assay, 50 X 103 PC cells were plated in triplicates into six-well
plates in triplicates and cultured in serum-free DMEM media for 12h. Following, cells
were first pre-treated with NAC (2.5 mM) for 30 mins and then incubated with 1%
hypoxia or oxidative stress condition (H2O2). Cells were counted at indicated time-points
by using automated cell counter (Invitrogen, CountessTM).
Chapter 5
20 x 103 scr and MUC4 kd CAPAN1 cells were plated in triplicates into six-well and
cultured in serum-free DMEM media for 12h. Following, cells were treated with EGF
(20ng/ml) containing DMEM media supplemented with 2% FBS. Cells were counted at
indicated time-points by using automated cell counter (Invitrogen, CountessTM).
Chapter 6
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For growth kinetics assay, 50 X 103 PaSC cells were plated in triplicates into six-well
plates in triplicates and cultured in serum-free DMEM media for 12h. Following, cells
were cultured in 2% serum containing DMEM media and counted at indicated timepoints by using automated cell counter (Invitrogen, CountessTM).
II.14 Anchorage-dependent colony formation assay: Briefly, PaSC cells were plated
at densities of 2000 cells per well in 6-well plates and cultured in regular DMEM medium.
After overnight incubation, unattached cells were removed and attached cells were fed
with fresh regular medium every three days for 2 weeks. At the end of the experiment,
the colonies were stained with 0.2% crystal violet solution (Sigma-Aldrich) containing
50% methanol. At least two independent experiments were performed in triplicate.
II.15 Luciferase promoter assay: To perform this assay, previously designed and
established pGL3-MUC4 deletion constructs were used (14). PC cell lines were plated in
six-wells in triplicates and repeated thrice. Transient transfection was performed with
MUC4 deletion constructs using lipofectamine 2000 (Life Technologies; Carlsbad, CA,
USA). Next day, the media was first changed to 10% FBS containing DMEM for 12h (to
alleviate cellular stress of transfected cells) and then to serum free media for additional
8h. Subsequently, transfected cells were treated with BA for 4h in serum free condition.
Following treatment, cells were lysed using reporter lysis buffer (Promega; Madison, WI)
and subsequently, the activity of luciferase and beta-galactosidase activity was
measured using Steady-Glo Luciferase assay system (Promega, E2510) and βgalactosidase assay kit (Promega, E2000). Fold activation of luciferase activity in BAtreated cells were calculated and compared with untreated cells. Putative transcription
binding sites on MUC4 distal promoter were determined by ALGGEN PROMO software
(where similarity score of >0.85 was used to screen transcription factor binding sites).
II.16 Plasmids and cloning strategy: Standard PCR and molecular cloning
techniqueswere used to make constructs. For expression in the mammalian system,
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p3X-FLAGCMV9 (vector contain N-terminal plasma membrane targeted sequence,
Sigma) plasmids were used to make various constructs. DNA fragments encoding the
carboxyl-terminal region of MUC4 (150 amino acids) with deletion of first EGF-L, second
and third EGF-L, all three EGF-L motifs, cytoplasmic tail (of 21 amino acids) and
truncated constructs (expressing only MUC4-EGF and CT in different combinations) as
depicted in Fig. 2A were amplified using specific primers from synthesized cDNA. In
frame GFP was placed upstream of MUC4 fragment for the live cell imaging (as our EGF
ligand is tagged with Rhodamine). The protein expressions of the designed
3XFLAG.GFP.MUC4 truncated constructs were confirmed in the AsPC1 PC cell line by
performing transfection, using lipofectamine 2000 according to manufacturer’s protocol
(Fig. 2B). All the constructs were verified by sequencing.
II.17 Internalization experiment via different approaches
Live Imaging by Time-Lapse Fluorescence Microscopy: Cells seeded on a Lab-Tek
chambered coverglass system (Nunc, Rochester, NY). Live images of the cells were
obtained a Zeiss LSM 5 Pascal confocal microscope (Zeiss). Temperature was
maintained at 37°C with a water heated stage and lens warmer (Zeiss). The laser
excitation setting was maintained at 543 nm for Rhodamine-tagged EGF (Invitrogen),
with emission detected by appropriate filter sets as supplied by the manufacturer. For
live pulse chase, cells were starved for 8h followed by a 15 min. binding of the EGF
ligand at 40C. Cells were then washed three times with PBS followed by incubation in
complete media, and then the movement of EGF bound EGFR was monitored for the
indicated time-points.
Flow cytometry: PC cells were seeded in triplicates on six-well plate. After cells
confluency reach to 60-70%, cells were serum starved for 8h followed by EGF
stimulation at 370C for indicated time points which leads to EGFR internalization.
Following internalization, we replaced the media to 10% serum containing media for
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recycling purpose for 30 to 60 mins. Subsequently, cells will be washed 3 times with cold
PBS and fixed with 4% paraformaldehyde. The mean florescence intensity will be
measured by using flow cytometry approach at 568 nm as the ligand is labeled with
Rhodamine.
Confocal microscopy: PC cells were seeded on coverslips. After cells confluency
reach to 60-70%, cells were serum starved for 8h followed by EGF stimulation
(unlabeled) at 370C for indicated time points which leads to EGFR internalization.
Following internalization, we replaced the media to 10% serum containing media for
recycling purpose for indicated time-points. Subsequently, cells will be washed 3 times
with cold PBS and fixed with 4% paraformaldehyde. To pinpoint EGFR localization,
colocalization experiment of EGFR with Rab5A (early endosome marker) and Rab7 (late
endosome marker) was performed using the similar above mentioned protocol (section
II.7)
II.18 Cell motility assay: A six-well chamber insert containing polyethylene
teraphthalate membranes with a pore size of 8 μM (Becton Dickinson, Franklin Lakes,
NJ, USA) was used for motility assay. The PC (CD18/HPAF) and PaSC cells were
seeded at 1 × 106 and 0.5 x 106 in serum free media. After 48 h, cells reached to the
lower chamber (serum containing media) were stained with Quick-Diff kit staining
solution, while cells still present on the upper chamber were removed. Stained migrated
cells were counted in 8 different random fields and the average number of motile cells
per representative field was calculated.
II.19 GTP-loaded Rab5 pull-down assay: Protein A+ G-Sepharose beads (SigmaAldrich Corp., St Louis, MO, USA) were coated with anti-Rab5-GTP mouse monoclonal
antibody (Cat No. 26911, NewEast Biosciences). Beads were then incubated with
protein lysates obtained from scr and MUC4 kd PC cells for 2h at 4oC. Precipitated
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active Rab5 was detected by immunoblotting using anti-Rab5A polyclonal antibody (SC309, Santa Cruz Biotech (SCB), Dallas, Texas, USA).
II.20 Statistical analysis: All results are representative of at least three independent
experiments. The in vitro data are expressed as the mean±standard deviation (S.D.),
whereas the in vivo data are represented as mean±standard error (S.E.). Statistical
comparisons of the two groups were made using a student’s t-test (two-tailed, unpaired)
using Microsoft Excel 2010, where a p value of less than 0.05 was considered
statistically significant. For correlation analysis, the Pearson and regression coefficients
were determined between two groups.
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Figure 2. Strategy to design deletion constructs for MUC4 cytoplasmic domain
and their confirmation at protein level. A. Pictorial representation of the proposed
construct designs for MUC4 cytoplasmic domain which consists of 3-EGF-L domains,
transmembrane domain and cytoplasmic tail. The overall MUC4 structure consist of
large tandem repeat (TR) domain at N-terminal end and NIDO, AMOP, vWD, EGF-like
and Trans-membrane (TM) domain towards 3’extermities. MUC4 also consist of short
(22aa) cytoplasmic tail (CT) and one putative cleavage site (GDPH) supposed to
generate mucin like MUC4-α and growth factor like MUC4-β subunits. DNA fragments
encoding the carboxyl-terminal region of MUC4 (150 amino acids) with deletion of first
EGF-L, second and third EGF-L, all three EGF-L motifs, cytoplasmic tail (of 21 amino
acids) and truncated constructs (expressing only MUC4-EGF and CT in different
combinations) were amplified using specific primers from synthesized cDNA. In frame
GFP was placed upstream of MUC4 fragment for the live cell imaging (as our EGF
ligand is tagged with Rhodamine). B. IB confirming the protein expression of synthesized
MUC4 deletional constructs in transfected AsPC1 cell line. Here, NO-CT represents
MUC4-CD without CT; N-EGF represents MUC4-CD without any EGF domain; 1-EGF
represents MUC4-CD without 2nd and 3rd EGF; 2-EGF represents MUC4-CD without 1st
EGF and 3-EGF is the construct which has the full intact MUC4-CD.
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Table 2A Primary antibodies used in the study for Immunoblotting (IB) and
Immunofluorescence (IF) and ChIP purposes

Serial
no.

Antibody

Company

Dilution

Analysis
performed

1

β-Actin

1:5000

IB

2.

HIF-1α

Sigma
NB100-479, Novus
Biologicals

1:500

IB

3.

EGFR

SC-03, SCB

1:1500

IB

SC-101665

1:500

IB

2775, Cell Signaling

1:3000

IB

AP1802a, Abgent
PAB1750, Abnova
2708, Cell Signaling

1:200
1:3000
1:1000

IF
IB
IB

9234, Cell Signaling

1:1000

IB

10.

LC3
p62
p70 S6Kinase
phospho-p70
S6Kinase (Thr389)
p53

SC-126, SCB

1:1000

IB

11.

p21

SC-6246, SCB

1:1000

IB

12.

MDM2

SC-965, SCB

1:500

IB

13.

4691. Cell signaling

1:1000

IB

4060, Cell signaling

1:1000

IB

15.

Akt
phospho-Akt
(Ser473)
LAMP1

ab24170, Abcam

1:200

IF

16.

ATG7

2054-1, Epitomics

1:5000

WB

17.

8-OHG

ab10802, Abcam

1:150

IF
IB
IF
IHC

4.
5.
6.
7.
8.
9.

14.

phospho-EGFR
(Ser1046)
LC3

18.

MUC4 (8G7)

In-house generated

1:1000
1:400
1:800

19.

MUC4 (2175)

In-house generated

1:1000
1:500

IB
IF

20.

Muc4 (4A-rabbit
polyclonal against
mice)

1:400

IHC

21.

MUC1 (HMFG2)

1:5
1:5

IB
IF

Designed by us and
developed by
GenScript

(Piscataway, NJ,
USA)
In-house generated
(Gifted by Dr.
Hollingsworth)
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Serial
no.

22.

Antibody

c-Jun

Company

SC-1694,SCB

Dilution

Analysis
performed

1:500

IB

1:500

IF

5 µg

ChIP

23.

p-c-Jun

9261, Cell Signaling

1:1000

IB

24.

FAK

SC-558, SCB

1:500

IB

1:500

IB

25.

FXR

SC-134481, SCB
1:200

IF

26.

src

SC-18, SCB

1:500

IB

27.

p-src

6943, Cell Signaling

(1:1000

IB

28.

SP1

9389S, Cell Signaling

1:1000

IB

29.

GAPDH

5174S, Cell Signaling

RAB5A

SC-309, SCB

1:3000
1:500
1:50

IB
IB
IF

31.

RAB11

SC-6565, SCB

1:500

IB

32.

EEA1

SC-6415, SCB

33.

RAB7

2094, Cell Signaling

1:700
1:50
1:1000
1:200

IB
IF
IB
IF

34.

RIN1

bs-6094R, Bioss
antibodies

1:1000

IB

35.

Alpha-SMA

ab7817, abcam

36.

GFAP

SC-9065,SCB

1:500
1:200
1:1000
1:500

IB
IF
IB
IF

37.

MUC16

Clone M11, Dako

1:1000

IB

38.

Alpha-tubulin

236-10501,
Thermofisher
scientific

1:400

IF

39.

β-catenin

C2206, Sigma

1:300

IF

40.

Calnexin

C5C9,Cell Signaling

1:300

IF

41.

Giantin

ab37266, abcam

1:1000

IF

30.
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Table 2B Human primers sequences used for PCR
(qRT:quantitative real-time)
Gene

Primers sequence

FXR_ qRT_F

5′-GCGCGTCAGCAGGGAGGATC-3′

FXR_ qRT_R

5′-CACACAGTTGCCCCCGTTTTTAC-3’

MUC4_ qRT_F

5’-GCAGAGAGCCAGTGTTTGTACAATCAG-3’

MUC4_ qRT_R

5’-AGGCCTCGCAGCCCTTCCCAGGAA-3’

c-Jun_ qRT_F

5’- TCCACGGCCAACATGCT -3’

c-Jun_ qRT_R

5′- CCACTGTTAACGTGGTTCATGAC-3’

β-actin_ qRT_F

5′- GACCTGTACGCCAACACAGT -3

β-actin_ qRT_R

5′- AGTACTTGCGCTCAGGAGGA -3′

EGFR_ qRT_F

5’-AGGCAC AAGTAA CAGGCTCAC-3’

EGFR_ qRT_R

5’-AAGGTCGTAATTCCTTTGCAC-3’

TGF-α_ qRT_F
TGF-α_ qRT_R
EGF_ qRT_F
EGF_ qRT_R

5'- AGATAGACAGCAGCCAACCCTGA-3'
5'- CTAGGGCCATTCTGCCCATC-3’
5'-CCTGCCTAGTCTGCGTCTTT-3'
5'-CACAATACCCAGAGCGAACA-3'

Cyclin D1_ qRT_F

5’-CCTCTGTGCCACAGATG-3’

Cyclin D1_ qRT_R

5’-GGGTCACACTTGATCACTC-3’

Rab5A_ qRT_F

5’-ACTTCTGGGAGAGTCCGCTGTT-3’

Rab5A_ qRT_R

5’- GTGTCATCAAGACATACAGTTTGG-3’

Twist_ qRT_F

5’ CGGGTCATGGCTAACGTG -3’

Twist_ qRT_R

5’-CAGCTTGCCATCTTGGAGTC -3’

Vimentin_ qRT_F

5’-GACAATGCGTCTCTGGCACGTCTT-3’

Vimentin_ qRT_R

5’-TCCTCCGCCTCCTGCAGGTTCTT-3’
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Gene

Primers sequence

MUC4_Intron1_F

5'-GTCTATGTCCTGAATGGTATTGCCTA-3'

MUC4_Ex-2_R

5’-GAGGAGCTGTCTCCATCACATTGT-3’

MUC4-5’UTR_F

5’- CTTCGGAGAAACGCACTTGGTTCG-3’

MUC4_Ex-1_F

5’- CTGGAGGAGGGTCCCCTGGGTG-3’

MUC4_Ex-2_R

5'-GTCACACAACCCAGTCAACAACCGA-3'

MUC4_Ex-3_F

5’-GACAACACCGTCACTGAAGACAGACG-3’

MUC4_Ex-7_R

5’- GAGAAGCCCATGAGCACCGGGTTG-3’

MUC4_Ex-8_F

5’- GATGGCTATTTCGAAAACAGCCCACTG-3’

MUC4_Ex-12_R

5’- TGGAGCGGTACTGAGCCGCAAA-3’

MUC4_Ex-16_F

5’- CTGCGCAACGCAAGCATCGGACT-3’

MUC4_Ex-22_F

5’- TTGCTGTGGACACCCAAGTCGC-3’

MUC4_Ex-23_F

5’- CCAACACTGGATGGTCATCTCGGAG-3’

MUC4_Ex-26_R

5’- CAGCTGAGTTCAGGAAATAGGAGAACCTG-3’

MUC4_qRT_Int-1_F

5’-ATTCTATTTGTAGCAATTGTGA-3’

MUC4_qRT_Ex-2_R

5’-TTGAAGAAGCTGCAGTTGATTGTC-3’

MUC4_qRT_5’UTRF
MUC4_qRT_EX-1R

5’-CTCTTTTGTCCTCTTCCCAGGTTCCCT-3’
5’-ACATGCGGAAGGAGGCAGAGACACA-3’
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Table 2C CHIP primer sequence for MUC4 distal promoter

Gene

Primers sequence

hmuc4Promo_c-jun2s
(Comprising two c-Jun
sites)

5’-TCCCGTGGAATATTAACTTACA-3’

hmuc4Promo_c-jun1s
(Comprising one c-Jun
site)

5’-ATCGGATGCCTTGGGAGGAGAGAA -3’

hmuc4Promo_c-jun_R
(Common reverse
primer)
hmuc4Promo_c-jun0s_F

5’- AAATGGCTCTGTCTTCATCTGGGT -3’

5’-ACTCTGGAAAATGGGCATATTGA-3’

(No c-Jun binding sites)
hmuc4Promo_c-jun0s_R

5’-CGTGCGCACTCCTGTTCACCTCTT-3’

(No c-Jun binding sites)
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CHAPTER III
Hypoxia-induced oxidative stress promotes MUC4
degradation via autophagy to enhance pancreatic
cancer cells survival
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III.1 Synopsis
Pancreatic cancer (PC) and associated pre-neoplastic lesions have been reported to be
hypoxic, primarily due to hypovascular nature of PC. Though presence of hypoxia under
cancerous condition has been associated with the overexpression of oncogenic proteins
(MUC1), multiple emerging reports have also indicated the growth inhibitory effects of
hypoxia. In spite of being recognized as the top-most differentially expressed and
established oncogenic protein in PC, MUC4 regulation in terms of micro environmental
stress has not been determined. Herein, for the first time, we are reporting that MUC4
protein stability is drastically affected in PC, under hypoxic condition in a HIF-1α
independent manner. Mechanistically, we have demonstrated that hypoxia-mediated
induction of reactive oxygen species (ROS) promotes autophagy by inhibiting
pAkt/mTORC1 pathway, one of the central regulators of autophagy. Clinically,
immunohistoflorescence analyses revealed significant negative correlation (p value =
0.017) between 8-hydroxy Guanosine (8-OHG) and MUC4 in primary tumors (n=25).
Moreover, we found pronounced colocalization between MUC4 and LAMP1/LC3 in PC
tissues and also observed their negative relationship in their expression pattern,
suggesting that areas with high autophagy rate had less MUC4 expression. We also
found that hypoxia and resultantly arise ROS have negative impact on overall cell growth
and viability, which was partially, though significantly (p<0.05), rescued in the presence
of MUC4. Altogether, hypoxia-mediated oxidative stress induces autophagy in PC,
leading to the MUC4 degradation to enhance survival, possibly by offering required
metabolites to stressed cells (1).
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III. 2 Background and rationale
Pancreatic cancer (PC) is the fourth leading cause of cancer related mortalities in United
States with an overall survival rate of only 6% (2). Currently gemcitabine is used as a
standard therapy for advanced PC; however, its clinical outcome is quite modest due to
development of acquired and inherent chemo-resistance. One of the prominent features
of PC which contributes to this chemoresistance and cancer progression is the presence
of extreme hypoxia. Unlike other solid tumors, PC is hypovascular and characterized by
enormous desmoplastic reactions (3, 4). Tumor hypoxia is a condition when cancer cells
are deprived of oxygen and is primarily found in regions that are distant from the tumor
blood vessels, particularly, center of the tumor. Therefore, these microenvironments
suffer from low nutrient availability and production of waste products (acidosis).
Ultimately, it results in the development of a stressful environment which adversely
affects tumor cell proliferation and survival, and leads to the clonogenic selections of
only those cells who can withstand hostile environment (5). In order to survive and
remain viable, cancer cells induce both HIF-1α dependent and independent
mechanisms.
PC is characterized by aberrant mucins expressions, such as MUC1, MUC4 and
MUC5AC (6-9). Under normal condition, the expressions of these mucins are low or
undetectable, but under disease conditions, their expression increases. Studies have
established that MUC1, a transmembrane protein, is positively regulated by hypoxia and
has been linked with increase survival, angiogenesis and altered metabolomics in PC
(10-12). Similar to MUC1, MUC4 is also a transmembrane protein, but it does not
express in normal pancreas (13). MUC4 appears quite early in preneoplastic stage
(PanIN-I) and its expression increases with the severity of the disease (8). We have
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previously established that aberrant overexpression of MUC4 leads to increased tumor
growth, survival, metastasis and therapy-resistance in PC (14-16). So far, various
intrinsic and extrinsic factors have been associated with its aberrant expression during
PC progression (17). However, how environmental stimuli such as hypoxia can regulate
MUC4 expression is still not clear.
Therefore, in the present study, we investigated the regulation of MUC4
expression by hypoxia, and examined the clinical significance of this association in PC.
Our findings indicate that hypoxia negatively regulates MUC4 expression in PC, and also
provided evidence for a novel regulatory mechanism which leads to MUC4 degradation
due to hypoxia-induced oxidative stress.
III.3 Results
A. MUC4 expression is down-regulated in PC cell lines in response to hypoxia
To understand the effect of hypoxia in MUC4 expression, we treated MUC4 expressing
PC cell lines, CAPAN1, CD18/HPAF and T3M4, with 1% of hypoxia for 24 hours (h).
There was significant downregulation of MUC4 at the protein level in all three PC cell
lines (Fig.3.1A), with concomitant increase in HIF-1α levels. Substantially, we observed
similar decrease in MUC4 levels in hypoxia treated Colo357 cells (Fig.3.1B).
Immunofluorescence analysis also validated reduction in MUC4 expression, whereas
MUC1, an established HIF-1α target, was significantly increased in CD18/HPAF cells
(Fig.3.1C). To further substantiate our findings, we gave prolong (or chronic) hypoxia to
CD18/HPAF cells for 72h and 96h. Consistently, we observed significant downregulation
of MUC4, whereas MUC1 expression remains persistently high (Fig.3.1D). The qRTPCR analysis showed insignificant reduction in MUC4 expression at transcript levels in
all tested PC cell lines (Fig.3.1E), suggesting that hypoxia may affect the stability of
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MUC4 protein. Altogether, the results indicate that MUC4 expression reduces under
hypoxic condition due to modulation in MUC4 protein stability.
B. Decrease in MUC4 expression under hypoxia is HIF-1α independent
Previous studies have linked hypoxia-mediated alterations in mucins expression with
induced HIF-1α expression (10-12, 18, 19), which led us to ask whether hypoxiamediated downregulation of MUC4 expression is HIF-1α dependent. To ascertain the
role of HIF-1α transcription factor in MUC4 reduction, we silenced HIF-1α expression by
utilizing ShRNA approach and by pharmacological inhibitor, YC-1. Under both normoxic
and hypoxia conditions, HIF-1α knocked down (kd) led to MUC4 downregulation in
CAPAN1, as compared to its respective control (Fig. 3.2A). Furthermore, treatment of
both CD18/HPAF and CAPAN1 cells with YC-1 inhibited the expression of MUC4 in a
dose-dependent manner (Fig.3.2B), suggesting the role of HIF-1α in the upregulation of
MUC4 expression. Additionally, inhibition of HIF-1α degradation upon MG132 (ubiquitinproteasome inhibitor) treatment of CD18/HPAF cells did not rescue MUC4 degradation,
in fact further downregulation in MUC4 expression was observed (Fig.3.2C), possibly
due to MG132-mediated induction of autophagy (20-22). This data further strengthened
the fact that reduced MUC4 protein expression under hypoxia is HIF-1α independent,
and it is the stability of MUC4 which is primarily affected under hypoxia. To further prove
our conjecture, we treated CD18/HPAF cells with cycloheximide (CHX, protein
translation inhibitor) for indicated time-points and observed significant decrease in MUC4
expression under hypoxic condition as compared to normoxia (Fig.3.2D), establishing
that MUC4 protein stability is reduced under hypoxic conditions. Immunofluorescence
analysis in PC tissues (n=25) also revealed 56% (14/25) and 68% (17/25) expression of
MUC4 and HIF-1α, respectively. MUC4 and HIF-1α were co-expressed in 44% (11/25)
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of patients, however, were simultaneously absent in 20% (5/25) of PC patients
(Fig.3.2E-F). Altogether, the results indicate that MUC4 expression is positively
associated with HIF-1α; therefore, hypoxia-mediated downregulation of MUC4 is HIF-1α
independent.
C. Decrease in MUC4 expression under hypoxia is ROS-dependent
Because hypoxia-mediated reduction in MUC4 is HIF-1α independent, therefore, our
next question was to explore the mechanism responsible for significant downregulation
of MUC4 expression under hypoxia. It is already known that hypoxia has various HIF-1α
dependent and independent functions (23). Recent studies have shown that mucins
expression is regulated by reactive oxygen species (ROS) (24), and induction of ROS
under hypoxia, is an established feature. It prompted us to ask whether hypoxiamediated ROS induction is responsible for MUC4 reduction. To address this question,
we treated CD18/HPAF cells with 5 mM of ROS scavenger; N-acetyl cysteine (NAC), for
24h in the presence and absence of hypoxia. Interestingly, we observed attenuation of
MUC4 reduction under hypoxic condition in NAC treated cells (Fig.3.3A). Notably, NAC
treatment alone was sufficient for MUC4 upregulation (Fig.3.3B), by attenuating basal
levels of ROS already present in cancer cell lines (Fig 3C). The measurement of 2′,7′Dichlorofluorescin diacetate (DCFDA) florescence showed 41% and 63% reduction in
ROS levels upon NAC treatment under both normoxic and hypoxic condition,
respectively, further strengthening that NAC-mediated neutralization of ROS is
responsible for MUC4 upregulation (Fig. 3D). Treatment of both CD18/HPAF and
CAPAN1 PC cells with another antioxidant, α-tocopherol succinate (α-TS), also showed
similar increase in MUC4 expression (Fig. 3E). Additionally, treatment of CAPAN1 with
exogenous hydrogen peroxide (H2O2), a form of non-ionic ROS, resulted in concomitant
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reduction in MUC4 expression in a dose-dependent manner (Fig.3F), which was further
confirmed in CD18/HPAF cells (Fig. 3G). Immunofluorescence experiment also
exhibited that the negative impact of hypoxia and ROS on MUC4 expression was
abolished in the presence of NAC (Fig. 3H). Altogether, these data suggests that ROS is
playing a key role in hypoxia-mediated negative regulation of MUC4 in PC.
D. Hypoxia-mediated autophagy induction leads to reduced MUC4 stability
As demonstrated earlier, inhibition of ubiquitin-proteasome pathway was failed to rescue
MUC4 suppression under hypoxic condition (Fig.3.2C). Multiple studies have
established that autophagy and ubiquitin proteasome systems (UPS) are functionally
coupled, and inhibition of UPS system by MG132 induces autophagy (20-22).
Furthermore, the link between ROS and autophagy is also well established (25, 26).
Altogether, these studies incited us to propose that HIF-1α independent hypoxiamediated induction of oxidative stress promotes autophagy which reduces the protein
stability of MUC4. Therefore, we first evaluated the status of autophagy in PC cells,
under hypoxic and oxidative stress conditions. Interestingly, the levels of LC3-I and II
were significantly increased in hypoxia treated CAPAN1 and CD18/HPAF cells
compared to normoxic controls (Fig.3.4A). Further, treatment of CAPAN1 cells with
H2O2 showed increased LC3-I and LC3-II expression levels in a dose-dependent manner
(Fig.3.4B). The results were verified in CD18/HPAF cells where increase in LC3 was
accompanied with the concomitant reduction in p62 expression (Fig.3.4C), further
emphasizing autophagy induction under oxidative stress conditions. Increased
autophagosome formation in oxidative stress and hypoxic condition was also confirmed
by monodansylcadaverine (MDC) staining in CAPAN1 cells (Fig.3.4D). Further,
treatment of CAPAN1 cells with increasing doses of rapamycin (RAP), an autophagy
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inducer by inhibiting mTORC1 complex, resulted in reduction in MUC4 expression in a
dose-dependent manner, with concomitant increase in LC3-I and II levels (Fig.3.4E).
These results were substantiated by treatment of CAPAN1 cells with autophagy inhibitor,
vinblastine (VB) (27, 28) in the presence and absence of ROS. Consistent to our
premise, the suppression of MUC4 expression by ROS was significantly abolished by
VB treatment, as compared to H2O2 treated CAPAN1 cells (Fig.3.4F). VB inhibits the
fusion of LC3 carrying autophagosome vesicles with lysosomes, and thus, prevents the
degradation of proteins, causing accumulation of LC3. Immunofluorescence experiment
further confirmed increase in MUC4 expression and colocalization with accumulated LC3
positive vesicles in VB-treated CD18/HPAF and CAPAN1 cells (Fig.3.4G and H). To
further substantiate our findings, we did immunofluorescence staining for MUC4 and
LAMP1+ lysosomal vesicles in CAPAN1 and observed their colocalization (Fig.3.4I).
Moreover, significant increase in MUC4 expression upon ATG7 kd in CD18/HPAF cell
line, establish the involvement of autophagy in MUC4 degradation (Fig.3.4J). Altogether,
we have demonstrated that hypoxia-mediated ROS stimulation causes induction of
autophagy process, which leads to MUC4 degradation and reduced stability.
E. Hypoxia inhibits Akt/mTORC1 pathway to induce autophagy
Recent report by Wang et al has demonstrated the involvement of Akt activation in
mTORC1 regulated autophagy process (29). Additionally, chronic hypoxia has also
shown to suppress Akt activation in hypoxia treated PC cells (30). Similarly, we also
observed that levels of phosphorylated Akt and mTORC1 effector, pS6 kinase, were
consistently reduced in hypoxia-treated PC cells, whereas expression of EGFR, pEGFR,
Akt and S6 kinase remained unchanged (Fig.3.5A). We observed significant reduction in
p53 expression in hypoxia-treated cells lines, suggesting the possible accumulation of
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genomic and cellular defects in stressed PC cells. We also observed increase in p21
expression in hypoxia-treated T3M4 and CD18/HPAF cells, suggestive of growth arrest
of PC cells (Fig.3.5B), which was corroborated by our growth kinetics analysis in
hypoxia-treated and untreated CD18/HPAF cells (Fig.3.5C) and by a recent study where
hypoxia has shown to cause growth inhibition in PC cell lines (31). To assess the role of
ROS on pAkt reduction, we analyzed its expression in the presence and absence of
NAC. Interestingly, hypoxia-mediated downregulation of pAkt in CD18/HPAF cells was
abolished upon NAC administration, further emphasizing that the reduction in pAkt levels
under hypoxia is ROS-dependent (Fig.3.5D). From this data, we were also able to
reasoned that p53 downregulation under hypoxia is occurring due to induced expression
of MDM2 (ubiquitin ligase), though we did not see any change in their levels after NAC
treatment, implying the involvement of ROS-independent mechanisms in these
alterations. Further, treatment with NAC attenuates the growth inhibitory effects of
hypoxia (Fig.3.5E) and H2O2 (ROS stress) on PC cells (Fig.3.5F). These results were
further supported by performed MTT assay as significant loss in cell viability (p<0.05)
was noticed in H2O2 treated PC cells (Fig.3.5G). In order to know the effect of hypoxia
on cell viability and death, MTT assay was performed. CD18/HPAF cells exhibited
significant loss of viability under hypoxia, which was partially rescued in the presence of
ROS scavenger (NAC) and further augmented upon autophagy inhibitor chloroquinone
treatment (CQ) (Fig.3.5H). Similar to cell growth results, under normoxia, NAC did not
demonstrate any change in cell viability, whereas, CQ significantly reduces the cell
viability. Interestingly, PC cell lines demonstrate high autophagy rate even at basal
levels (Fig. 3.5I), affirming protumorigenic role of autophagy in PC (32). Consistent to
cell viability results, we observed increased cellular apoptosis and necrosis upon
hypoxia treatment (p<0.05), which was significantly (p<0.05) suppressed by NAC and
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augmented by CQ treatment (Fig. 3.5I), suggesting that reduction in PC cell viability and
death under hypoxic condition is oxidative stress-dependent, and induction of autophagy
is a survival mechanism.
F. MUC4 gives survival advantage to hypoxia-stressed PC cells
To determine the role of MUC4 in the survival of PC cells under hypoxia and oxidative
stress, we gave 1% hypoxia treatment to MUC4 kd and scrambled (Scr) CAPAN1 cells
(Fig.3.6A). Noticeably, under hypoxia, MUC4 scr CAPAN1 cells exhibited 6%, 21% and
53% reduction in cell viability on day 1, 3 and 5, respectively, compared to normoxic
cells. On the other hand, MUC4 kd cells exhibited 10%, 27% and 64% loss in cell
viability on day 1, 3 and 5, respectively, compared to normoxic kd cells, suggesting the
role of MUC4 in maintaining the viability of PC cells under stressed condition (Fig. 3.6B).
Similar results were obtained when MiniMUC4 overexpressing MIA PaCa-2 cell model
was used (33). In this model, MUC4 non-expressing MIA PaCa-2 cell lines ectopically
express MiniMUC4, which consists only 10% of the total VNTR of wild-type MUC4 (Fig.
3.6C). Growth kinetics was performed in these cells for 24 and 48h after H202 treatment
in the presence and absence of NAC. Intriguingly, we observed 85% and 63% reduction
in cell viability in H2O2 treated vector and MiniMUC4 expressing MIA PaCa-2 cells, upon
24h of H2O2 treatment (Fig. 3.6D). At 48h, we observed 71% and 55% reduction in cell
numbers in H2O2 treated vector and MiniMUC4 expressing MIA PaCa-2 cells,
respectively. Administration of NAC was able to rescue H2O2-mediated decrease in cells
numbers in vector and MiniMUC4 expressing MIA PaCa-2 (Fig. 3.6D). These results
indicate that presence of MUC4 alone cannot completely abolish oxidative stressfacilitated PC death. However, presence of MUC4 does offer better survival and viability
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advantage to PC cells under hypoxic and oxidative stress conditions than MUC4 kd or
null cells.
G. Clinical validation of MUC4 association with oxidative stress and degradation
via lysosomal pathway
To validate the link between MUC4 and hypoxia-induced autophagy, we performed
immunofluorescence analysis for MUC4 and LAMP1 in PC tissues, and observed
significant co-localization between them (Fig.3.7A). One of the consistent and intriguing
finding was the inverse relationship between LAMP1 and MUC4 expression. Ducts
having high MUC4 expression exhibited low expression of LAMP1 and vice versa, as
demonstrated in the intensity plot diagram (Fig.3.7A). Due to the established association
of increased expression of LAMPs with increased lysosomal function and autophagy
involvement (34), their inverse expression pattern may indicate that MUC4 does enter to
the lysosomes, and may undergo degradation. Additionally, presence of MUC4 in LC3positive vesicles in PC tissues, confirmed the association between MUC4 with
autophagy (Fig.3.7B).
To know the clinical association between MUC4 and oxidative stress, we
performed immunofluorescence analysis by staining PC tissues for MUC4 and 8-hydroxy
guanosine (8-OHG, commonly used marker for oxidative stress) (35, 36). We observed
8-OHG and MUC4 expression in 64% and 56% of PC patients, respectively. Validating
our in vitro data, MUC4 and 8-OHG exhibited significantly inverse expression status
under in vivo condition, as shown in representative images (Fig.3.7C). It was further
established by quantifying the mean florescence intensities (MFI) of 8-OHG in MUC4 low
(MUC4L) and MUC4 high (MUC4H) regions, and the difference was found to be
statistically significant (p=0.017) (Fig.3.7C). In our analysis, we also observed that
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oxidative stress does not always correlate with increase HIF-1α expression (Fig.3.7D).
The statistical analysis of MFI of different spots/fields (n=40) of RAPID autopsy tissue
array (having 25 PC patients tissues) revealed their Pearson correlation of 0.56 with an
R2 value of 0.31 (Fig.3.7E). Altogether, we can conclude that MUC4 expression is
differentially regulated by HIF-1α and oxidative stress, which is possible in varied PC
microenvironment.
III. 4 Discussion
By far, PC has one of the most complicated microenvironment among other solid
cancers due to its myriad of unique properties (4). Unlike most of the solid tumors, PC is
characterized by hypo-vascularization due to the deposition of extracellular matrix, which
causes extreme hypoxia and oxidative stress (4). Chronic and severe hypoxia has been
shown to inhibit tumor cell proliferation, which ultimately led to cell death (37).
Nevertheless, tumor hypoxia is also the predict marker for the worse clinical outcome.
To resolve these two opposite observations, hypoxia has been projected to create a
selection pressure which causes the survival of only those clones which are highly
aggressive and resistant towards fluctuating microenvironmental stress (38).
Alike, aberrant overexpression of mucins has been implicated in PC survival,
aggressiveness, drug resistance and maintenance of stem cell phenotype (3, 13-15).
Most of these attributes are frequently assign to their interaction with receptor tyrosine
kinases, cell surface proteins and components of extracellular matrix (39, 40). Present
study provides an additional oncogenic mechanism by which MUC4 contributes to the
survival of PC cells under hypoxic conditions through its degradation via autophagy.
Among cancers, such as renal and pancreatic cancer, the hypoxia-mediated induction of
MUC1 has been associated with HIF-1α (10-12). Nevertheless, we observed significant
reduction in MUC4 expression under hypoxia in multiple PC cell lines. Intriguingly, we
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observed that similar to MUC1, MUC4 is also positively regulated by HIF-1α, however, in
spite of increased HIF-1α stability (by inhibiting its proteasomal degradation); MUC4 was
degraded persistently under hypoxic condition. Therefore, downregulation of MUC4
expression under hypoxia, even in the presence of induced HIF-1α expression, signifies
the presence of other predominant pathways independent of HIF-1α.
Studies have demonstrated that ROS induction is one of the most common HIF1α independent mechanism activated under hypoxic conditions (41). Moreover,
established role of ROS in autophagy induction (42) and emerging data linking mucins
regulation by ROS (24), prompted us to postulate that ROS induced autophagy plays
crucial role in MUC4 downregulation. Consistent to our proposition, we did observe
MUC4

downregulation

under

hypoxic,

oxygen-deficient

or

chemically-induced

(rapamycin) autophagy, which was attenuated upon inhibition of ROS and autophagy.
So far, studies have not demonstrated the involvement of autophagy in mucins
degradation. The apparent presence of MUC4 in LAMP1 and LC3-positive vesicles in
PC tissue, imply that MUC4 does enter to autophagy/lysosomal pathway under in vivo,
and provided the first evidence of mucins degradation by autophagy pathway. Despite of
both cancer promoting and suppressing role of autophagy, majority of the available data
hints toward its role in promoting survival and proliferation of PC cells (26, 43). Our study
also suggests that MUC4 degradation via ROS-mediated autophagy might be a survival
mechanism in PC, as MUC4 kd CAPAN1 and MUC4-null MIA PaCa-2 cell lines were
less viable under microenvironmental stress conditions compared to CAPAN1/Scr and
MiniMUC4 expressing MIA PaCa-2 cells, respectively. Recent studies have clearly
established that pancreatic tumors are nutrient deprived and heavily-dependent on
macropinocytosis, leading to uptake of small extracellular proteins by cancer cells (44,
45). These internalized proteins then undergo autophagy process and provides
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necessary metabolites to ensure the survival of highly stressed PC cells. Due to
reportedly reduced levels of extracellular proteins concentration under clinical settings
(46, 47), we anticipate that requirement or dependency to internalize and degrade
overexpressed

membrane

proteins

(such

as

MUC4)

by

hypoxic/oxidatively

stressed/nutrient deprived PC cells is conceivably more than extracellular proteins and
needs further investigations.
Mechanistically, we observed significant downregulation of phospho-Akt in
hypoxia treated PC cells. Attenuation of ROS level by NAC treatment, suppresses the
hypoxia facilitated Akt activation, which was further related with the resumption of cell
proliferation. These data were further supported by a recent report by Sayin VI et al.
where in vivo administration of NAC and vitamin-E have demonstrated to increase the
tumorigenicity of lung cancer by downregulating the levels of ROS, DNA damage, and
p53 (48). We also observed downregulation of p53 under hypoxia, which further reduces
upon ROS attenuation, and therefore, questioned the utility of antioxidant-based
therapies in PC. Looking into earlier clinical trials on dietary antioxidants in cancer
condition, we have not received encouraging results (49, 50). Moreover, NAC treatment
leads to the attenuation of apoptotic functions of ROS-inducers, further emphasizing
towards the optimization of antioxidant therapies against PC (51). However, due to
observed overexpression of HIF-1α even under normoxic condition, current study
encourages HIF-1α targeting, which will led to the downregulation of multiple oncogenic
proteins, including mucins. It will definitely be our future interest to observe how HIF-1α
inhibition leads to MUC4 downregulation. Our in silico analysis has clearly shown that
MUC4 promoter does not contain HIF-1α bindings sites, indicating the involvement of
other protein mediators in HIF-1α facilitated MUC4 regulation. One of the possible
mechanisms could be EGFR downregulation upon HIF-1α inhibition, as recent study
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from our lab has shown that inhibition of EGFR leads to MUC4 downregulation in PC
cells, and need to be investigated (52).
In conclusion, the present study provides evidence that hypoxia negatively
regulates MUC4 expression in PC by affecting its stability. Moreover, we found that
hypoxia-mediated reduction of MUC4 is HIF-1α independent, and further investigation
directed us to know the involvement of ROS induced autophagy in MUC4 degradation
(Fig.3.8). Similar to cytokines, we observe functional redundancy in mucins, implying
that induction in MUC1 expression under hypoxia may be sufficient to compensate for
MUC4 downregulation, and need to be addressed. Lastly, due to the diverse effect of
hypoxia and highly complicated PC microenvironment, we can speculate that MUC4
expression could be differentially regulated by HIF-1α and oxidative stress, which leads
to differential expression and regulation of MUC4 within the same tumor due to the
different local microenvironment.
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Figures and Figure legends
Figure 3.1. MUC4 is negatively regulated by hypoxia in PC cell lines. A. CAPAN1,
CD18/HPAF and T3M4 cells were cultured under normoxia or hypoxic (1% O2)
conditions for 24 h. Following treatment, lysates were collected and western blots were
performed. Protein expression of MUC4 and HIF-1α was analyzed by 2% agarose and
10% polyacrylamide gel-based electrophoresis, respectively. B. MUC4 expressing PC
cell line, Colo357, was exposed to 1% hypoxia for 24 h. As anticipated, upon hypoxia
treatment, HIF-1a expression was significantly induced, whereas MUC4 protein showed
significant reduction, as compared to untreated controls. C. CD18/HPAF cells were
grown on coverslips followed by 24 h incubation under normoxia or hypoxia. After the
completion of treatment, cells were fixed, permeabilized and then subjected to
immunofluorescence experiment to observe changes in the expression of MUC1 and
MUC4. D. Prolong hypoxia treatment was given to CD18/HPAF cells for 72 h and 96 h
and the expression of MUC4 and MUC1 was analyzed. E. qRT-PCR experiment was
performed to detect changes in the mRNA expression levels of MUC4 in hypoxia treated
and untreated CD18/HPAF, T3M4 and CAPAN1 PC cell lines.
(ns stands for no significant difference, Scale bar = 20 μM).
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Figure 3.2. HIF-1α independent mechanisms play predominant role in hypoxiamediated suppression of MUC4. A. After transiently knocking down HIF-1α, CAPAN1
cells were incubated under 1% hypoxic conditions for 24 h. Following treatment, total
protein was isolated and western blot was performed to observe the effect of HIF-1α
silencing on MUC4 expression under both hypoxic and normoxic conditions. B.
CD18/HPAF and CAPAN1 cells were exposed to different concentration of YC-1 (10 or
20 μM), an inhibitor of HIF-1α, for 16 h. Immunoblotting was performed to detect
changes in MUC4 and HIF-1α expression. C. CD18/HPAF cells were first pre-treated
with MG132 (10 μM) for 30 mins. Following pre-treatment, cells were incubated under
1% hypoxic conditions for 4, 6 and 8 h in the presence of MG132. Even after inhibition of
ubiquitin-proteasome pathway, MUC4 degradation did not prevent, whereas, HIF-1α
protein which is known to be degraded solely by proteasome pathway was stabilized
upon MG132 treatment under both normoxic and hypoxic condition. D. Similar to
MG132, CD18/HPAF cells were pre-treated with CHX (50 μg/ml) for 30 mins followed by
1% hypoxia treatment for 2, 4 and 6 h in the presence and absence of CHX. 2% agarose
gel electrophoresis was performed to see the effect of these inhibitor treatments on
MUC4 expression in the presence or absence of hypoxia. We observed that CHXtreatment significantly reduces the levels of MUC4 under hypoxic condition, compared to
CHX treated cells alone, confirming the negative effect of hypoxia on MUC4 protein
stability. E. Representative images obtained from normal colon and PC tissues (from
three different patients) showing MUC4 and HIF-1α co-expression at same tissue spots.
F. The bar graph showing the percentage positive and negative expression for MUC4
and HIF-1α in stained PC tissue arrays. (Scale bar = 20 μM).

122

Figure 3.2

CD18/HPAF
6h
4h

C
0h
1% Hypoxia
MG132

-

+
-

+

+
+

+

8h

+
+

+

+
+ (kDa)
~950

MUC4

HIF-1α

100
55

β-actin

D
1% Hypoxia
CHX

CD18/HPAF
2h
4h

0h

-h

+
-

+
+ h +

MUC4

+
+h +

6h

+h

+
+

(kDa)
~950
)
0

4
130
100
0
55
0

HIF-1α
β-actin

5

123

Figure 3.2

E

DAPI

HIF-1α

Merge

PC3

PC2

PC1

Normal Colon

MUC4

D

F
80

% Positive expression

70
60
50
40

30
20
10
0
MUC4

HIF-1α

MUC4 +,
HIF-1α +

MUC4+,
HIF-1α -

(Parameters)

124

HIF-1α +, MUC4-, HIFMUC4 1α -

Figure 3.3. MUC4 expression is negatively regulated by hypoxia induced ROS. A.
CD18/HPAF cells were treated with NAC in the presence and absence of hypoxia for 24
h. Western blot was performed to analyze alteration in the expression of MUC4 and HIF1α. B. MUC4 expression was analyzed in lysates obtained from CD18/HPAF cell line
treated with different concentrations of NAC for 24 h. C. Flow cytometry was performed
to measure DCFDA florescence in order to detect changes in ROS levels in CD18/HPAF
cells upon NAC treatment in the presence and absence of hypoxia. D. The bar graph
showing mean florescence intensity (MFI) measured for DCFDA dye in indicated
immortalized normal pancreatic and cancer cell lines. (E). After 12 h of serum starvation,
CD18/HPAF and CAPAN1 cells were treated with α-tocopherol succinate (α-TS) for 24 h
at indicated concentrations. Following treatment, MUC4 expression was analyzed by 2%
agarose gel electrophoresis. F and G. CAPAN1 cells and CD18/HPAF cells were treated
with H2O2 followed by MUC4 expression analysis. H. Immunofluorescence experiment
was performed to further confirm the effect of hypoxia and exogenous ROS on MUC4 at
protein level in the presence and absence of ROS neutralizer, NAC.
(Scale bar = 20 μM).

125

Figure 3.3
A

CD18/HPAF

1% Hypoxia
NAC (5 mM)

-

+

+
-

+
+

(kDa)
~950

MUC4
HIF-1α

100
55

β-actin

B
CD18/HPAF
2.5
NAC (mM)

-

+

+

5
(kDa)
~950

MUC4
55

β-actin

C

126

Figure 3.3
D

*

*

*

*

*

E
CD18/HPAF
α-TS (μM)

0

50

100

CAPAN1
200

150

250

0

50

100

150

200

250

(kDa)
~950

MUC4
55
β-actin

F
CAPAN1
H2O2 (μM)

0

40

80 160 320 500

(kDa)
~950

MUC4
55
β-actin

G
H2O2 (μM)

CD18/HPAF
0

40

(kDa)
)~950

MUC4

0
55

β-actin

55

127

Figure 3.3

128

Figure 3.4. Hypoxia-mediated ROS production induces autophagy, which leads to
reduced MUC4 stability. A. Cell lysates of CD18/HPAF and CAPAN1 were collected
after 24 h incubation with or without 1% hypoxia to analyze the expression of LC3-I and
II by western blot. B. CAPAN1 cells were treated with increasing concentrations of H2O2
to observe the effect of oxidative stress on autophagy. C. To further substantiate that
presence of oxidative stress induces autophagy, CD18/HPAF cell line was treated with
40 and 80 μM of H2O2 followed by the analysis of LC3 and p62 levels, using
immunoblotting. D. Representative image showing increased autophagosome formation
in H2O2 and CoCl2 (hypoxia mimetic) treated CAPAN1 cells. For the detection of
autophagy vacuoles, MDC staining was performed (Scale bar = 10 μM). E. CAPAN1
cells were treated with 10, 20 and 50 nM of rapamycin (RAP), an autophagy inducer, for
24 h. Cell lysates were prepared to analyze the expression of MUC4 and LC3. F.
CD18/HPAF cells were treated with VB (10 μg/ml) for 24 h under hypoxic conditions to
observe the effect of autophagy inhibition on MUC4 expression. G. Additionally, confocal
microscopy revealed that inhibition of autophagy due to VB treatment leads to increased
expression and retention of MUC4 in LC3-positive vesicles. The bar graph is showing
the person correlation coefficient between MUC4 and LC3 colocalization in VB-treated
and untreated CD18/HPAF cells. (Scale bar = 20 μM). H. To confirm an association
between MUC4 and autophagy, autophagy was blocked in CAPAN1 cells (plated on the
coverslips) by treating them with VB (10 µM) for 8 h. Cells were fixed and
immunofluorescence staining was performed to look for the colocalization between
MUC4 and LC3 (Scale bar = 20 μM). VB treated PC cells exhibited increased expression
and retention of MUC4 in accumulated LC3-positive vesicles. I. Confocal image
demonstrating significant co-localization between MUC4 and LAMP1 in CAPAN1 cell
line. J. To specifically pinpoint the role of autophagy in MUC4 degradation, we used
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targeted siRNA oligonucleotides to transiently knock down ATG7 in CD18/HPAF PC
cells to inhibit autophagy. Consistently, we observed significant increase in MUC4
expression upon ATG7 silencing. (**p<0.01: statistically highly significant, Scale bar = 20
μM).
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Figure 3.5. Hypoxia-mediated oxidative stress promotes autophagy by inhibiting
pAkt/mTORC1 axis and reduces cell viability. (A) T3M4, CD18/HPAF and CAPAN1
cells were incubated under 1% hypoxic conditions for 24 h. Following treatment, cell
lysates were collected and used for western blotting to observe changes in the proteins
expression of HIF-1α, EGFR, pEGFR (Ser1046), Akt, pAkt (Ser473), S6kinase,
pS6kinase (Thr389) and p53. B. Immunoblots showing changes in the expression of p21
in hypoxia (1% O2) treated T3M4 and CD18/HPAF cell lines. C. Growth kinetics was
performed for CD18/HPAF for 24 and 48 hrs in the presence and absence of 1%
hypoxia. D. To know whether hypoxia-mediated suppression of pAkt and p53 is ROSdependent, CD18/HPAF cells were first pre-treated with NAC (5 mM) for 30 mins.
Following pre-treatment, cells were incubated under 1% hypoxia. Cell lysates were
subsequently collected and immunoblot experiment was performed for Akt, pAkt
(Ser473), p53, and MDM2 expression levels. E. The graphical representation to
demonstrate the effect of hypoxia and neutralization of consequently produced ROS (by
concomitant treatment with 2.5 mM of NAC) on the proliferation of CD18/HPAF and
CAPAN1 cell lines. F. Cell numbers were quantified after 24 h of H2O2, NAC and
NAC+H2O2 treatment of CD18/HPAF and CAPAN1 PC cells. G. CD18/HPAF and
CAPAN1 cell lines were treated with different concentrations of exogenous H2O2.
Following treatment, MTT assay was performed to analyze the effect of treatment on
cellular viability. H. To explore the role of hypoxia-induced oxidative stress and
autophagy on cell death and viability, MTT assay was performed. CD18/HPAF cells
were exposed to 1% hypoxia in the presence and absence of NAC (2.5 mM) and CQ (50
µM) for 24 h. Post-treatment, MTT assay was performed and optical density was
measured at 570 nm. I. The graphical representation of Annexin (indicator of earlyapoptosis) and propidium iodide (PI, indicator of late apoptosis and necrotic cells)
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staining performed on CD18/HPAF cells treated for 24 h with hypoxia alone, hypoxia
followed by NAC (2.5 mM) or CQ (50 µM) treatment for further 12 h.
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Figure 3.6. Hypoxia-mediated reduction in cell viability is rescued by MUC4
overexpression. A. Immunoblot confirming MUC4 knocked down in CAPAN1 cells. B.
The graphical representation to demonstrate the effect of 1, 3 and 5 days of hypoxia
treatment on the proliferation of MUC4 kd and scr CAPAN1 cells. (LE: Low exposure;
p<0.05: statistically significant; **p<0.01: statistically highly significant; ns: no significant
difference). C. Immunoblot representing the ectopic expression of MiniMUC4 in MUC4
non-expressing MIA PaCa-2 cell line. D. The graphical representation to demonstrate the
effect of 24 h and 48 h of combinatorial or individual treatment of H2O2 and NAC on the
proliferation of MIA PaCa-2/psectag and MIA PaCa-2/MiniMUC4 expressing cell lines.
(*p<0.05 signifies statistically significant results; ns means insignificant changes; Scale bar
=20 μM)
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Figure 3.7. In vivo validation of MUC4 association with oxidative stress and
degradation via lysosomal pathway. A. Confocal images showing colocalization
between MUC4 and lysosomal marker (LAMP1), and thus clearly indicate that MUC4
does enter to lysosomal compartment. In spite of significant colocalization between
MUC4 and LAMP1, similar to CAPAN1 cell line, MUC4 and LAMP1 expression pattern
was inversely associated under in vivo settings. Tumor cells having more LAMP1
expression exhibited reduce MUC4 expression in stained Whipple tissue samples.
Histogram representation of the intensities plots for MUC4 and LAMP1 is further
confirming our observation. B. Immunofluorescence staining was performed in PC tissue
section to observe the colocalization between MUC4 and LC3 molecules by confocal
microscopy. C. Representative images of PC tissues stained with MUC4 and oxidative
stress marker (or high ROS indicator; 8-OHG). Box-plot showing the significant
difference between the MFI observed for 8-OHG in MUC4L (n=20) and MUCH (n=16)
fields. D. Representative images obtained from confocal microscopy showing that
presence of oxidative stress does not always correlate with HIF-1α expression, as PC
tissue spots demonstrating high 8-OHG expression had less HIF-1α expression and vice
versa. E. Scatter graph showing relationship between the MFI levels of HIF-1α and 8OHG in clinical samples.
(Scale bar = 10 μM).
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Figure 3.8. Schematic presentation of the summary of the paper. Hypoxia is induced
collaboratively

by

hypovascularization,

desmoplastic

reactions

and

continuous

proliferation of tumor cells, which further leads to increase ROS production and generate
oxidative stress condition. Produced ROS inhibits the activation of Akt which further
leads to mTORC1 inhibition and induction of autophagy. Induce autophagy facilitates
MUC4 degradation. The inhibitors used in this study suppress the activity of different
proteins. For example, NAC and α-TOS act as ROS scavenger, rapamycin inhibits
mTORC1 and VB inhibits the fusion of autophagosomes (AP) with lysosomes (L) and
thus, prevent the formation of autophagolysosomes (APL) which causes MUC4
accumulation.
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IV. 1 Synopsis
The majority of pancreatic cancer (PC) patients are clinically presented with
obstructive jaundice with elevated levels of circulatory bilirubin and alkaline
phosphatases. In the current study, we examined the implications of bile acids
(BA), an important component of bile, on the pathophysiology of PC and
investigated their mechanistic association in tumor-promoting functions.
Integration of results from patient samples and autochthonous mouse models
showed an elevation in BA levels (p<0.05) in PC serum samples compared to
healthy controls. Similarly, an elevated BA levels was observed in pancreatic
juice derived from PC patients (p<0.05) than non-pancreatic non-healthy
(NPNH) controls, further establishing the clinical association of BA with the
pathogenesis of PC. The tumor-promoting functions of BA were established by
observed

transcriptional

upregulation

of

oncogenic

MUC4

expression.

Luciferase assay revealed distal MUC4 promoter as the primary responsive site
for BA. In silico analysis recognized two c-Jun binding sites on MUC4 distal
promoter, which was biochemically established using ChIP assay. Interestingly,
BA treatment led to an increased transcription and activation of c-Jun in a FAKdependent manner. Additionally, BA receptor, namely FXR, which is also
upregulated at transcriptional level in PC patient samples, was demonstrated as
an upstream molecule in BA-mediated FAK activation, plausibly by regulating
Src activation. Altogether, these results demonstrate that elevated levels of BA
increase the tumorigenic potential of PC cells by inducing FXR/FAK/c-Jun axis
to upregulate MUC4 expression, which is overexpressed in pancreatic tumors
and is known to be associated with progression and metastasis of PC.
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IV.2 Background and rationale
In 2014, about 45,000 new cases of pancreatic cancer (PC) were diagnosed in
the United States, of which pancreatic ductal adenocarcinoma represents the
major histological type (1). The majority of tumors (about 75%) arise at the head
of the pancreas (2). Anatomically, the pancreatic duct is placed close to the
common bile duct, which both unite at the point known as the ampulla of Vater,
and secrete their contents into the duodenum, which is the proximal site of the
intestine (3). Approximately, 70% of PC patients develop extrahepatic
cholestasis due to blockage of the common bile duct by increasing tumor size
and results in multiple organ failure and early death (4). Due to this bile duct
obstruction,

extrahepatic

cholestasis

exhibits

obstructive

jaundice,

and

indication of both hyperbilirubinemia and the increased circulatory levels of BA.
BA are amphiphilic molecules and are the main component of bile along with
cholesterol, phospholipids, and bilirubin (5). By utilizing a series of enzymatic
modifications, BA are synthesized in the liver using cholesterol as a precursor.
Even after their synthesis, they are further modified by bacterial species present
in the colon and form secondary BA (5). Dietary fat is a stimulus for BA
secretion into the intestine, which is required for the proper digestion of fatty
foods (5). Though bile-reflux has been associated with esophageal and gastric
cancers, BA association with PC pathogenesis has not been investigated (6, 7).
A recently performed meta-analysis has revealed increased risk of PDAC with
patients having the history of cholecystectomy (8). It has been proposed that the
mechanism attributed to this is the increased levels of cholecystokinin, which is
known to stimulate the growth of human PC cell lines and promote pancreatic
carcinogenesis in hamsters (9).
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BA have been shown to participate in the progression of tumors using
multiple mechanisms including, alteration in the expression of oncogenic mucins
(10, 11). Interestingly, PC is characterized by aberrant mucins expression (1214). Among multiple mucins expressed in PC, MUC4 is one of the topdifferentially expressed protein (15). We and others have established the
oncogenic functions of MUC4 in PC, and inhibition of MUC4 expression has been
associated with reduced PC cell proliferation, migration, and chemoresistance
(16-18). MUC4 is one of the most differentially expressed proteins in PC;
therefore, comprehending the mode of its regulation will give us an opportunity to
develop novel therapeutic strategies. In the present study, we have evaluated the
role of BA in the regulation of MUC4 expression in PC. The findings from the
current study, for the first time, have demonstrated that BA levels are significantly
high in the serum and pancreatic juice samples obtained from PC patients. Using
highly defined spontaneous mouse model of PC, we found that BA levels
increase with the severity of PC disease condition, which led us to propose its
tumor-promoting functions, which we have mechanistically explained by BAmediated induced expression of oncogenic MUC4 mucin. Mechanistically, BAmediated upregulation of MUC4 was found to be primarily dependent on FAKdependent c-Jun activation. Further studies led us to establish the role of FXR as
the upstream molecule in this FAK/c-Jun/MUC4 axis.
IV.3 Results
A. BA levels are elevated in serum and pancreatic juice during pancreatic
cancer
According to our hypothesis, BA play important roles in PC development by
regulating the expression of oncogenic proteins, including MUC4. Therefore, we
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first analyzed the in vivo levels of BA under PC disease condition. We observed
that PC patients had significantly (p<0.05) higher circulatory bile acid levels as
compared to the control group (Fig.4.1A). Additionally, we observed a significant
increase in circulatory BA levels in 10-15-wk- and 20-25-wk-old (fully developed
PC tumor) of KPC mice compared to their littermate controls (Fig.4.1B),
strengthening the association of BA with the pathobiology of PC disease. We
included controls from different age group for BA estimation and did not observe
any noticeable change in their serum BA levels, which is also evident from the
demonstrated standard errors (Fig.4.1B). Additionally, earlier report by Uchida K
et al. have demonstrated that circulatory BA levels when expressed in terms of
units per rat did not ostensibly change, regardless of their age (19). Consistently,
pancreatic juice obtained from PC patients (n=18) had significantly high BA levels
(p =0.048) of 65 μM,

compared to the non-pancreatic non-healthy (NPNH,

patients with symptoms mimicking pancreatic disease but found to be free of
pancreatic pathology) subjects (n=5), where the mean concentration of BA was
13.65 μM (Fig.4.1C). Taken together, high BA levels in PC condition suggest
their possible involvement in the pathobiology of PC.
B. BA up-regulate MUC4 expression in PC cells
BA are known to execute their oncogenic functions by altering the expression
levels of mucins such as MUC1, MUC2, MUC4 and MUC5AC in oesophageal,
gastric and colon cancers (10, 11, 20-23). Interestingly, PC is characterized by
altered mucins expression. We along with others have clearly established that
mucins play important role in the pathogenesis of PC (12-14). In order to analyze
the effect of BA on MUC4 expression, we treated PC cell lines with different
concentrations of DCA and CDCA for 24 h. We observed a significant increase in
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MUC4 expression in CD18/HPAF cells at all concentrations, ranging from 5-100
μM with the maximal increase at 50 μM concentration for both DCA and CDCA
(Fig.4.2A). Corrobortively, our time course experiment in DCA and CDCA treated
CD18/HPAF cells revealed increase in MUC4 expression starting from 6h
treatment with maximum increase at 24h (Fig. 4.2B). BA-mediated increase in
MUC4 expression was further confirmed in T3M4 (Fig.4.2C) and CAPAN1 cell
lines (Fig.4.2D). Unlike CD18/HPAF, presence of two bands for MUC4 protein in
T3M4 and CAPAN1 cells indicates the presence of allelic VNTR polymorphism in
MUC4 genes in these cell lines (24). Furthermore, immunofluorescence
experiment revealed significant increase in MUC4 expression in DCA or CDCA
treated CD18/HPAF cell line (Fig.4.2E). Altogether, the results suggest that BA
may play important role in the pathogenesis of PC by positively regulating MUC4
expression.
C. BA transcriptionally upregulates MUC4 expression in PC
In order to know whether BA-mediated upregulation of MUC4 is at transcriptional
level, PC cells were treated with DCA or CDCA in conjunction with actinomycinD, which inhibits the process of transcription. Intriguingly, we observed a
significant increase in MUC4 expression by 4.09- and 4.49-fold in DCA and
CDCA treated CD18/HPAF cells, respectively, which was attenuated to 0.18- and
0.16-fold in DCA and CDCA treated CD18/HPAF cells when treated in
combination with actinomycin-D (Fig.4.3A). Similarly, in T3M4 cells, we observed
a 2.40-fold increase in MUC4 upon DCA treatment, was attenuated to 0.38-fold,
when given in the presence of actinomycin-D, whereas a 2-fold MUC4
upregulation in CDCA treated T3M4 cells was reduced to 0.54-fold in the
presence of CDCA and actinomycin-D treatment (Fig.4.3A).
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To highlight the DCA and CDCA responsive regions on the MUC4
promoter, Luciferase reporter assay was performed (Andrianifahanana et al.,
2005). Our results demonstrated that both distal (P-1641) and proximal (P-1809
and P-2150) constructs were responsive to BA in CD18/HPAF cells (Fig. 4.3B).
Of particular interest was the deletion construct P-1641, which evidenced a
statistically significant 2.95- and 3.24-fold upregulation of the reporter gene in
response to DCA and CDCA treatment, respectively (Fig. 4.3B). A similarly
enhanced transcriptional activity by 1.93-fold was also noticed in DCA and CDCA
treated CD18/HPAF cells transfected with P-2150 construct, however, these
changes were insignificant. P-1809 construct demonstrated increase in luciferase
activity by 1.21- and 1.91- fold upon DCA and CDCA treatment, respectively (Fig.
3B), nevertheless, these changes were significant only for CDCA treatment.
Correspondingly, compared to untreated controls, T3M4 cells transfected with P1641 fragments showed 3.04- and 2.55-fold increase (p<0.05), in luciferase
activity upon DCA and CDCA treatment, respectively (Fig. 4.3C). P-1809
deletion construct demonstrated 1.53- and 1.78-fold increase in luciferase activity
upon DCA and CDCA, respectively. Similarly, P-2150 construct exhibited 1.4and 2-fold increase in luciferase activity in the presence of DCA and CDCA,
respecitively. However, the increase in luciferase activity at proximal promoter
regions upon BA treament were statistically insignificant in T3M4 cell lines.
Taken together, our data suggests that the distal promoter region of MUC4 gene
is mainly responsible for BA-mediated transcriptional upregulation of MUC4 in
both CD18/HPAF and T3M4 cell lines.
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D. BA increase the expression and nuclear localization of c-Jun
Due to an observed maximal increase in the region -2572 to -3135 (present in P1641) to BA treatment in PC cell lines, we performed in silico analysis to
delineate putative transcription factors binding sites for transcription factors on
this promoter region (Fig. 4.4A). Two c-Jun binding sites were identified on
MUC4 distal promoter (P-1641), which were absent on the proximal promoter
fragment (P-1809 sequence) (Singh et al., 2007), and therefore, were suggestive
of making distal promoter (P-1641) more responsive to BA treatment (Fig. 4.4B).
It incited us to propose that BA-facilitated upregulation in MUC4 expression in PC
cell lines is c-Jun dependent. Firstly, we were interested to know whether BA
itself has any effect on c-Jun expression levels. Intriguingly, in CD18/HPAF cells,
we observed 1.95-, 2.9-, and 3.46-fold increase (p<0.05) in c-Jun expression at
10, 50, and 100 μM of DCA treatment over untreated cells. On the other hand,
1.78-, 2.16-, and 3.87-fold increase (p<0.05) in c-Jun expression was noticed at
10, 50 and 100 μM concentration of CDCA treatment, respectively (Fig.4.4C).
The increased expression of c-Jun in response to both DCA and CDCA
treatments was also confirmed by immunoblot analysis in PC cell lines
(Fig.4.4D). Immunofluorescence experiments also revealed a significant increase
in c-Jun expression and nuclear localization in both DCA- and CDCA-treated
CD18/HPAF cells (Fig.4.4E). Further, nuclear and cytoplasm fractionation after
BA treatment in CD18/HPAF cells, revealed significant increase in c-Jun
expression in the nuclear extracts than untreated cells (Fig.4.4F).
To investigate the direct involvement of c-Jun in BA-induced MUC4 expression,
we performed ChIP assay to analyze c-Jun binding on MUC4 distal promoter
(Fig.4.4G). Using a primer set covering only one c-Jun binding site (or region-II),
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we observed 4.01- and 1.64-fold enrichment upon DCA and CDCA treatment of
CD18/HPAF cells, respectively. However, primers encompassing both c-Jun
binding sites (region-I), showed a significant (<0.05) enrichment of 6.74- and
2.61-folds, compared to untreated cells after DCA and CDCA treatments in
CD18/HPAF cells (Fig.4.4G), suggestive of the cumulative effects of both c-Jun
binding sites in inducing the transcription of MUC4 gene. As a negative control,
we synthesized primers against the non-c-Jun binding MUC4 promoter fragment
and found no difference. Taken together, BA increase the expression and
nuclear localization of c-Jun, which then occupy MUC4 promoter to increase its
transcription.
E. BA mediated increase in FAK activation induced c-Jun expression
To elucidate the signaling pathways responsible for increased MUC4
transcription to BA treatment, CD18/HPAF cells were treated with a panel of
inhibitors targeting different signaling pathways prior to BA treatment.
Interestingly, pharmacological inhibition of both FAK and MAPK pathway showed
attenuation of DCA- and CDCA-mediated MUC4 upregulation (Fig.4.5A).
Inhibition of PI3K pathway did not have perceptible effect on MUC4 expression,
whereas, inhibition of JNK did suppress MUC4 upregulation but only in the
presence of CDCA (Fig.4. 5A). The attenuation of BA-mediated upregulation of
MUC4 upon FAK inhibition was further confirmed using an immunofluorescence
experiment (Fig.4.5B). Earlier JNK and MAPK pathways have been associated
with BA, however, effects of BA on FAK has not been studied so far, particularly,
in terms of MUC4 regulation. Moreover, due to observed maximal effect of FAK
pathway on BA-facilitated MUC4 expression, we decided to focus on FAK
pathway and analyzed the activation status of FAK in BA-treated PC cells. As
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anticipated, we observed a high expression of activated FAK or pFAK (Y397) in
DCA and CDCA-treated CAPAN1 and CD18/HPAF cells (Fig.4.5C), whereas
expression of total FAK remains constant. As earlier experiments have linked cJun expression with BA-mediated upregulation of MUC4, our next question was
to explore whether alteration in FAK has any impact on c-Jun expression.
Interestingly, we observed that selective pharmacological inhibiton of FAK, led to
significant decline in the expression levels of c-Jun and MUC4 in PC cell lines,
both at transcript and protein levels (Fig.4.5D and E). To further substantiate our
results, we performed ChIP experiment and observed significant reduction in
enrichment for c-Jun binding on MUC4 promoter when BA treatment was
concomitantly given with FAK inhibitor, as compared to BA alone (Fig.4.5F),
suggesting that FAK activation is a prerequisite for DCA- and CDCA-mediated
MUC4 upregulation in PC cells due to its direct involvement in the induction of cJun expression.
F. FXR activation is a prerequisite for BA-mediated MUC4 upregulation via
src/FAK/c Jun axis
Farenosoid-X-receptor (FXR), a well established nuclear receptor, is known to be
activated by BA. Upon its activation, FXR gets translocated to the nucleus, where
it alters the trancriptional expression of multiple genes (Fig.4.6A). Interestingly,
the overall expression of FXR did not get influence by BA treatment, as FXR
levels were high in the cytoplasmic fraction of untreated cells than DCA and
CDCA treated cells. Expression profiling of FXR receptor in PC cell lines showed
its significant overexpression in HPAC, CD18/HPAF; CAPAN1, Panc10.05 and
Panc1 cell lines (Fig.4.6B-C), compared to immortalized normal pancreatic cells
(HDPE). Interestingly, significantly high FXR levels in CD18/HPAF cells explains
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drastic increase in MUC4 expression even at very low concentration of BA
treatment, compared to T3M4 and CAPAN1 cell lines (Fig.4.1B,C and D). Due to
observed downregulation of activated FAK expression levels along with c-Jun
levels upon transient knockdown of FXR in CD18/HPAF and T3M4 PC cell lines,
it is likely that FXR is acting upstream in this FAK/c-Jun/MUC4 axis
(Fig.4.6D).The key question which arises is that how FXR expression regulates
the activity of FAK. It is well-known in the literature that src kinase is one of the
critical regulator of FAK activity (26). As we have observed thar BA treatment do
affect the phosphorylation of src (Fig.4.6E), we assumed that FXR-mediated
phosphorylation of FAK is p-src-dependent, and FXR knocked down PC cells
indeed showed significant reduction in p-src levels compared to si control
(Fig.4.6E). To further substantiate our results, we gave BA treatment to FXR
knockdown CD18/HPAF cells and found significant abrogation of BA-mediated
MUC4 upregulation (Fig.4.6F). A 2.1-fold increase in MUC4 expression due to
DCA treatment was reduced to 1.32-fold in FXR silenced CD18/HPAF cells
(Fig.4.6F). Similarly, a 1.92-fold increase in MUC4 expression upon CDCA
treatment was reduced to 1.13-fold when CDCA treatment was given to FXR
knockdown cells (Fig.4.6F). Altogether, the results suggest that FXR activation
due to BA exposure is responsible for the initiation of FAK/c-Jun/MUC4 axis in
PC cells, by plausibly regulating the activity of src kinase.
G. Clinical association between MUC4 and BA receptor FXR
In clinical samples, we clearly observed that similar to PC cell lines, mRNA
expression for FXR was higher in 47% of PC tissues (n=15), as compared to the
tumor adjacent normal pancreatic tissues (n=4) (Fig.4.7A). Though the
upregulation of FXR in PC patients was not statistically significant (p>0.05), but
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considering significant increase in the levels of BA, which are activators of FXR
receptor, both in the circulation and pancreatic juice of PC patients, we can
speculate that pancreatic tumors have increased activity of FXR receptor, which
is sufficient to initiate FAK/c-Jun/MUC4 signaling cascade. In order to confirm an
in vivo association between MUC4 and FXR, we measured the transcript levels
of MUC4 in same clinical samples and performed regression analysis (Fig.4.7B).
A fairly positive correlation (R2=0.60) between MUC4 and FXR, further
substantiated our in vitro findings. Moreover, using confocal microscopy, we
observed co-expression of both FXR and MUC4 at the same PC tissue spots
(Fig.4.7C).
IV.4 Discussion
Anatomically, the common bile duct and the pancreatic duct are close in
proximity, and reunite at the ampulla of Vater. This led us to believe that BA can
reflux to the pancreatic duct under pathological conditions. Growing pancreatic
tumor often obstruct the bile ducts, preventing the flow of bile to the duodenum,
leading to jaundice, a frequently occuring clinical manifestation in PC patients
(27). Multiple studies have established BA as tumor-promoting agents in multiple
cancers, including Barrett's metaplasia and colorectal, biliary, and hepatocellular
cancers (11, 28-30). However, the role of BA in PC has not been clearly
understood, which prompted us to study its influence on the tumorigenic
properties of PC. In order to establish our hypothesis, BA levels were measured
in the serum and pancreatic juice obtained from PC patients and NPNH
individuals.

Encouragingly,

we

observed

a

significant

increase in

BA

concentration in those PC patients compared to controls. We also observed
increased mRNA expression of BA receptor, FXR, in PC tumors compared to a
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normal pancreas. Due to increased BA levels, which act as FXR agonist, it can
be speculated that not only its expression, activity of FXR also get increased
under PC condition, which we have confirmed as well due to increased nuclear
expression levels of FXR upon BA treatment. Similar to our observation, Lee et
al. have also observed increased expression of FXR in the PC tissues and
established its protumorigenic role in PC disease condition (31). Altogether, this
is a first experimental evidence establishing that BA do enter the pancreatic duct
and increases the tumorigenic potential of PC cells by altering the expression of
oncogenic MUC4 mucin.
Our luciferase promoter assay revealed MUC4 distal promoter as the
major BA responsive site. Further, in silico analysis demonstrated the presence
of two activator protein 1 (AP-1) motifs on this region, which has also been
reported in our earlier publication (32). Consistent with the previous findings
observed in gastric cells (33), we noticed that BA treatment increase c-Jun
expression, one of the members of the AP-1 family. Furthermore, ChIP
experiments confirmed an increase in c-Jun binding on MUC4 distal promoter
when exposed to BA treatment. Interestingly, by utilizing the same c-Jun
transcription

factor,

BA

are

known

to

increase

the

transcription

of

cyclooxygenase gene, by facilitating increased c-Jun binding on COX promoter in
esophageal adenocarcinoma cells (34). Importantly, c-Jun overexpression has
already been associated with carcinogenesis and cancer progression in multiple
cancers (35, 36). Although BA responsiveness was maximally observed at distal
promoter (P-1641), we also observed increased luciferase activity in proximal
promoter region, P-1809 transfected CD18/HPAF cells, upon CDCA treatment,
implying the involvement of other transcription factors in CDCA-mediated
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upregulation of CD18/HPAF cells due to the absence of c-Jun binding sites on
this region and requires further investigation (32). Inspite of the presence of cJun bindings sites on MUC4 proximal promoter (P-2150), we observed an
insignificant increase in luciferase activity upon BA treatment, suggesting that BA
might be affecting the expression and binding of transcription factors having
inhibitory effects on proximal promoter region, and therefore, neutralizing the
positive effects of c-Jun.
Multiple forms of BA have been previously identified as potent inducers
of MUC4 expression in esophageal carcinogenesis associated with bile reflux
(10, 29). Mechanistically, PI3K signaling, protein kinase C and hepatocyte
nuclear factor-1α were attributed to BA-facilitated increase in MUC4 expression
(10, 11). However, in the current study, we have established the role of FAK in
MUC4 regulation in PC cells upon BA treatment. Selective pharmacological
inhibition of FAK led to the attenuation in BA-mediated MUC4 upregulation.
Moreover, we observed downregulation of c-Jun expression upon FAK inhibition,
suggesting that c-Jun activation is a downstream event occurring after FAK
activation. Nadruz et al. have also established the link between c-Jun and FAK
molecules in ventricular myocytes (37). Unlike CDCA, the inhibition of the JNK
pathway had no remarkable effect on DCA-induced MUC4 expression,
suggesting that different BA transduce differential signaling, and therefore,
affects the expression of molecules, which is MUC4 in our case, to different
extent. Moreover, the data also implies differential mode of c-Jun activation in the
presence of DCA and CDCA. Earlier studies have shown that c-Jun can get
activated in JNK-independent manner (38, 39). For instance, in neuronal cells,
DNA damage causing induction of neuronal c-Jun kinase has been shown to
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increase c-Jun phosphorylation (Besirli and Johnson, Jr., 2003). Upon injury, cJun is found to be activated in Schwann cells by MAP kinases, which is again
occurring independent of JNK (Deng et al., 2012). In addition to FAK pathway,
inhibition of MAPK pathway also led to attenuation of BA-mediated MUC4
upregulation, which further strengthened our notion that MAPK pathway could be
involved in c-Jun activation. Future studies will be focused to understand the indepth involvement of different signaling pathways in MUC4 regulation after BA
treatment.
BA are known to interact with nuclear family receptors including;FXR
and pregnane X receptor (PXR) in order to influence the transcription of their
target genes. In the current study, for the first time, we have established the
direct involvement of FXR protein in MUC4 regulation. In the clinical samples, we
observed a fair positive correlation between FXR and MUC4 mRNA expression
profiles. Upon FXR kd, BA-mediated upregulation of MUC4, FAK and c-Jun was
abrogated, placing FXR as an upstream molecule in this FAK/c-Jun/MUC4 axis
in PC. Das A et al have shown that FXR promotes the migration of endothelial
cells by regulating the expression of FAK and MMP9 (40). However, the
molecular mechanism of FXR-facilitated FAK activation is still unexplored. Due to
observed increase in src kinase activity upon BA treatment, we assumed its role
in this FXR-mediated increased FAK activation and found to be plausible as FXR
silencing led to reduced p-Src levels in PC cell lines, and needs to be further
validated. Interestingly, previous study in our lab has also shown that
Guggulsterone, a selective pharmacological FXR inhibitor, also leads to a MUC4
downregulation at transcriptional level in PC cells by utilizing src/FAK pathway
(41). In addition to FXR, other BA receptors could also be implication in BA166

facilitated MUC4 upregulation. Interestingly, TGR5 has found to be upregulated
in 67% of PC patients (data not shown) and recent report has shown its
tumorigenic role in gastrointestinal cancers, including PC (42). Further studies
will be helpful and required to mechanistically delineate the association between
TGR5 and PC disease condition.
Future studies will be directed to get the better insight of BA on the
pathobiology of PC by bile duct ligation or cholecystectomy using autochthonous
murine models, which will delineate the role of BA on pancreatic tumor growth
and metastasis. Moreover, the significantly induced levels of BA indicates their
possible usefulness for diagnostic purposes, and needs to be validated in more
number of patient samples to assess and establish its clinical utility.
Altogether, the current study, for the first time, has established that BA
levels rises both in the circulation and pancreatic juice in PC, and they exert their
protumorigenic

functions

by

upregulating

oncogenic

MUC4

expression.

Mechanistically, we have demonstrated that BA binding to FXR receptor leads to
FAK activation, followed by increased c-Jun expression and its nuclear
translocation, which in turn causes increased transcription of the MUC4 gene
(Fig. 4.7D). The current study also supports emerging epidemiological data that,
similar to colorectal cancer, fat-rich diet could be one of the risk factors for PC
development

and

progression.

Therefore,

targeting

BA

receptors

an

administration of BA antagonists can significantly impact the outcome of PC
patients.
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Figures and Figure legends
Figure 4.1. BA are significantly upregulated in PC condition. A.
Representation of BA levels in the serum samples obtained from the PC patients
(n=36) and healthy (n=10) individuals using a commercially available total BA
estimation kit. The difference in BA levels between normal and PC patients were
found to be statistically significant. B. To understand the association of BA with
PC progression, we measured BA levels in established KPC mice model at early
(5-7 wk), medium (10-15 wk) and advanced stages (20-25 wk). The BA levels
were found to increase with the severity of the disease. C. Box-plot representing
the levels of BA in the pancreatic juice obtained from PC patients. We observed
significant increase in BA concentration in the pancreatic juice obtained from PC
patients (65 μmol/L) compared to NPNH controls (13 μmol/L). (All values are
mean ±S.E, ns means non-significant)
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Figure 4.1
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Figure 4.2. BA are positive regulators of MUC4 expression. A. CD18/HPAF
cells were serum starved for 8h prior to BA treatment. Following 24h of BA
treatment, cell lysates were collected, quantified and resolved using gel
electrophoresis. Immunoblot showing increase in MUC4 expression upon DCA
and CDCA treatment of CD18/HPAF cells at indicated concentrations. B.
CD18/HPAF cells were treated with 50 µM of DCA or CDCA for indicated time
points. MUC4 protein expression starts increasing at 6 h and maximal increase
was noticed at 24 h. C. Immunoblot showing increase expression of MUC4 in
DCA and CDCA treated T3M4 PC cells cells at indicated concentrations. D.
Immunoblots confirming MUC4 upregulation by BA treatment in CAPAN1 cells.
E. Representative confocal images showing the positive effect of BA on MUC4
expression in CD18/HPAF cells. (LE: Low exposure, scale bar = 20 µM)
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Figure 4.2
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50 µM DCA

Figure 4.3. BA-mediated positive regulation of MUC4 is at transcriptional
level. A. After 8h of serum starvation, both CD18/HPAF and T3M4 cell lines were
treated for 12h with 50 µM of DCA, CDCA or vehicle control (ethanol) in the
presence or absence of actinomycin-D (2 µg/ml). Following treatment, cDNA was
prepared from isolated RNA and used for real-time PCR to analyze the
quantitative expression of MUC4 gene. The represented graph is demonstrating
that inhibition of transcription attenuates DCA- and CDCA-mediated increase in
MUC4 expression in both CD18/HPAF and T3M4 cell lines. B. Luciferase assay
was performed in CD18/HPAF cell line transfected with MUC4 promotertruncated constructs, followed by 4h treatment of 50 µM of DCA and CDCA. A
significantly elevated luminescence was detected upon BA treatment, primarily at
the distal promoter region. C. Similar to CD18/HPAF cells, T3M4 cells also
showed significantly elevated luminescence at the distal promoter region upon
BA (50 µM) treatment. (*p<0.05, ** p<0.01, *** p<0.001, ns means nonsignificant)
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Figure 4.4. BA affect the expression, activation and nuclear translocation of
c-Jun, which led to enhanced c-Jun binding on MUC4 distal promoter. A. By
utilizing PROMO software, we obtained differential transcription factors binding
sites on the highly responsive region for BA on MUC4 promoter region. B.
Sequence of the MUC4 distal promoter (P-1641) which has two binding sites for
c-Jun protein (marked red).

C. Graph showing increase in c-Jun mRNA

expression in a dose-dependent manner in CD18/HPAF cell line, treated for 2 h
with DCA and CDCA. C. CD18/HPAF and T3M4 cell lines were treated with BA
(50 μM) for 4 h and cell lysates were collected. D. Immunoblot was performed to
observe change in c-Jun expression in DCA- and CDCA-treated CD18/HPAF
and T3M4 cell lines, compared to their respective untreated controls. E. Confocal
images showing significant increase in c-Jun and MUC4 protein expression in
CD18/HPAF cells treated with DCA or CDCA. Graph showing the quantification
of the c-Jun positive nuclei in DCA and CDCA treated CD18/HPAF cells. F.
Immunoblot showing significant increase in the expression levels of c-Jun in the
nuclear fraction obtained from BA (25 μM)-treated CD18/HPAF cells, whereas
cytoplasmic fraction did not demonstrate any noticeable alteration in c-Jun
expression. G. ChIP experiment was performed to observe the effect on
enrichment for c-Jun binding on MUC4 distal promoter in the presence or
absence of DCA (50 μM) and CDCA (50 μM). We observed a significant increase
in fold-enrichment at both region-I (containing two c-Jun binding sites) and
region-II (containing one c-Jun binding sites). (*p<0.05, ** p<0.01, *** p<0.001,
scale bar = 20 µM)
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Figure 4.5. BA-mediated upregulation of MUC4 is dependent on FAK
activation. A. Concomitant treatment of 25 µM of DCA or CDCA in the presence
or absence of selective pharmacological signaling inhibitors for 12h led us to
know that the FAK pathway is mainly responsible for MUC4 upregulation upon
BA exposure, as attenuation of this pathway maximally suppresses the BAmediated upregulation of MUC4, compared to the other signaling inhibitors.
Besides FAK, inhibiton of MAPK pathway also led to reduced MUC4 expression.
B. Images obtained from immunofluorescence experiment showing MUC4
upregulation in DCA (25 μM) and CDCA (25 μM) treated CD18/HPAF cells,
which is attenuated upon inhibiting FAK activity (or phosphorylation). C. Increase
in FAK activity was confirmed by analyzing pFAK (Tyr397) expression upon BA
(25 μM) treatment of CD18/HPAF and CAPAN1 cell lines for 4h. D. Graphical
representation of relative mRNA expression for MUC4 and c-Jun gene altered
upon inhibition of FAK pathway in both CD18/HPAF and T3M4 cell lines. E.
Immunoblot showng that inhibition of FAK pathway, using 15 µM of FAK Inhibitor
14, leads to downregulation of MUC4, pFAK and c-Jun in CD18/HPAF cells. F.
Graph representing the relative fold enrichment for c-Jun on AP-1 sequence
motifs present on MUC4 distal promoter when CD18/HPAF cells were
concomitantly treated with DCA and CDCA in the presence and absence of FAK
inhibitor for 4 hours. (*p<0.05, scale bar = 20 µM)
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Figure 4.6. Activation of FXR is required for BA-mediated MUC4
upregulation via Src/FAK/c-Jun axis. A. Nuclear fraction obtained from 50 µM
of DCA and CDCA treated CD18/HPAF cells, demonstrated increased levels of
FXR compared to the untreated control. On the other hand, FXR expression was
more on the cytoplasmic fraction in untreated cells than DCA and CDCA treated
cells. B. FXR expression was found to be significantly high in PC cell lines than
normal pancreatic cells (HDPE). C. Reverse-transcriptase PCR was performed
to analyze FXR expression in PC cell lines panel. Following PCR, 2% agarose
gel was run to detect the bands using ethidium bromide dye.

D. FXR was

transiently knockdown in CD18/HPAF and T3M4 cell lines using 150 nM of
siRNA oligos and confirmed using immunoblotting. Interestingly, FXR knockdown
cells exhibited significant decline in FAK, pFAK (Tyr397), src, p-src (Tyr416), cJun, p-c-Jun (Ser63) and MUC4, suggestive of FXR involvement as the most
upstream molecule in this BA-mediated FAK/c-Jun/MUC4 axis. E. CD18/HPAF
cells were treated for 2h with 25 µM of DCA and 50 µM of CDCA. Following
treatment, the expression of src and p-src (Tyr 416) were analyzed using 10%
PAGE. (*p<0.05, **p<0.01, ns means non-significant). F. The graphical
representation of the result obtained from real-time PCR showing that
knockdown of FXR in CD18/HPAF cell line leads to significant attenuation of both
DCA (25 µM) or CDCA (25 µM)-mediated MUC4 upregulation.
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Figure 4.7. Clinical association between MUC4 and FXR in PC tissues. A.
Expression profiling of FXR was performed in cDNA samples prepared from
pancreatic tumor tissues (n=15) and tumor adjacent normal (n=4). Similar to its
agonists, the levels of FXR was upregulated in tissues obtained from PC patients
than tumor adjacent tissues. B. Data showing regression analysis which was
performed to correlate MUC4 and FXR in clinical samples at transcriptional
levels. C. PC tissues (obtained from Whipple procedure) showed the coexpression of both MUC4 and FXR at same tissue spots, suggestive of their
direct association. (scale bar = 20 µM). D. Schematic representation of the
overall summary of the paper: Treatment with BA leads to the activation of FXR
receptor, which gets engage in the activation of FAK pathway, possibly by
activating src kinase. Increase in FAK-mediated signaling leads to an increased
transcription of c-Jun gene. Increased expression and activation of c-Jun is
followed by its increased nuclear translocation, leading to increased MUC4
transcription, which plays an important role in the proliferation, survival,
metastasis and chemoresistance of pancreatic tumors.
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CHAPTER V
Multifaceted role of MUC4 in regulating the trafficking of
RTKs in Pancreatic Cancer
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V.1 Synopsis
The importance of EGFR signaling in PC has been acknowledged recently by multiple
groups. However, the most interesting came in 2013, where Ardito and colleagues have
clearly shown that EGFR activation is indispensable for the progression and
development of PC. Interestingly, aberrant expression of MUC has been associated with
the protein trafficking of EGFR family proteins. For instance, MUC4 expression has been
linked with the increased protein stability of HER2 in PC cell lines, which was further
attributed to MUC4-mediated reduced internalization of HER2. In breast cancer,
modulation of MUC4 expression had significant impact on the expression of EGFR
family members including, EGFR/HER1 and HER2. In breast cancer, MUC4 silencing
led to decrease in the expression of Sprouty 2, an intracellular protein with established
functions in stabilizing EGFR receptor. Besides breast cancer, MUC4 has shown to
affect EGFR protein expression in glioblastoma. However, the precise mechanism
involved in MUC4-facilitated impact on EGFR family members in cancer condition is still
unexplored. In this chapter, I have disseminated the novel mechanisms involved in the
regulation of the trafficking of EGFR and HER2 proteins by MUC4 mucin in PC. Using
time-lapse live-cell imaging and confocal microscopy experiments, I have demonstrated
that presence of MUC4 is increasing both the internalization and recycling rate of RTKs
in PC cell lines upon ligand stimulation. It has been further associated with MUC4mediated regulation of RAB5A, a GTPase which regulates the rate-limiting step in
protein endocytosis, at the transcriptional as well as protein level. At mRNA level, MUC4
is inducing the activity of CREB via ERK activation, which is causing increased
transcriptional activation of RAB5A by binding to the cyclic-AMP response element
(CRE) present on RAB5A promoter. Moreover, I have observed that MUC4 regulates the
expression of EGFR ligands, particularly TGF-α, and thereby regulating the receptor
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recycling. Altogether, in this current chapter, I am presenting the multi-faceted roles of
MUC4 in regulating the fate and trafficking of EGFR family members.
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V.2 Background and rationale
PC progression is accompanied by multiple genetic mutations such as, K-ras, p53,
SMAD4, and so on [1]. Mutations along with inflammation can turned on various genes
which does not express in normal conditions. MUC4 is one of such aberrantly
overexpressed protein (~60%-70% of PC patients) in pancreatic cancer condition [2, 3].
MUC4 promotes tumorigenicity and has been directly associated with the growth,
survival and chemoresistance of the PC cells, and its inhibition suppresses pancreatic
tumor cell growth and metastasis [4-7]. Due to loss of cellular polarity, which is one of
the hall-marks of cancer, MUC4 spread over the entire cell surface and start interacting
with various cell-surface RTKs, including EGFR family members [8, 9]. Overexpression
as well as functional importance of EGFR family members is quite evident in PC [10, 11].
Based on numerous experimental approaches, it has been suggested that loss of EGFR
signaling could decline K-ras activity by 50%, and thus block the process of PC
tumorigenesis [12]. Though multiple studies have associated MUC4 overexpression with
the increased stability of RTKs over the cell surface, so far no studies have highlighted
any mechanism which contributes to this process. Being a well-established model
system to study receptor trafficking, it is known that EGFR fate is determined and
decided at multiple steps by myriad of trafficking proteins. Several line of evidence has
also established that proteins, which are known to participate in prolonging the RTKsinitiated active signal transductions, overexpress in cancerous condition. One of such
proteins is Rab GTPases subfamily which has been implicated in the regulation of
intracellular vesicle transport, such as receptor-mediated endocytosis, exocytosis,
degradation and recycling [13, 14]. Studies have demonstrated their aberrant expression
and activity in multiple cancers; for instance, Rab5A has been implicated in the
progression of multiple cancers, such as, lung, hepatocellular, cervical and ovarian
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cancers [15-18]. A study by Fukui K et al has clearly shown the involvement of Rab5A in
potentiating EGFR-mediated signal transductions in hepatocellular carcinoma [19].
Moreover, Rab5A is involved in the rate-limiting step of EGFR endocytosis, and
therefore, acts as a critical link between signal transduction and protein trafficking [20].
Considering the importance of MUC4 and Rab5A on the expression of EGFR family
members, we hypothesized that MUC4 regulates the endocytosis of EGFR by regulating
Rab5A expression and activity. Therefore, in the current study, for the first time, we have
addressed the novel role of oncogenic MUC4 protein in determining the fate of RTKs
endocytosis by Rab5A regulation in PC condition. To address this, we have performed
biochemical, time-lapse microscopy and qRT-PCR approaches. Our biochemical data
upon inhibiting protein synthesis and degradation has evidently revealed the involvement
of MUC4 in increasing the half-life of EGFR family members. Considering the
importance of RTKs in PC, deeper understanding of its prolonged presence as well as
activation onto the cell membrane due to MUC4 overexpression, will give us better
opportunity to therapeutically target PC.
V.3 Results
A. MUC4 increased the stability of RTKs in PC cells
Studies have evidently shown that MUC4 increase the stability of EGFR family
members in various cancers [8, 9], which we have also confirmed as significant
reduction in the EGFR and HER2 levels were noticed in MUC4 knocked down (kd)
CD18/HPAF and CAPAN1 cells (Fig. 5.1A). Digital merging of confocal microscopic
images of MUC4 (green) and EGFR (red) exhibited a noticeable colocalization (yellow)
of these proteins at both membrane (non-permeabilized) and cytoplasmic regions
(permeabilized) in PC cell lines (Fig. 5.1B). Corroboratively, our clinical data exhibited
substantial MUC4 and EGFR co-expression and co-localization in PC tissues (n=13)
than normal pancreas (n=3) and colon (n=1) (Fig. 5.1C), and further establishing their
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association both under in vivo and in vitro settings. To directly implicate the role of
MUC4 in EGFR stability, MUC4 scr and kd CD18/HPAF cells were treated with
cycloheximide, which is an inhibitor of protein translation, for indicated time points. As
anticipated, we observed significant depletion of EGFR in MUC4 silenced CD18/HPAF
cells at all time-points compared to their respective scr controls (Fig. 5.1D). Altogether,
these results indicate that in addition to HER2, MUC4 increases the stability of EGFR in
PC cells.
B. MUC4 influences the stability of RTKs by altering their rate of internalization
Because it is reported earlier that MUC4 modulates the rate of HER2
internalization and consequently its turnover [8], we hypothesized that MUC4 utilizes the
same mechanism to regulate EGFR expression. The kinase domain of HER3 shares
60% and 62% similarity with EGFR and HER2, respectively. However, both EGFR and
HER2 share 83% identity in their amino acid sequence encoding for kinase domains
[21]. It suggests that both EGFR and HER2 are more closely related to each other than
they are to HER3 [21], which further support our hypothesis. To address that, we utilized
time-lapse live-cell microscopy to monitor the fate of EGFR using rhodamine-tagged
EGF ligand in MUC4 kd and control CAPAN1 cells. It is well-known in the literature that
unlike TGF-α, EGF remains bound to EGFR and this EGF-EGFR complex undergoes
dissociation and degradation in the lysosomes, therefore, movement of labeled vesicles
from the cell membrane to endosomes actually indicates the levels and status of EGFR
[22]. At 50 ng/ml of EGF, a concentration which is known to induce receptor degradation
[23], significantly faster internalization was observed in MUC4 scr compared to MUC4 kd
cells. As soon as chamber was kept at 370C, scr cells exhibited pronounced punctate
formation, whereas in MUC4 kd cells, EGF vesicles remain persistently on the
membrane (Fig. 5.2A). Despite of increased internalization, control cells had
insignificant loss of EGF vesicles at 60 mins, whereas in MUC4 kd cells, there was
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significant loss of vesicles, which is highly apparent in the marked (by white box) cells
(Fig. 5.2A). Similar findings were observed in MUC4 kd CD18/HPAF cells, where control
cells had significantly higher internalization (after 10 and 30 mins. of pulse) followed by
insignificant depletion of internalized vesicles when compared to MUC4 kd cells (Fig.
5.2B).
To know EGFR localization, internalization experiment followed by colocalization
experiment was performed. After 15 min. of pulse and 30 min. of chase, most of the
EGFR vesicles are being recycled back to the plasma membrane in MUC4 scr CAPAN1
cells, whereas most of the internalized vesicles are depleted in MUC4 silenced cells and
accumulated in Rab5A and Rab7 positive compartments (Fig. 5.2C). Increased EGFR
staining on the Rab11-positive compartments at 30 and 60 mins of internalization in
MUC4 scr CD18/HPAF cells compared to kd cells, further confirms increased receptor
recycling, whereas more pronounced colocalization between LAMP1 and EGFR in
MUC4 kd CD18/HPAF cells compared to scr cells, suggests increased degradation of
EGFR receptor (Fig. 5.2D).
Earlier studies have implicated MUC4 cytoplasmic domain (MUC4-CD) as an
interacting partner of HER2. Moreover, CD of mucins have shown to regulate EGFR
trafficking [24], therefore, our next objective was to see whether overexpression of
MUC4-CD has any effect on EGFR internalization and stability. Intriguingly, we observed
increase in EGFR and p-EGFR expression in MUC4-CD overexpressing PC cell lines,
however, changes in EGFR expression was insubstantial in MUC4-CD overexpressing
MIA PaCa-2 cell line (Fig. 5.2E). Altogether, the results suggest that cytoplasmic domain
of MUC4 has stabilizing effect on EGFR expression in PC cells.
C. MUC4 impacts receptor internalization by altering the expression of Rab5A
As mentioned earlier, Rab5A catalyzes the rate-limiting step in the internalization
of RTKs and alterations in its expression have been noticed in various cancers [15-18].
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Therefore, we next wanted to analyze the expression status of Rab5A in PC cell lines.
Intriguingly, it was noticed that MUC4-expressing PC cell lines exhibited high Rab5A
transcript levels compared to non-expressing PC cells (Fig. 5.3A). Furthermore,
downregulation in Rab5A mRNA expression in MUC4 kd CAPAN1 cells compared to scr
cells and upregulation of Rab5A expression in MUC4 expressing MIA PaCa-2 compared
to MUC4 null MIA PaCa-2 cells (Fig. 5.3B), were enough to directly relate MUC4 with
Rab5A expression. Similar results were obtained at protein level Fig. 3C). In addition to
that, active-Rab5A (GTP bound) pull down assay revealed reduced Rab5A activity in
MUC4 kd CAPAN1 cells compared to control cells (Fig. 5.3D). Further, IF analysis
revealed co-localization between MUC4 and Rab5A in CD18/HPAF cell line and
confirmed their concomitant expression and localization in PC cells (Fig. 5.3E).
Increased Rab5A expression in MUC4-CD overexpressing AsPC1 cells further
associated the involvement of

Rab5A with MUC4-mediated increased RTKs

internalization (Fig. 5.3F). To solely implicate the role of Rab5A in MUC4-mediated
regulation of RTKs stability, Rab5A was overexpressed in MUC4 kd and scr CAPAN1
cells (Fig. 5.3G). Interestingly, we observed that loss of both EGFR and HER2 receptors
upon MUC4 silencing were attenuated when RAB5A was overexpressed. We also
validated the positive association between MUC4 and Rab5A expression levels in PC
tissues using confocal microscopy (Fig.5.3H). Increased RIN1 mRNA expression in PC
tissues compared to their adjacent controls (Fig. 5.3I); further established increase
activity of Rab5A in PC patients. Altogether, MUC4 regulates the expression and activity
of Rab5A and plausibly affects the internalization rate of RTKs in PC.
D. MUC4-mediated transcriptional regulation of Rab5A is CREB dependent
Earlier studies have clearly shown that promoter of Rab5A gene has cAMPresponsive element or CRE [25], which instigated us to propose that MUC4-mediated
transcriptional regulation is CREB-dependent. To validate the importance of CREB in
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Rab5A upregulation, we treated PC cell lines with CREB inhibitor to suppress CREBmediated

transcription

by

inhibiting

its

interaction

with

CBP,

and

observed

downregulation in Rab5A expression compared to untreated cells (Fig. 5.4A). Treatment
of CD18/HPAF cells with CREB activator, insulin, led to increased Rab5A expression at
mRNA level (Fig. 5.4B), further establishing the involvement of CREB activity on the
transcription of Rab5A gene.
Due to observed involvement of MUC4 in the regulation of Rab5A expression,
our next objective was to determine whether MUC4 expression impacts the expression
and activation status of CREB molecule. As anticipated, significant downregulation in pCREB expression was observed in MUC4 kd PC cell lines compared to the control cells,
without alteration in the expression of total CREB protein (Fig. 5.4C). ERK signaling has
established association with the phosphorylation of CREB [26, 27], which was also found
to be downregulated in MUC4 kd cells [28], and thus, provided the plausible link
between MUC4 and CREB activation. Expression profiling revealed significant
overexpression of both CREB and p-CREB in a panel of PC cell lines compared to
HDPE (immortalized normal pancreatic cells). Moreover, this increase was more
prominent in MUC4-expressing PC cell lines than MUC4 non-expressing PC cells,
supporting the role of MUC4 in CREB activation (Fig. 5.4D). Co-expression of MUC4
and p-CREB in PC tissues further signifies their positive association and validated our in
vitro results (Fig. 5.4E). Interestingly, p-CREB staining was highly nuclear and
expressed both in the ductal as well as in the stromal compartments. Taken together,
the data provides the mechanistic link which leads to MUC4-mediated increase in
Rab5A transcription via CREB regulation in PC condition.
E. MUC4-mediated regulation of the expression of EGFR family ligands also
determine the fate of receptors
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Although in our study, we have mentioned the role of MUC4 in determining the stability
of EGFR and HER2, the basal level of EGFR remains unchanged in MUC4-expressing
and non-expressing PC cell lines, suggesting that PC cell lines do possess some unique
mechanisms to stabilize the expression of EGFR receptor (Fig.5.5A). Interestingly,
addition of EGF ligand in these cell lines impacts the fate of EGFR quite differently in
MUC4 expressing vs. MUC4 non-expressing cell lines. As demonstrated, MUC4 nonexpressing; Panc1 and MIA PaCa-2 cell lines, had significant depletion of EGFR
receptor at both 60 and 120 mins, compared to MUC4 expressing CD18/HPAF and
CAPAN1 cell lines (Fig.5.5B). Due to these unique observations and the established
involvement of EGFR ligands on determining their fate, we decided to analyze the
expression levels of EGFR ligands in a panel of PC cell lines. Compared to MUC4 nonexpressing cell lines (HPNE, Panc1, AsPC1 and MIA PaCa-2), MUC4-expressing PC
cell lines exhibited significantly elevated levels of EGF and TGF-α ligands (Fig.5.5C).
TGF-α has established role in facilitating the recycling of EGFR [22], which can be
attributed to the observed increased recycling of EGFR receptor in the presence of
MUC4 and needs to be validated. Altogether, these results suggest that in the absence
of MUC4, PC cell lines attempts to stabilize EGFR expression by limiting the
concentration of ligands.
G. MUC4 increases the sensitivity of EGF-mediated migration and proliferation by
increasing oncogenic signaling
To understand the functional impact of prolonged cell surface localization of
EGFR in the presence of MUC4, cell-growth kinetics and Boyden chamber migration
assays were performed in the presence and absence of EGF ligand. CD18/HPAF MUC4
Scr cells showed significant increase by 39% (p<0.05) in cell growth in ligand treated as
compared to untreated cells (Fig. 5.6A). Silencing of MUC4 exhibited less impact on cell
growth as only 18% increase after EGF treatment. CD18/HPAF MUC4 Scr cells showed
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significant increase in cell migration by 39% (p<0.05) in ligand treated as compared to
untreated cells. Silencing of MUC4 exhibited less impact on cell migration as only 18%
increase in cell migration was noticed after EGF treatment in MUC4 kd CD18/HPAF cells
(Fig. 5.6B). Similar changes were also noticed in CAPAN1 cells, where presence of
MUC4 increases the responsiveness of EGF-mediated migration by 40%, whereas loss
of MUC4 attenuate such effects as only 25% increase in cell migration has been noticed.
Taken together, we can conclude from these results that MUC4 role in providing stability
to EGFR by preventing its internalization is definitely making cancer cells more sensitive
for EGF-mediated proliferative and migratory potential.
V.4 Discussion
Normal cells regulate their growth by regulating the secretion of growth factors and
expression of their respective cell surface receptors at the optimal time and
concentration to maintain their function [30]. On the other hand, cancer cells abrupt this
crucial regulation in order to grow unrestrictedly [30]. In this study, we have addressed
the implicated mechanisms by which EGFR and HER2 receptors provide prolong
proliferative advantage to PC cells. Normal epithelial cells with a well-defined
morphology with apical, basal, and lateral organization restrict the interaction of proteins
from one region to another. However, under cancer condition, cells lose its polarity which
subsequently leads to the disruption of this organization and facilitates novel proteinprotein interactions [31, 32]. For instance, MUC4 which expresses in apical regions in
normal polarized epithelial cells can interact with basolateral proteins, including
EGFR/Erbb family receptors in non-polarized cancerous cells, which has been evidently
shown in multiple cancers such as, pancreatic and ovarian cancers [8, 9]. As a
consequence, these interactions lead to the induction of multiple downstream signaling
events such as PI3K and MAPK-mediated signaling [33]. Although earlier studies have
indicated that presence of MUC4 regulates the stability of RTKs, the exact mechanism
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which can be attributed to this phenomenon has not been pinpointed. In the current
study, for the first time, we have indicated that MUC4 regulates the expression of
Rab5A, a key protein involved in EGFR/HER2 trafficking. Being a critical molecule
involve in protein endocytosis, alteration in the expression of Rab5A can significantly
impact the protein trafficking. Nevertheless, we have also shown that MUC4-mediated
regulation of Rab5A is responsible for the regulation of both HER2 and EGFR. MUC4
has been demonstrated to increase EGFR expression in triple-negative breast cancer
and glioblastoma [34, 35], but in the current study, we have clearly shown the
involvement of MUC4 in EGFR regulation, using both in vivo and in vitro studies.
Previous studies have shown that MUC1, a well-established mucin, imparts oncogenicity
in cancerous condition, by influencing EGFR internalization and nuclear translocation
[24]. Altogether, THE current study along with other studies have suggested that
upregulation of mucin, one of the characteristics of PC, plays important role in stabilizing
RTKs to support tumor growth.
We have demonstrated that MUC4 interaction with EGFR occurs in the
membranous and cytoplasmic regions under in vitro and in vivo settings [8]. Attenuation
of EGFR reduction upon MUC4 silencing in CD18/HPAF cells when treated with
lysosomal inhibitor, chloroquinone (CQ), indicates that MUC4 does regulate EGFR and
HER2 fate. Under physiological condition as well, MUC4-mediated regulation of EGFR
plays more significant role than MUC4-mediated HER2 regulation because of
significantly higher incidence of EGFR overexpression (~70%) than HER2 (`18%) in PC
condition. Nevertheless, EGFR is expressed primarily on the ductal epithelial cells,
unlike HER2, which expressed predominantly on stromal cells than pancreatic ducts
[36]. Though MUC4 interactions with HER2 has been attributed to HER2 increased
stability on the pancreatic cancer cell surface by our previous study [8], but the general
mechanism which actually leads to this phenomenon has not been addressed. In the

206

current study, we have established that MUC4-mediated regulation of EGFR family
members is dependent on Rab5A.
Rabs family members play critical role in controlling protein trafficking. Change in
their expression has been observed in multiple cancers [37-39]. Due to established role
of Rab5A in cancer and EGFR internalization, we focused ourselves on this molecule
and received intriguing observations. Due to increased expression of Rab5A in PC cell
lines as compared to normal pancreatic cells (HDPE), we proposed that Rab5A
negatively regulates EGFR internalization. Indeed, similar to MUC4, overexpression of
Rab5A leads to an increased rate of internalization and recycling and vice versa.
Moreover, overexpression of Rab5A in MUC4 kd CAPAN1 cells attenuates the
downregulation of both EGFR and HER2 compared to their respective controls.
Interestingly, MUC4 is a critical regulator of transcription of Rab5A gene. Previous study
has shown that Rab5A has multiple CRE sites [25], suggesting the plausible role of
CREB in Rab5A transcriptional regulation, which we have established using inhibitors
approach. Inhibition of CREB causes reduction in Rab5A expression, whereas CREB
activation by insulin is responsible for Rab5A upregulation at both mRNA and protein
levels. The connection between ERK and MUC4 signaling is well understood in the
literature [40]. Similarly, ERK-mediated regulation of CREB phosphorylation is also
known, which led us to comprehend that MUC4-mediated CREB activation is via ERK
signaling cascade. Besides regulating the expression of Rab5A, we believe that MUC4
also regulates its activity by regulating RIN1 expression [41, 42]. Interestingly, frequent
overexpression of RIN1 at mRNA level was observed in PC patients. Further studies are
still required to experimentally establish this link.
As mentioned in the introductory chapter-1c, there is significant increase in the
levels of EGFR ligands in both PDA spontaneous mouse models and human PC.
Interestingly, we observed significant influence of MUC4 expression on EGFR ligands,
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including, EGF and TGF-α. Of particular interest was TGF-α ligand due to its established
role in facilitating increased recycling of EGFR, which can possibly be attributed to the
MUC4-mediated increased recycling of both EGFR and HER2 [22]. However, it is still a
critical question how does MUC4 mechanistically regulate the expression of EGFR
ligands at transcriptional level? Altogether, from this data, it seems that MUC4 regulates
the fate of EGFR family members at multiple steps. Our functional studies have shown
that presence of MUC4 makes cancer cells more responsive to EGF-mediated
oncogenic effects. We observed significant increase in cell growth and migration upon
the addition of EGF in MUC4 Scr than the MUC4 kd PC cells. There are myriad of
evidence suggesting the overexpression of EGF under cancerous condition, including
PC [12, 43]. EGF overexpression has been linked with increased cancer cell migration
and proliferation due to its ability to activate multiple downstream signaling elements via
EGFR receptor.
Besides regulating the oncogenicity of pancreatic tumor cells, MUC4 mediated
regulation of EGFR internalization could also affect the therapeutic response, as one of
the widely accepted mechanisms of action of EGFR based mAbs is to induce receptor
internalization followed by degradation. We have observed significant attenuation of
EGFR specific monoclonal antibody (mAb) mediated EGFR degradation in the presence
of MUC4, suggesting that MUC4-EGFR interaction is not only stimulating the
proliferation of the cells but also makes cells resistant towards EGFR-based therapies.
In fact, presence of MUC4 has been associated with herceptin resistance in breast
cancer [44]. Altogether, these observations led us to think that in spite of having such
enormous importance of EGFR in PC; EGFR mAbs such as cetuximab, did not deliver
anticipated clinical benefits to the patients. Physical interaction between MUC4-EGFR
interactions, which is inhibiting mAbs-mediated internalization and receptor degradation
to attenuate signaling, could be an important contributing factor in drugs failure and
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resistance. Therefore, by modulating their interaction, we can possibly achieve increase
efficacy of EGFR-mediated therapeutic response. Further studies are required to
understand the relevance of MUC4 domains in terms of EGFR-directed monoclonal
antibodies. Conclusively, this study has highlighted a novel function of MUC4 in
regulating the trafficking of EGFR to potentiate EGF-mediated effects.
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Figure and Figure legends

Figure 5.1 In vitro and In vivo data shows an association between MUC4 and
EGFR in PC condition. A. CD18/HPAF and CAPAN1 cells were serum-deprived for 12
hours, and then cell lysates were collected. IB results showing significant reduction in
HER2, EGFR and pEGFR protein levels in MUC4 kd CD18/HPAF and CAPAN1 PC cell
lines, compared to scr control cells. B. IF images showing significant colocalization and
interaction between MUC4 and EGFR in CD18/HPAF and CAPAN1 cell lines under both
permeabilized and non-permeabilized conditions. A 0.2% saponin was used with
antibody solution for permeabilized condition, whereas antibody solution without
detergent was used for non-permeabilized condition. C. Confocal images demonstrating
co-expression of MUC4 and EGFR in stained PC tissues. Pearson correlation was
calculated using Image J software for each field from tissue spots of normal colon (NC),
normal pancreas (NP) and PC. The graph is clearly showing that colocalization between
MUC4 and EGFR was significantly high in PC P. D. IB showing significant depletion of
EGFR protein levels upon cycloheximide (50 µg/ml) treatment in MUC4 kd CD18/HPAF
cells compared to scr cells, suggesting that MUC4 has significant role in stabilizing
EGFR expression in PC cancer condition.
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Figure 5.2 MUC4 significantly impact EGFR trafficking. A. Images obtained from live
cell imaging experiment have revealed that EGF ligand tagged with Rhodamine (but
represented as yellow color for more clarity) is internalizing at very faster rate in MUC4
control cells compared to MUC4 scr cells. However, CAPAN1/scr cells also had
significant recycling of EGF-vesicles at 45 and 60 mins, compared to MUC4 kd PC cells.
B. Flow cytometry data revealed that MUC4 scr cells had significantly higher level of
uptake or internalization of EGF bound EGFR at 30 mins compared to MUC4 scr cells,
however, the bound receptor is getting depleted in MUC4 kd CD18/HPAF cells than scr
control cells. C. Confocal images showing the presence of EGFR and Rab5A in scr and
MUC4 kd CAPAN1 cells. Here, cells were stimulated with unlabeled EGF for 15 min. and
then EGF bound EGFR was chased after 30 mins at 370C. D. Confocal images showing
significant colocalization between EGFR and LAMP1 at 60 mins in MUC4 kd CAPAN1
cells compared to scr cells, suggesting increased degradation of receptor in scr cells. On
the other hand, increased colocalization between EGFR and RAB11 receptor in MUC4
scr cells compared to MUC4 kd cells, suggestive of increased recycling. E. Ectopic
expression of MUC4 cytoplasmic domain (MUC4-CD) in MIA PaCa-2 and AsPC1 cell
lines led to increased expression of both EGFR and p-EGFR compared to their
respective vector controls.
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Figure 5.3 MUC4 regulates the expression and activity of Rab5A. A. Quantitative
real-time PCR data showing increased expression of Rab5A in MUC4 expressing
(CAPAN1, CD18/HPAF, Colo357, HPAC, SW1990 and T3M4) PC cell lines, compared
to MUC4 non-expressing (HPNE, AsPC1, Panc1,MIA PaCa-2) cells. B. MUC4 kd
CAPAN1 and MUC4 ectopic expression in MIA PaCa-2 cell lines exhibited reduced and
high expression of Rab5A at mRNA levels, compared to their respective controls. C.
These results were also confirmed at protein levels. D. Active Rab5A was pulled down in
MUC4 scr and kd CAPAN1 cells. IB results are clearly showing that Rab5A pull down
was significantly more in MUC4 kd CAPAN1 cells compared to scr cells. E. Confocal
images demonstrating Rab5A expression in MUC4 scr and kd CD18/HPAF cells. F. IB
showing increased expression of Rab5A upon ectopic expression of MUC4-CD in MIA
PaCa-2 and AsPC1 cell lines. G. IB showing the expression levels of EGFR and HER2
in Rab5A overexpressing MUC4 kd and scr CAPAN1 cells. H. MUC4 and Rab5A
colocalization (or co-expression) was determined using immunofluorescence experiment
in RAPID autopsy tissue samples. I. Increased mRNA expression of RIN1 in PC patients
compared to tumor adjacent tissues, further confirm increased activity of Rab5A in PC
tissues than control.
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Figure 5.4 MUC4-mediated regulation of CREB activity is leading to Rab5A
regulation. A. Inhibition of CBP:CREB interaction by using pharmacological inhibitor
significantly reduces Rab5A expression in CAPAN1 and CD18/HPAF cells. B. CAPAN1
and CD18/HPAF cells were cultured in serum free media 12h prior to treatment.
Following, cells were treated with insulin (200 nM) for 4h and RNA isolation was
performed. The graph is showing upregulation of Rab5A mRNA expression upon insulin
treatment in both the tested cell lines, confirming the positive involvement of activated
CREB on the transcriptional induction of Rab5A gene C. IB showing reduced expression
of p-CREB and p-ERK in MUC4 kd PC cells, while total CREB remains constant. D. A
panel of PC cell lines was screened for p-CREB and CREB molecules using IB analysis.
Both CREB and p-CREB levels were relatively high in MUC4 expressing than MUC4
non-expressing PC cell lines, confirming the link between MUC4 and CREB activation.
E. IF images were taken for p-CREB and MUC4 in stained PC tissues. The significant
coexpression of both of these molecules on PC tissue spots was validating our in vitro
results under clinical settings.
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Figure 5.5 MUC4 regulates the expression of EGFR ligands. A. A panel of PC cell
lines was screened for EGFR expression using IB. B. PC cell lines were stimulated with
unlabeled EGF ligand (20ng/ml) for 60 and 120 min. Following stimulation, cells were
stained with EGFR. Significant depletion of EGFR was noticed in MUC4 non-expressing
MIA PaCa-2 and Panc1 cell lines, whereas CAPAN1 and CD18/HPAF cells also
exhibited depletion of the receptor; however it was significantly less than MUC4 nonexpressing cell lines. C. A panel of PC cell lines was screened for EGFR ligands; EGF
and TGF-α. The data showing the relative mRNA change value normalized with β-actin.
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Figure 5.6 MUC4 potentiates EGF-mediated proliferative and migratory potential.
A. 0.5X106 of scr and MUC4 kd CD18/HPAF cells were grown on the surface of Boyden
Chamber assay in serum free media. After 12h, EGF ligand (20ng/ml) was added on the
bottom chamber and cells movement was traced. Following 48h of treatment, cells
reached to the lower chamber were stained, while cells still present on the upper
chamber were removed. Stained cells were quantified by the use of microscope. Images
obtained are showing the effect of EGF ligand on the migration of MUC4 scr and kd
CD18/HPAF cells, and suggesting that presence of MUC4 does make PC cells more
responsive for EGF-mediated effects on cellular migration. B. Similar to migration, scr
cells also exhibited higher levels of proliferation upon EGF treatment, compared to
MUC4 kd cells, as depicted by growth kinetics experiment.
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Figure 5.7 Schematic diagrams showing that presence of MUC4 determines the
fate of EGFR. In the presence of MUC4, through the activation of MAPK pathway,
CREB is getting phosphorylated to p-CREB, which allows it to enter to the nucleus.
Inside the nucleus, p-CREB binds to the CRE element present on RAB5A promoter,
which increases the transcription of RAB5A gene. It is followed by increased synthesis of
RAB5A. Increased RAB5A expression will then leads to increased internalization of
EGFR receptor. However, internalized EGFR will be redirected to the recycling pathway
to the plasma membrane, rather than lysosomal degradation pathway. This preference
of EGFR for recycling route in the presence of MUC4 could be attributed to induce TGFα expression. This is one of the mechanism by which aberrant expression or
overexpression of MUC4 helps cancer cells to proliferate in an unrestricted manner.
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CHAPTER VI
Identification of MUC4 in Pancreatic stellate cells (PSCs)
and putative MUC4 alternate promoter
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VI.1 Synopsis
Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant disease with an
equally poor prognosis. Till date, no significant improvement has been made to improve
clinical outcomes of the PDAC patients, primarily due to the limited number of patients
eligible for surgical resections and the frequently occurring problem of radiation and
chemotherapy resistance of these tumors. Due to consistent failure of both conventional
and novel therapies, researchers are forced to re-scrutinize the involvement of tumor
environment in PDAC. The pancreatic tumor microenvironment is comprised of
abundant amount of stroma containing many cells types, but the majority of them are
pancreatic stellate cells (PaSC). It is well established that PaSC are responsible for
enormous desmoplastic reactions which is apparent in almost 90% of the PC patients.
These desmoplastic reaction leads to fibrosis which is observed in two major diseases of
the pancreas—chronic pancreatitis and pancreatic cancer. Considering the importance
of PaSC in the pathobiology of PC disease, there has been an exponential upsurge in
research in this field in last few years, with numerous research groups channelizing their
energies to elucidate the biology and function of these cells. However, the major
problem that we are currently facing is the lack of consensus among PaSC markers.
Still, alpha smooth muscle actin (a-SMA) is widely used to detect activate stellate cells in
PC.
While studying the role of different cell types on MUC4 expression, I came to this
very intriguing observation that PaSC does have MUC4 mucin expression, whereas
other transmembrane mucins such as MUC1 and MUC16 were completely absent. This
is the first report which has shown MUC4 expression in cells of non-epithelial origin.
Interestingly, inactivation of PaSC by using retinoic acids (RA) leads to drastic reduction
in MUC4 expression. Further, confocal microcopy has shown significant expression
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levels of MUC4 in glial fibrillary acidic protein (GFAP, marker of myofibroblasts) positive
PaSC. Encouragingly, PC tissue samples have also shown presence of MUC4 in few αSMA-positive cells, a marker of activated PaSC. Moreover, MUC4 knocked down (kd) in
PSC, using two targeted ShRNA constructs, has shown significant reduction (p>0.05) in
a-SMA expression. We also evidenced decline in the proliferative and migratory
properties of MUC4 kd PaSC, as compared to the Scr control cells, emphasizing that
MUC4 plays an important role in determining the activation status of PaSC. This study
gives us an additional reason to target MUC4, which not only leads to the killing of PC
cells, but will also inhibits the activation of PaSC.
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VI.2 Introduction
Pancreatic cancer (PC) is the fourth leading cause of cancer mortality in United States
with 5-year survival of only 6% (1). Due to lack of diagnostic markers, early metastasis
(invasion to local and distant organs), frequently developed chemo-resistance and lack
of reliable therapies, PC is a very lethal disease. Moreover, PC has expected to become
the second leading cause of cancer-related deaths in next 15 years (2). Among many
unique hallmarks, PC is characterized by extreme desmoplastic reactions, which has
shown to accelerate PC growth and metastasis. One of the major contributors of
pancreatic desmoplasia is pancreas residing fibroblasts cell population, also known as
pancreatic stellate cells (PaSC) or myofibroblasts. In normal pancreas, PaSC are
quiescent in nature, but inflammation, hypoxia and pancreatic injury leads to their
activation, which is accompanied by the absence of lipid droplets, and their increased
migratory and proliferative potential (3, 4). Activated PaSC synthesizes and secretes
excessive extracellular matrix proteins, which reduces the accessibility of chemotherapy
agents to the cancer site. In addition, activated PaSC are also known to contribute in PC
metastasis.
Considering the highly important role of PaSC in PC progression, metastasis and
chemo-resistance, recent studies have been directed to inhibit their activation (3, 4). Our
research group from past two decades has established MUC4, a transmembrane
protein, as one of the critical oncogenic protein because it facilitates survival, growth and
metastasis of PC (5-7). MUC4 is one of the top differentially expressed proteins in PC
(8). Earlier, expression of mucins was thought to be confined to epithelial cells. However,
emerging reports have demonstrated presence of mucins on non-epithelial cells. For
instance, MUC3 expression has been noticed in synovial lining cells, macrophages and
fibroblasts derived from rheumatoid arthritis (RA), osteoarthritic (OA) and normal human
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synovial tissues (ST) (9). Similarly, these cell types also exhibited expression for
MUC5AC, though at extremely low levels. In addition, MUC1 expression was observed
in activated human T-cells (10, 11). However, there is no report so far which has shown
the presence of MUC4 in non-epithelial cells. While studying the role of PC tumor
microenvironment in MUC4 regulation, we obtained one of the most intriguing findings,
which was the presence of MUC4 in PaSC. In addition to its expression, we have also
demonstrated the role of MUC4 protein on the activation status and functional properties
of PaSC.
VI.3 Results
A. Presence of MUC4 mucin on activated cancer associated fibroblast cells
Normal and healthy pancreas contains less number of fibroblast cells, and they are
generally inactive until or unless there is any stimulatory signal present. When cultured
in the presence of tumor (KCT961)-derived conditioned media, inactivated fibroblasts
cells (ImPaSC, obtained from WT mice) become activated, marked by significant
increase in the expression of both α-SMA and Ki67 staining (Fig. 6.1A). Real-time PCR
experiment led us to know significant increase in MUC4 expression by ~20-fold in
activated ImPaSC, compared to inactivated ImPaSC (Fig. 6.1B). To further establish
these findings, we used another PaSC cell lines (immortalized with E6/E7 antigen)
derived from human PC patients. Similar to CD18/HPAF PC cells, human PaSC cells,
which are already activated, showed positive expression for MUC4 promoter, though at
significantly less molecular weight (Fig. 6.1C). However, other transmembrane mucins
such as MUC1 and MUC16, were absent in PaSC cells (Fig. 6.1C). We further verified
the presence of MUC4 in PaSC using different anti-MUC4 antibody (2175) (Fig. 6.1D),
however, difference in its molecular weight in PaSC and CD18/HPAF cells was relatively
less than our previous observation (Fig. 6.1C). Immunofluorescence staining showed
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significant colocalization between MUC4 and GFAP (marker of PaSC) which further
supported our findings (Fig. 6.1E). Confocal microscopy performed for MUC4 and αSMA in PC tissue array further validated our in vitro findings (Fig. 6.1F). We observed
that small fractions of PaSC cells were positive for MUC4 expression in PC tissue spots.
IHC performed for MUC4 in human PC tissues and KPC mice model also demonstrated
the presence of MUC4 in cells other than epithelial cells, with morphology similar to
myofibroblast cells (Fig. 6.1G-H).
B. Presence of MUC4 determines the activation status of PaSC
Due to observed MUC4 expression in activated PaSC, we were prompted to
hypothesize that MUC4 expression is required for the functionality and activation of
PaSC. To address our hypothesis, we made stable MUC4 kd PaSC using two different
MUC4 targeting constructs. As depicted in Fig. 6.2A, MUC4 was significantly
downregulated in PaSC cells at protein levels, which was further confirmed with the help
of IF and qRT-PCR techniques (Fig. 6.2B-C). In MUC4 kd PaSC cells, we observed
significant decrease in α-SMA expression, which is a marker of activated cancer
associated fibroblasts or PaSC, at both mRNA and protein levels (Fig. 6.2D-E),
suggesting that MUC4 does involve in the maintenance of the activation status of PaSC.
Alternatively, upon inducing quiescence in PaSC by using RA (12, 13), significant
decline in MUC4 expression was noticed in RA-treated PaSC at both protein (Fig. 6.2F)
and mRNA level (Fig. 6.2G). Altogether, our results demonstrate that MUC4 expression
and activation of PaSC cell are directly associated with each other.
C. Suppression of MUC4 reduces the proliferation and migration of PaSC
It is well-established in the literature that activation of PaSC is accompanied by increase
in their migration and proliferation (3). Therefore, analysis of the migratory and
proliferative potential upon MUC4 silencing would be another way to prove that MUC4
243

plays important role in the activation status of PaSC cells. Similar to PC cell lines,
suppression of MUC4 expression led to significant decrease in cell proliferation (p<0.05),
particularly on day 5 and 6, compared to scr control cells (Fig. 6.3A). Further, we
observed decrease in number of colonies in our anchorage dependent assay upon
MUC4 kd PaSC cells compared to control (Fig. 6.3B). At molecular level, we observed
decrease in the EGFR and cyclin D1 protein expression, without any noticeable effect on
Akt and ERK activation (Fig. 6.3C). To relate MUC4 kd with the migration of PaSC, we
did Boyden chamber motility assay and observed that kd of MUC4 led to significant
reduction in migration of PaSC cells to the lower chamber compared to scr control cells
(Fig. 6.3D). We observed reduction in the expression and arrangement of the tubulin
proteins in MUC4 kd PaSC than scr cells (Fig. 6.3E). Further, significant decrease in the
expression of vimentin protein in MUC4 kd cells than control cells, validate the role of
MUC4 in the motility of PaSC, however, N-cadherin expression did not change with
MUC4 silencing (Fig. 6.3F). Similar to their protein data, we observed decline in the
mRNA expression of twist, vimentin, cyclin d1 and EGFR in MUC4 kd PaSC compared
to control cells (Fig. 6.3G).
D.

Identification of novel MUC4 promoter

From earlier results, it is quite apparent that molecular weight of MUC4 is less in PaSC
cells compared to PC cells; which led us to postulate that the observed difference is
possibly due to exon deletion, which is quite common among mucins. Screening of
MUC4 cDNA from exon-1 to exon-26 using RT-PCR revealed that MUC4 in PaSC cells
does not utilize classical promoters (CP) and has exon-1 deletion (Fig. 6.4A). Using
promoter prediction V2 software, two highly likely predicted promoter sites on intron-1
(primarily at the end) were recognized, which we have referred as alternate promoter or
AP (Fig. 6.4B). Certainly, we did observe amplified expected PCR product in PaSC
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using forward primer against intron-1 and reverse primer against exon-2, and
sequencing was done to confirm that the amplified band is MUC4 only. Further, we
found that this identified AP is present only in MUC4-expressing PC cells and is
completely absent in MUC4 non-expressing PC cell lines, excluding the possibility of
DNA contamination in utilized cDNAs obtained from these PC cell lines (Fig. 6.4C).
These results were further verified using quantitative RT-PCR. We observed that AP is
maximally expressed by HPAC and Panc10.05 cell lines, whereas CP expression is
maximal in CAPAN1, Panc10.05, Colo357 and QGP-1 cell lines (Fig. 6.4D). To validate
the presence of AP in clinical samples, we did RT-PCR in cDNA obtained from PC
tissues. We observed the presence of MUC4 at transcriptional level in tumor adjacent
and tumor tissues, whereas AP was found to be utilized by tumor tissues only,
associating the presence of AP with the aggressiveness of pancreatic tumors (data not
shown). Using in silico analysis, a putative AUG translation site in-frame codon was
detected at the beginning of exon 2 of MUC4 gene. It suggested that the protein which is
being synthesized by utilizing MUC4 AP will have most likely all the MUC4 domains
present, except leader sequence due to exon-1 deletion.
E. Differential localization of MUC4 in PaSC and PC cell lines
As mentioned earlier that MUC4 in PaSC has an exon-1 deletion, which led us to
assume that MUC4 localized differentially in these two different cell types. For that, we
utilized confocal microscopy approach. As anticipated, we observed that MUC4 in PaSC
cells have more surface localization, whereas its localization in early endosomes
(signified by EEA-1 staining) and Golgi (marked by giantin staining) was significantly less
compared to PC cell line (Fig. 6.5). In spite of the absence of leader sequence, MUC4
does enter into endoplasmic reticulum (ER), which is possible and has been observed
for other proteins that do not possess leader sequence (Fig. 6.5). We observed that
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MUC4 enters to lysosomes in both PaSC and CD18/HPAF PC cells. Altogether, these
results suggest that MUC4 localization is different between PaSC and PC cell lines.
VI.4 Discussion
In this study, we have analyzed in detail the expression and functions of MUC4 in
activated PaSC cells. The current study is the first evidence where presence of MUC4
has been observed in cell type other than epithelial cells. Upon exploring its function, we
realized that MUC4 increase the activation status of PaSC under both in vitro and in vivo
settings. Metastasis is one of the main reasons of PC related deaths, in which activated
PaSC has shown to play important role. By orthotopic transplantation of a suspension of
human PC cells (MiaPaCa-2, AsPC-1, BxPC-3), alone or in combination with primary
human PaSCs, directly onto the mouse pancreas, two separate studies by Vonlaufen et
al. and Hwang et al. have shown that the combination of human PaSCs and PC cells
has significantly high degree of desmoplasia, increased primary tumor growth and
increased regional/distal metastasis compared to PC cells alone (4, 14). Therefore,
increased activation of PaSC and the implicated role of MUC4 further strengthened the
rationale to target MUC4, which not only leads to the killing of PC cells, but will also
inhibits the activation of PSC.
Moreover, we have also seen that this alternate form of MUC4 is present on
aggressive PC tissues (n=6), whereas it was completely absent in tumor adjacent
tumors (data not shown), suggesting that during the course of evolution, PC cells
undergo many changes in which utilization of MUC4 AP is one of the them. Although in
this study, we have highlighted the expression and functions of MUC4, it is still not clear
when and how AP of MUC4 is being regulated and utilized by PC cells, which we would
like to delineate in future.
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Importantly, we have identified the usage of AP in MUC4-expressing PC cell
lines and human PC tissues using RT-PCR approach. The AP of MUC4 was identified
on intron-1. The concept that intronic sequences can also act as alternate promoters is
not new. For instance, in a study by Scohy et al., authors have demonstrated the
presence of a novel, tissue-specific α-fetoprotein mRNA isoform in the yolk sac and fetal
liver, with a transcription site present on the first intron of the α-fetoprotein gene (15).
This isoform is synthesized by the usage of an AP located ∼100 bp downstream of the
enhancer element (15). However, the direct evidence validating the presence of MUC4
AP is still lacking and needs to be established. Currently, these results are being
validated using 5’Rapid Amplification cDNA ends (RACE) experiment. With the help of in
silico analysis, we predicted that MUC4 isoform driven by alternate promoter is using the
translation site present on exon-2. Further studies also prompted us to assume that
identified isoform of MUC4 has altered localization in PaSC vs. PC cell lines due to the
absence of exon-1 which encodes for MUC4 leader sequence. Along with aberrant
expression, accumulating evidence has associated altered subcellular localization of
mucins with the poor prognosis and survival of cancer patients (5). Loss of leader
sequence encoding exon-1 in MUC4 due to alternate promoter usage will definitely
impact MUC4 subcellular localization. This study has paved the way to initiate
investigations which will provide us in-depth understanding of MUC4 both at the cellular
and molecular levels.
Taken together, this study for the first time has shown the expression of MUC4 in
non-epithelial cells. Further functional studies established that presence of MUC4 does
alter the migratory and proliferative potential of PaSC cells and is directly related with the
activation status of PaSC. Further, studies with more number of activated pancreatic
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cancer fibroblast or stellate cells will strengthen our observations and is a part of our
future investigations.
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Figure and Figure legends
Figure 6.1. Identification of MUC4 expression in activated pancreatic stellate cells.
A. IF experiment revealed that ImPaSC cells obtained from WT mice become activated
when cultured in tumor-derived (KCT961) conditioned media, as marked by induced
expression of α-SMA and ki-67, compared to untreated control cells. B. The bar graph is
showing Muc4 expression at mRNA level in mice PaSC co-cultured with or without tumor
cells (KCT961). C. The transmembrane mucins; MUC1, MUC4 and MUC16 were
profiled in CD18/HPAF and PaSC cells by immunoblotting, which did reveal the
presence of MUC4, whereas other two membranous mucins were absent. D.
Immunoblotting by using another antibody against MUC4 (2175) is confirming the
presence of MUC4 in PaSC and CD18/HPAF cells. E. IF analysis revealed noticeable
co-localization between MUC4 and PaSC cells. GFAP is a marker of stellate/fibroblast
cells, whereas 8G7 and 2175 antibodies were used to detect MUC4 expression. F.
Confocal microscopy was utilized to detect MUC4 expression in activated stellate cells
(marked by positive α-SMA staining) in pancreatic tissues obtained from RAPID autopsy
program. G. IHC images obtained from stained human PC tissues are showing the
presence of MUC4 in cells other than ductal epithelial cells. H. In 25-wk age of KPC
mice, when PC is fully developed, MUC4 was stained using IHC protocol.
Correspondingly, Muc4 was observed in non-ductal cells, which share a significant
similarity in the morphology with myofibroblast cells.
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Figure 6.2. MUC4 kd has significant impact on the activation status of PaSC. A.
Stable kd for MUC4 was performed in PaSC cells and immunoblot technique was used
to confirm MUC4 silencing in PaSC. B. Images obtained from IF experiment further
confirmed significant kd of MUC4 protein expression in PaSC. C. The graph is
representing the data obtained from qRT-PCR and showing fold change in MUC4
expression in scr and MUC4 kd PaSC cells. D. Scr and MUC4 kd PaSC were cultured
alone or in the presence of CD18/HPAF derived conditioned media (tumor conditioned
media or TCM). Here, bar graph is showing the effect of MUC4 silencing on the
expression of α-SMA at transcriptional level. Supportively, MUC4 kd led to significant
decline in α-SMA mRNA expression in both TCM treated and untreated PaSC cells,
compared to respective scr control cells. E. IB showing the effect of MUC4 silencing on
the protein expression for α-SMA and GFAP in PaSC cells. F. To induce quiescence,
PaSC were treated with RA (500 nM) which led to significant reduction in MUC4
expression as shown by immunofluorescence staining. G. Inhibition of MUC4 expression
was further noticed at transcriptional level in RA treated and untreated PaSC cells.
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Figure 6.3. MUC4 kd PaSC exhibits negative effects on their proliferative and
migratory potential. A. Growth kinetic experiment was performed for indicated timepoints in MUC4 scr and kd PaSC cells, which showed significant reduced cell number at
day 6 in both MUC4 kd PaSC than scr cells. B. The bar graph is showing the results
obtained from anchorage dependent assay which was performed on MUC4 kd and scr
PaSC cells. C. IB results showing the effect of MUC4 suppression in PaSC on the
protein expression of EGFR, pEGFR, Akt, pAkt, ERK, pERK and cyclin D1. Reduced
EGFR and cyclinD1 expression in MUC4 kd PaSC than control cells, signifying that
aberrant expression of MUC4 does influence the proliferation of PaSC cells. D. Images
showing the results obtained from Boyden chamber assay, which was performed to
analyze the effect of MUC4 kd on the motility of PaSC cells. E. IF images showing the
impact of MUC4 silencing on the intensity and arrangement of α-Tubulin of PaSC cells.
F. IB showing the impact of MUC4 kd on the protein expression of N-cadherin and
vimentin molecules. G. The bar graph is showing the influence of MUC4 suppression on
the mRNA expression of twist, vimentin, cyclinD1, EGFR and MUC4.
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Figure 6.4. Identification of MUC4 promoter in PaSC cells, PC cell lines and PC
tissues. A. 2% Agarose gel was ran to detect the PCR product amplified using RT-PCR
technique, which was performed to screen PaSC from exon-1 to exon-26 of MUC4 gene.
B. Promoter V2 software was used to identify the presence of highly likely prediction
sites for MUC4 promoter on intron-1.

C. Agarose gel showing the expression of

classical promoter (detected by using 5’UTR+Ex-2) and AP (Intron-1+ex-2) in MUC4
expressing and non-expressing PC cell lines. D. Quantitative RT-PCR was done to
measure the levels of both ALP and CLP in PC cell lines.
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Figure 6.5. Altered MUC4 localization in PaSC and PC cells. Confocal images
obtained the difference in the localization of MUC4 protein in PaSC and CD18/HPAF
cells. Here, β-catenin is used as a plasma membrane marker, EEA-1 is used as a
marker of early endosomes, Lamp1 is used as a marker for lysosomes, calnexin is an
ER marker and Giantin is a Golgi marker.
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A.Summary/Conclusions
B. Future directions
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A. Summary/Conclusions
Aberrant overexpression of various members of the mucin family of proteins (i.e.,
MUC1, MUC4, MUC16, and MUC5AC) is one of the hallmarks of PC. It starts
appearing in precursor lesions (i.e., pancreatic intraepithelial neoplasia [PanIN])
and increases with severity of disease. There are multiple studies which has
associated the functional significance of mucins in PC pathobiology, and
recognized their usefulness as diagnostic and therapeutic targets. In terms of
their regulation, mucin expression is known to be controlled by inflammatory
cytokines, including TGF-β, interferon-γ (IFN-γ), interleukins, and tumor necrosis
factor-α (TNF-α) (1-3). MUC4 is one of the most differentially overexpressed
mucins associated with oncogenic transformation in PC (4-8). It functionally
contributes to enhanced motility, invasiveness, metastasis, and drug resistance
of PC cells (9, 10). Earlier, our studies have demonstrated that IFN-γ, an
inflammatory cytokine, and all-trans retinoic acid (RA) synergistically upregulate
MUC4 in PC cells (11). The cellular complexity of the PC stoma leads to hypoxia
due to huge desmoplastic reactions (12, 13). Moreover, as the size of tumor
grows, metabolic activities expedite which cause increased generation of ROS,
which prompted us to speculate that microenvironmental stress also has role in
MUC4 regulation in PC. In this dissertation, I have examined the role of
microenvironmental stress and bile acids on MUC4 expression. Moreover, I have
also highlighted the novel mechanism by which MUC4 regulates the expression
of EGFR family members. Further, I have discussed one of the most intriguing
finding that MUC4 is expressed by PaSC, where its transcription is facilitated by
an alternate promoter, which is locate on intron-1 of MUC4 gene. The detailed
summary of all these observations is as follows
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a. The role of PC micro-environmental stress on MUC4 regulation:
Pancreatic cancer (PC) has been reported to be most hypoxic among solid
tumors, primarily due to its hypovascular nature and extreme desmoplastic
reactions (14). Emerging evidence demonstrates that HIF1α regulates MUC1
expression under hypoxia in PC. It enhances hypoxia driven angiogenesis and
tumor cells survival by regulating the metabolic programming of PC cells. Our
group has demonstrated that MUC4, which remains undetectable in the normal
pancreas, is aberrantly overexpressed in the precursor lesions and progressively
increase with the severity of PC. In this study, for the first time, I have
demonstrated that under hypoxia, the stability of MUC4 protein is significantly
affected in PC, in a HIF-1α independent manner. Further, I have demonstrated
that hypoxia-mediated induction of reactive oxygen species (ROS), promotes
autophagy by inhibiting pAkt/mTORC1 pathway, one of the central regulators of
autophagy, leading to MUC4 degradation. Due to established functional
redundancy in mucins, hypoxia-mediated induction of MUC1 may be sufficient to
functionally compensate for autophagic degradation of MUC4. Altogether,
hypoxia-mediated degradation of MUC4 provides necessary metabolites to
ensure the survival of highly stressed PC cells.
b. The pathobiological implications of BA in PC: The pancreatic duct is
placed in close proximity to the common bile duct, and they both unite at the
point called as the ampulla of Vater. Approximately, 70% of PC patients develop
extrahepatic cholestasis due to obstruction of common bile duct by gradually
increasing tumor size, and exhibits obstructive jaundice which is characterized by
increased circulatory BA levels. Moreover, most of the pancreatic tumors (about
75%) occur at the head of the pancreas. The tumor-promoting functions of BA
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are established for multiple cancers such as esophageal, gastric and colorectal
cancers, which made me inquisitive to comprehend whether BA play tumorigenic
role in PC development and progression. Interestingly, I observed high
circulatory BA levels (p<0.05) and its receptor expression, namely FXR, in PC
patients compared to controls. Moreover, significantly high levels of BA in
pancreatic juice obtained from PC patients than non-pancreatic non-healthy
(NPNH) controls, suggest that there is a direct involvement of BA in the
pathobiology of PC disease. Using defined spontaneous mouse model of PC
(KPC), BA levels has shown to progressively increase with the severity of PC,
which supported our postulation that BA do have tumor-promoting functions.
Mechanistically, I have demonstrated that BA exposure led to induced mRNA
expression of MUC4, which is primarily dependent on FAK-mediated induced
expression of c-Jun. Using quantitative ChIP assay, I have shown that c-Jun
binds to the AP-1 motifs present on MUC4 distal promoter region, a maximal
responsive region for BA. This is the first study which has shown the direct
involvement of c-Jun in MUC4 regulation. Further studies established FXR as the
upstream molecule in this FAK/c-Jun/MUC4 axis. Therefore, targeting BA
receptors or administration of BA antagonists can significantly impact the disease
outcome.
c. MUC4 potentiates EGF-mediated signaling by regulating receptor
trafficking in PC: Multiple studies have linked aberrant overexpression of MUC4
in cancer condition with the increased stability of HER2 over the cell surface,
which facilitates sustained proliferation (15-17), one of the hallmarks of cancers;
however, no studies have so far highlighted the implicated mechanism. In this
study, I have highlighted the novel role of oncogenic MUC4 protein in
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determining the fate of RTKs internalization, particularly EGFR. In PC tissues,
calculated Pearson colocalization coefficient led me to know that ~60% of
patients have both MUC4 and EGFR expression. By utilizing time-lapse live-cell
imaging and confocal microscopy, it became apparent that presence of MUC4
increases the rate of internalization and recycling of EGFR and HER2 receptors
to the plasma membrane compared to MUC4 kd PC cells. Mechanistically, the
altered rate of EGFR and HER2 receptors in MUC4 kd cells was associated with
the role of MUC4 in regulating the activity of Rab5A, one of the member of Rab
GTPase family, which is known to catalyze the rate-limiting step of receptor
internalization. Overexpression of Rab5A in MUC4 kd PC cells was able to
attenuate the loss of EGFR and HER2 receptors, suggesting that MUC4 utilizes
the common mechanism to regulate their fate. Besides Rab5A, we have also
demonstrated that MUC4 regulates the expression of EGFR ligands such as,
TGF-α and EGF. Altogether, we have found that MUC4 has multifaceted role in
the regulation of the EGFR family receptors in PC. Considering the importance of
RTKs in PC, deeper understanding of its prolonged presence as well as
activation onto the cell membrane due to MUC4 overexpression, will give us
better opportunity to therapeutically target PC.
d. Discovery of MUC4 mucin in activated pancreatic stellate cells (PaSC):
While studying the role of PC tumor microenvironment in the regulation of MUC4,
I obtained one of the most intriguing findings, which was the presence of MUC4
in PaSC cells (immortalized with E6/E7), whereas other mucins (MUC1 and
MUC16) were absent. This was an unexpected finding given that MUC4 is
normally expressed in the epithelial cells. Using confocal microscopy, these
results have further confirmed the presence of MUC4 expression in α-SMA
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(representing active PaSC) positive cells in PC tissue sections. Unlike PC cell
lines, treatment with RA, which has well-established role in inducing PaSC
quiescence, leads to reduced transcriptional expression of MUC4 in PaSC. It
directed us to postulate that MUC4 expression determines the activation status of
PaSC, which we have addressed by silencing MUC4 expression in PaSC by
using targeted ShRNA constructs. Suppression of MUC4 expression leads to
significant reduction (p>0.05) in α-SMA, vimentin and EGFR expression.
Functionally, significant decline in the proliferative and migratory potential was
observed in MUC4 kd PaSC cells, compared to the control cells. Altogether,
these results indicate towards the involvement of MUC4 expression in
determining the activation status of PaSC. This study has given us an additional
strong rationale to therapeutically target MUC4, as it will not only kill PC cells, but
will also inhibit the activation of PaSC cells, which has prominent role in PC
desmoplasia.
e. Identification of Alternate promoter for MUC4 gene: MUC4 gene contains a
GC-rich and TATA-less proximal regulatory region and a distal regulatory region
flanked by a TATA box (18, 19). In addition to these promoters, I have identified
a putative alternate promoter (AP), which is located on the intron-1 region of
MUC4 gene. The size of MUC4 protein in PaSC was significantly smaller than
PC cell lines, which was indicating a plausible deletion of exon. Screening of
MUC4 cDNA from exon-1 to exon-26 using RT-PCR revealed that MUC4 in
PaSC cells does not utilize CP and has deletion of exon-1 which encodes for the
leader sequence of MUC4. Using promoter prediction V2 software, two highly
likely predicted promoter sites on intron-1 (primarily at the end) were recognized.
Certainly, I observed amplified expected PCR product in PaSC using forward
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primer against intron-1 and reverse primer against exon-2, and further confirmed
using sequencing. Further, I found that this identified AP is being used by MUC4expressing PC cells as well. Supportively, in silico analysis has revealed that
there is a presence of open reading frame at the beginning of exon-2, from where
active translation could take place. Along with aberrant expression, accumulating
evidence has associated altered subcellular localization of mucins with the poor
prognosis and survival of cancer patients. Loss of leader sequence in MUC4 due
to AP usage leads to significant change in MUC4 subcellular localization in PaSC
compared to CD18/HPAF PC cell line (which primarily utilize MUC4 CP). This
study has paved the way to initiate investigations which will provide us in-depth
understanding of MUC4 both at the cellular and molecular levels.
B. Future directions
a. The role of PC micro-environmental stress on MUC4 regulation
Similar to cytokines, functional redundancy also exists among mucins, implying
that hypoxia-mediated induction of MUC1 expression may be sufficient to
compensate for MUC4 downregulation. We would like to experimentally
authenticate our assumption by using MUC1 kd CD18/HPAF and CAPAN1 cell
lines. Being the least molecular weight, it seems logical that nutrient-deprived,
hypoxic and oxidatively stressed PC cells are inducing MUC1 (~250 kDa)
expression, while simultaneously facilitating the degradation of high molecular
weight MUC4 protein to save cellular energy expenditure. It would be interesting
to study the impact of hypoxia on the expression and stability of other high
molecular weight mucins, such as MUC16 and MUC5AC in PC condition. As
shown in chapter 3, presence of MUC4 provides survival benefits to cancers cells
residing in highly stress conditions and led us to hypothesize that MUC4
273

degradation in hypoxia may be critical for the viability of PC cells by reducing
energy consumption, which is an urgent need for the survival of hypoxic cells. To
directly relate MUC4 with the metabolism of stressed PC cells, we would like to
do the quantitative measurement of metabolites in MUC4 kd and control PC cells
with or without hypoxia treatment. Moreover, we have seen that HIF-1α and
MUC4 has direct relationship both in vitro and in vivo system. One of the possible
mechanisms could be EGFR downregulation upon HIF-1α inhibition, as recent
study from our lab has shown that inhibition of EGFR leads to MUC4
downregulation in PC cells, and need to be investigated.
b. The pathobiological implications of BA in PC
In this project, we have associated BA-induced MUC4 expression with FXR
expression, which is found to be overexpressed in 47% of PC patients. However,
another BA receptor, TGR5 was upregulated in 67% of PC patients and
emerging studies have shown its tumorigenic role in GI cancers, including PC.
Further studies will be helpful and required to mechanistically delineate the
association between TGR5 and PC disease condition. We would also like to
study whether TGR5 is involved in mucins regulation. As mentioned earlier, PC
also has aberrant expression for MUC1, MUC5AC and MUC16; we would like to
see the impact of BA exposure on these mucins. BA levels have been found to
be elevated in chronic pancreatitis condition, one of the known risk factor for PC
development. As mentioned earlier, mucins overexpression appears early and
increases with the progression of PC. Although in my dissertation research, I
have primarily focused on the role of BA at the late stages of PC when most of
the patients exhibit obstructive jaundice, it will be important to study the
implications of the BA at the initial stages of PC. To get the better insight of BA
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on the pathobiology of PC, bile duct ligation or cholecystectomy using
autochthonous murine models could be extremely important to reveal its
importance at the initial and later stages of pancreatic tumor. Moreover, the
significantly induced levels of BA indicates their possible usefulness for
diagnostic purposes, and needs to be validated in more number of patient
samples to assess and establish its clinical utility. In addition to FAK pathway,
inhibition of MAPK pathway also led to attenuation of BA-mediated MUC4
upregulation. Future studies will be focused to understand the in-depth
involvement of different signaling pathways in MUC4 regulation after BA
treatment.
c. MUC4 potentiates EGF-mediated signaling by regulating receptor
trafficking in PC
In this project (chapter 5), we have shown that MUC4 is plausibly regulating the
expression of TGF-α at transcriptional level. TGF-α has known function to direct
EGFR towards recycling route. Therefore, by delineating the mechanism involved
in MUC4-mediated regulation of TGF-α ligand, we would be able to explain the
observed involvement of MUC4 in increased EGFR receptor recycling to the
plasma membrane. Because we did not see an apparent interaction of MUC4-CD
either with EGFR or HER2, we believe that the observed interaction between
these receptors and MUC4 is primarily occurring at the MUC4 N-terminus. We
would like to study this in-depth using MUC4 N-ter. We already have MiniMUC4
construct which consists 10% of VNTR of WT-MUC4, from which MUC4 C-ter
can be detached using restriction enzymes. The remaining MUC4 N-ter could be
used to do pull down experiments to confirm that this site is mainly interacting
with EGFR and HER2 proteins. Although recent studies have shown the success
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of erlotinib therapy in PC, treatment of PC patients with this drug did not lead to
anticipated improvement on the clinical outcome of PC patients. Interestingly, in
breast cancer, MUC4 overexpression has been considered as one of the reasons
for Herceptin failure, which further provide more strength to our rationale to
address this question. Therefore, our next objective would be to analyze whether
presence of MUC4 influences the sensitivity and efficacy of EGFR-targeting
therapies.
d. Discovery of MUC4 mucin in activated pancreatic stellate cells (PaSC)
In this research project (chapter-6), I have clearly shown that presence of MUC4
in PaSC affects its activation status, migration and proliferation. However, how
does control and MUC4 kd PaSC affect the migration and proliferation of PC
cells is still need to be explored. For that, we would take the help of 3D co-culture
technique. Moreover, PaSC are considered to be partner-in-crime with PC cells
and increase the incidence of both regional and distant metastasis of PC cells.
Therefore, we would like to address whether expression of MUC4 in PaSC is
responsible for increasing the metastatic potential of PC cells? Orthotopic
implantation of the combination of PC cells with MUC4 scr or kd PaSC cells
would be extremely helpful to delineate the functional importance of MUC4
expression on PaSC in PC development and progression.
Because we have observed that MUC4 cDNA in PaSC have all the exons
present, except extremely short exon-1. Therefore, the observed difference in the
molecular weight of MUC4 protein between PaSC and PC cell lines is plausibly
due to other reasons. One of the most likely reasons could be the presence of
allelic VNTR polymorphism in MUC4 gene in these cell lines, which also cause
large variations in the size of MUC4 protein among PC cell lines (20).
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Importantly, most of the conducted experiments involve only one PaSC, which is
one of the biggest limitations of this study. Therefore, we would like to confirm
MUC4 expression with additional PaSC cell lines, where UNMC rapid autopsy
program could be of great help. We will obtain PaSC and PC cells from the same
PC patients and analyze MUC4 expression both at genomic and protein levels.
e. Identification of Alternate promoter for MUC4 gene
The identification of alternate promoter of MUC4 gene in PC cell lines, PaSC and
human PC tissues is primarily done by using RT-PCR technique followed by
sequencing. Although we have considered all the precautions required to negate
the possibility of DNA contamination, we will further evidence the presence of AP
using more confirmatory techniques, such as 5’ rapid amplification of cDNA ends
(RACE). Moreover, as mentioned earlier, we detected the presence of AP only
on cDNA derived from PC tissues, whereas tumor adjacent tissues did not
demonstrate the presence of AP. We correlated the usage of MUC4 AP with the
aggressiveness of PC cancer, which needs to be studied in details. Additional
studies focused to delineate the regulation of MUC4 AP would be advantageous
to understand when and why MUC4 AP usage is preferred over MUC4 CP. For
that, we would like to perform in silico analysis on MUC4 AP which will highlight
the putative sites for the binding of transcription factors. Construction of
luciferase promoter constructs against AP segment will further help us to confirm
the influence of revealed transcription factors.
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General Hypothesis and Objectives
Over the past few decades, multiple studies have established key roles of mucins in
malignant diseases. The expression of mucins is significantly altered during
tumorigenesis and other pathological conditions. In this dissertation, I have primarily
focused on MUC4, which is one of the most differentially expressed proteins in PC and
has strongly been implicated in the progression, metastasis and chemoresistance of PC.
MUC4 is not expressed in the normal pancreas, but the early pancreatic intraepithelial
neoplasia (PanINs) precursor lesions have been shown to express MUC4, which further
increases as the disease progresses. The ability of NIH3T3 fibroblasts cells to form
tumors in nude mice upon ectopic expression of MUC4 was the first evidence which has
experimentally proved its oncogenic function. Considering the significant role of MUC4 in
tumor biology, additional studies are required to highlight its novel functions and
regulatory mechanisms. Although studies have associated extrinsic (cytokines) and
intrinsic factors (NCOA3) with the regulation of MUC4, there is no study which has
addressed the role of PC microenvironmental stress (hypoxia and oxidative stress) on
MUC4 expression. Both Hypoxia and MUC4 has been associated with PC
aggressiveness and chemoresistance. Moreover, hypoxia has been shown to regulate
mucins expression in solid tumors. All these studied led me to hypothesize that hypoxia
has a significant impact on MUC4 expression in PC, which aggravate the PC conditions.
Besides PC microenvironment, the critical anatomical position of pancreas can influence
the growth of pancreatic tumors. However, these mechanisms are unexplored. The
majority of tumors (about 75%) arise at the head of the pancreas. Most of the PC
patients develop extrahepatic cholestasis due to common bile duct obstruction by
increasing tumor size which results in hyperbilirubinemia and elevated circulatory levels
of bile acids (BA). Multiple studies have implicated BA as tumor promoter for various
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cancers. A recently performed meta-analysis has shown that patients with the history of
cholecystectomy have significantly higher risk to develop PDAC. These studies incited
me to hypothesize that BA play important role in PC tumorigenesis by regulating the
expression MUC4 oncogene.
In addition to regulation, I have also focused to elucidate the novel functional
properties of MUC4 in PC. MUC4 is known to regulate the fate of EGFR family proteins
in several cancers including PC. However the precise mechanism involved is still
ascertain. Emerging reports have shown altered expression of RAB proteins in various
cancers. Additionally, a recent study has shown that mucins can also regulate the
expression of RABs to influence the trafficking of oncogenic proteins in cancer. It
brought me to my next hypothesis that MUC4 determines the fate of EGFR family
members by modulating the expression and activity of RAB GTPases in PC. In addition
to PC cells, MUC4 expression has recently been detected in activated PaSC.
Interestingly, our preliminary studies have shown reduction of MUC4 expression upon
treatment with RA, which is known to change the status of activated PaSC to quiescent,
suggesting a plausible link between MUC4 expression and activation status of PaSC. It
led me to hypothesize that MUC4 regulates the activation status of PaSC and thereby,
promotes desmoplastic reactions in PC microenvironment, which is known to exacerbate
PC condition.
Broadly, the aims for my dissertation research were as follows:
1. To elucidate the role of microenvironment stress (hypoxia and oxidative stress) on
MUC4 regulation in PC.
2. To investigate the impact of bile acids (BA) on MUC4 expression in PC.
3. To identify the novel functions of MUC4 in epithelial (ductal tumor) and nonepithelial
(PaSC) cells under PC condition.
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